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Abstract 
 
Small-molecule agonists have been identified for Toll-like Receptors (TLR) 2, TLR4, TLR7 and 
TLR8 thus far, and chemotypes other than those of canonical ligands are yet to be explored for a 
number of innate immune receptors. The discovery of novel immunostimulatory molecules would 
enhance the repertoire of tools available for interrogating innate immune effector mechanisms, and 
provide additional venues for vaccine adjuvant development. It is with this in mind that we aimed 
to identify novel immunostimulatory compounds by high-throughput screening, characterize 
transcriptomal ‘signatures’ of innate immune stimulation and explore mechanisms of adjuvanticity 
for TLR2, TLR2/7 and TLR8 agonists.  
 
A multiplexed, reporter gene-based high-throughput assay capable of detecting agonists of TLR2, 
TLR3, TLR4, TLR5, TLR7, TLR8, TLR9, nucleotide-binding oligomerization domain-like 
receptors (NOD) 1 and NOD2 was utilized in screening 123,943 compounds, in which 
amphotericin B (AmpB) and nystatin were identified as prominent hits. The polyene antifungal 
agents act as TLR2- and TLR4-agonists. The TLR4-stimulatory activity of AmpB was similar to 
that of monophosphoryl lipid A, suggestive of TRIF-biased signaling. The adjuvantic activity of 
AmpB, at a dose of 100 micrograms, was comparable to several other candidate adjuvants in rabbit 
models of immunization. (Chapter 2) 
 
We sought to identify transcriptomal signatures of innate immune stimulating molecules using 
next-generation RNA sequencing with the goal of being able to utilize such signatures in 
identifying novel immunostimulatory compounds with adjuvantic activity. We observed that the 
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CC family of chemokines, particularly CC chemokines 1, 2, 3, 4, 7, 8, 17, 18, 20, and 23, were 
broadly upregulated by most TLR and nucleotide-binding domain and leucine-rich repeat–
containing receptors (NLR) stimuli, while the CXC chemokine family appeared to show 
distinctions in upregulation. Extracellular receptors such as TLR2, TLR4 and TLR5 induced the 
transcription of CXC chemokines including CXCL5, CXCL6 and CXCL8, whereas intracellular 
receptors such as TLR7 and TLR8 upregulated CXC chemokines 11 and 12. A comparison of a 
variety of TLR agonists in a standardized rabbit immunization model indicated prominent 
adjuvantic activity for TLR2 agonists. Strong chemokine induction by TLR2 agonists was 
observed in human peripheral blood mononuclear cells. In addition, human foreskin fibroblasts 
stimulated with TLR2/6 agonists, but not TLR1/2 agonists resulted in chemokine production, 
which was consistent with strong expression of TLR2 and TLR6, but not of TLR1, in fibroblasts. 
TLR2/6 stimulated fibroblasts demonstrated functional chemotactic responses to human T cell and 
natural killer cells subsets. (Chapter 3) 
 
We hypothesized that an ESAT-6-based subunit vaccine adjuvanted with a TLR2/7 hybrid would 
induce balanced T helper (Th) 1/Th2 responses capable of conferring protection against M. 
tuberculosis. We therefore covalently linked a potent TLR2 agonist with a dual TLR7/8 agonist, 
and observed that the resulting TLR2/7 hybrid molecules remained active, though less potent, 
against TLR2 and TLR7. The TLR2/7 hybrid was equipotent to the two individual TLR agonists 
in a standardized rabbit immunization model, but induced higher ‘quality’ antibodies as measured 
by surface plasmon resonance. Linear epitope mapping revealed that the hybrid induced 
immunoreactivity to more contiguous epitopes in a model antigen. The hybrid molecule was able 
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to induce increases in ESAT-6-specific interferon-γ spot-forming units in the lungs of mice, and 
reduce the mycobacterial burden in the lungs following M. tuberculosis challenge. (Chapter 4) 
 
Part-structures of the 2-aminobenzimidazole scaffold were examined with a view to identifying 
structural requisites corresponding to the smallest possible fragment of the benzimidazole core that 
would allow for retention of TLR8-agonistic activity. TLR8-specific agonistic activity was 
retained in 1-pentyl-4-phenyl-1H-imidazol-2-amine. The crystal structure of this compound bound 
to TLR8 ectodomain displayed binding interactions that are common to other TLR8 agonists. This 
compound showed markedly attenuated proinflammatory properties in ex vivo human blood 
models. Structure-activity relationship (SAR) studies revealed that 4-(2-(benzyloxy)phenyl)-1-
pentyl-1H-imidazol-2-amine inhibited TLR signaling in a variety of TLR reporter cell lines, as 
well as in pharmacologically-relevant human blood model systems. A kinase screen of this 
compound showed relative specificity for calmodulin kinases. (Chapter 5) 
 
The effects of TLR8 agonists on innate immune function suggest that these compounds could 
potentially be useful as vaccine adjuvants in neonatal vaccines. We examined how TLR8 agonists 
influence processing of soluble antigens by antigen presenting cells. TLR8-active compounds were 
unique in inducing pyroptosis-like death in monocytes, leading to the formation of CD14+ 
extracellular vesicles (ECV) of 100-400 nm diameter. ECV formation was dependent on myeloid 
differentiation primary response gene 88 (MyD88), interleukin-1 receptor-associated kinases 
(IRAK) 1 and 4, and p38 mitogen-activated protein kinase (MAPK). The monocyte-derived ECVs 
contain near-intact soluble antigens, and stimulate antigen-specific recall responses in autologous 
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CD4+ T lymphocytes. The formation of antigen-loaded, monocyte-derived ECVs may be a distinct 
mechanism underlying the adjuvantic activities of TLR8 agonists. (Chapter 6) 
 
The results presented here highlight the applicability of high-throughput screens for the 
identification of novel innate immune stimuli, and identified transcriptomal profiles to aid in 
determining adjuvanticity of new compounds, as well as aiding in target identification. The insight 
gained into mechanisms of adjuvanticity for the TLR2, TLR2/7, and TLR8 agonists highlights the 
utility of TLR agonists as vaccine adjuvants, and justifies the continued study of small-molecule 
innate immune stimuli for applications in vaccines.  
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Chapter 1.1 Pattern Recognition Receptors of the Innate Immune System 
The immune system is an incredibly intricate machine capable of discriminating subtle differences 
in foreign molecules, and then marshalling effector mechanisms to eliminate invading pathogens, 
with minimal damage to the host. Many of the initial responses to colonization or invasion by 
pathogens, or to the presence of non-self molecules are derived from the innate wing of the immune 
system. The innate immune system is characterized in a broad sense as being rapidly activated, not 
antigen specific, and without memory. In the absence of memory, the innate immune system relies 
on germline-encoded pattern recognition receptors (PRRs) to identify conserved microbial 
patterns, referred to as pathogen-associated molecular patterns (PAMPs), that are common across 
diverse families of microbial and viral pathogens. The innate immune system not only acts as an 
early defense against invading pathogens, but also serves to direct the subsequent adaptive immune 
responses, which are highly specific and endowed with long-term memory. 
 
There are four major families of PRRs in the human: the Toll-like receptors (TLRs), nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs), RIG-like receptors (RLRs), and C-
type lectin receptors (CLRs).1 PRRs serve as sentinels for the immune system against both 
extracellular and intracellular pathogens and, as such, these receptors are distributed throughout 
the cell, including the cell surface, within the cytosol, and within the endosomal pathway. The 
biology of the TLRs will be discussed below.  
 
There are 10 functional TLRs in humans. All of the TLRs are approximately 90 kDa 
transmembrane proteins that are located on the cell plasma membrane, or within endosomal 
vesicles.2 Structurally, TLRs contain a Toll-interleukin receptor (TIR) domain for signal 
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transduction, a single alpha helix spanning the membrane, and an extracellular leucine-rich repeat 
(LRR) domain for ligand binding. The global structural similarities notwithstanding, the TLRs can 
be divided into 5 subfamilies based on sequence similarity: TLR2, TLR3, TLR4, TLR5, and TLR9 
subfamilies.2 The subsequent chapters will focus on the two largest of the subfamilies: the TLR2 
and TLR9 subfamilies. 
 
Chapter 1.1.1 TLR2 Subfamily 
The TLR2 subfamily is the largest of the subfamilies and contains TLRs -1, -2, -6, and -10. All 
four of the members are expressed on the cell surface and detect extracellular PAMPs. They share 
approximately 60% sequence identity overall, and almost 90% sequence identity in the TIR 
domains.3 This family is unique among the TLRs in that TLR2 can heterodimerize with TLR1 and 
TLR6, while all of the other TLRs are known only to signal through homodimerization.4 TLR2 
utilizes two distinct co-receptors depending on the TLR binding partner; the TLR1/2 heterodimer 
utilizes CD14, while the TLR2/6 heterodimer functions with the transmembrane protein CD36 for 
cargo and receptor internalization.5 Despite the differences in co-receptors, the TLR1/2 and 
TLR2/6 complexes signal through the same adaptor molecules following ligand recognition. Upon 
ligand binding, the adaptor protein myeloid differentiation primary response gene 88 (MyD88) is 
recruited to the TIR domains of the TLRs, and ultimately results in signal transduction to the 
transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which 
leads to innate immune activation. The TLR2 family additionally recruits the adaptor protein 
MAL/TIR domain-containing adaptor protein (TIRAP), which is unique to the TLR2 and TLR4 
subfamilies, and is critical to MyD88-independent signal transduction to NF-κB.6-7  
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The TLR2 family has evolved to sense a wide variety of PAMPs commonly associated with cell-
wall-derived lipopeptides from numerous gram-negative and gram-positive bacteria, and also 
mycoplasma.8 TLR1/2 heterodimers sense triacylated species common in gram-negative bacteria 
and synthetic molecules such as PAM3CSK4,
9-10 while TLR2/6 heterodimers recognize diacylated 




Despite the diversity in TLR2 binding partners, the downstream adaptive immune responses are 
remarkably similar within a given animal model. It is to be noted, however, that the mouse, which 
is the primary animal model used in immunology, appears to diverge from the human with respect 
to adaptive immune responses following TLR2 stimulation, and has left the nature of T helper (Th) 
cell polarization up for debate. Investigators who have utilized the mouse as a model system tend 
identify TLR2 agonists as biasing towards humoral immunity through Th2 polarization via the 
identification of Th2 markers such as interleukin (IL)-4, IL-5, and the mouse antibody isotype 
IgG1.11-13 Additionally, the immunological outcomes of TLR2 stimulation in mice further point to 
Th2 driven immunity by exacerbation of Leishmania major infection, which is thought to be 
controlled through Th1 driven cellular immunity, following immunization with the TLR2/6 
adjuvant PAM2CSK4, while the same adjuvant leads to protection from Th2 controlled Brugia 
malayi infection.12 
 
Many others have found the opposite in human responses to TLR2 agonists, and tend to associate 
TLR2 stimulation with Th1 polarization. They have demonstrated the presence of the Th1 markers 
IL-2, IL-12, and interferon (IFN)-γ in human PBMCs following TLR2 stimulation, and an absence 
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of IL-4.14-17 This builds upon previously reported IL-12 induction from isolated human dendritic 
cells stimulated with TLR2 agonists.18 While there is not yet clarity in defining TLR2 agonists by 
T helper polarization, this remains an active area of research and will be discussed in greater detail 
in chapters 3 and 4. 
 
Chapter 1.1.2 TLR9 Subfamily 
The TLR9 subfamily is composed of the endosomal receptors TLR7, -8, and -9. Within this family, 
TLR7 and TLR8 are most closely related with 42% identity and 73% similarity in their amino acid 
sequences.19-20 The TLR9 subfamily shares many of the signaling molecules with the TLR2 family, 
including the co-receptor CD14 and the adaptor protein MyD88,21 but differs significantly in 
ligand specificity and adaptive immune polarization. The TLR9 subfamily is further distinguished 
from the TLR2 family through additional signal transduction to the Interferon Regulatory Factors 
(IRFs), which exert transcription control of Type I and Type II IFNs. 
 
All three members of this family recognize various forms of genetic material; TLR7 and TLR8 
both recognize single stranded RNA, while TLR9 senses unmethylated deoxycytidyl-
deoxyguanosine (CpG) motifs in DNA.2 Additionally, small molecules targeting TLR7 and -8 
have been identified by many research groups, including ours, and will be given significant 
attention in chapters 4-6.22-29 While TLR7 and -8 share similarities in ligand recognition, they 
differ substantially in subsequent cytokine responses. TLR7 stimulation results in activation of the 
transcription factors IRF3 and IRF7, which lead to the secretion of the Type I interferons IFN-β 
and IFN-α, respectively.30 TLR8 on the other, hand drives robust Type II interferon responses, 
namely IFN-γ, mediated through IRF1.31  
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Small molecule agonists of TLR9 have remained more elusive and there are currently no published 
small molecule TLR9 agonists. Despite the lack of small molecule TLR9 agonists, three broad 
classes of TLR9 active CpG DNAs have been identified based on distinct cellular activation and 
cytokine induction profiles.32-33 Class A CpG oligodeoxynucleotides (ODN) elicit strong natural 
killer (NK) cell and plasmacytoid dendritic cell (pDC) responses characterized by the induction of 
Type I interferons, while Class B CpG ODNs are potent activators of B lymphocytes. The final 
class of CpG ODNs described are the Class C ODNs.34-35 Members of this class share the qualities 
of both Class A and B ODNs by eliciting both B cell activation and pDC-mediated Type I IFN 
production.32  
 
Chapter 1.2 TLR Cellular Expression 
As TLRs are sensors for various pathogens and their engagement serves to catalyze subsequent 
innate and adaptive immune responses, they have broad expression in both hematopoietic and 
nonhematopoietic cell lineages. Antigen presenting cells (APC) such as monocytes, macrophages, 
and dendritic cells (DC) show broad, but not identical, TLR expression patterns. Monocytes and 
macrophages, in particular, show expression of many of the TLRs, but are not homogeneous in 
composition, with tissue specific expression of the various TLRs.2 DCs on the other hand have 
very specific TLR expression patterns, with pDC exclusively expressing TLR7 and -9, while the 
two major circulating conventional DC (cDC) populations, CD1c+ and CD141+, express TLR1, -
2, -3, -4, -5, -6, and -8, based on western blotting and PCR.36-37 However, there is evidence based 
on costimulatory marker upregulation that both populations of cDCs respond to TLR7 agonists, 
while only the CD1c+ respond to TLR8 agonists.38-39 Lymphocytic populations also bear TLRs, 
with NK cells expressing TLR2, -3, -4, -5, -7, and -9 40-41 and B cells expressing TLR1, -2, -4, -6, 
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-7, and -9.42 Lastly, T lymphocytes, including both CD4+ and CD8+, show expression of TLR3, -
4, -7, and -9.43 
 
Cells of non-hematopoietic lineages also express TLRs. While not as well studied as leukocytes, 
epithelial cells express TLRs and likely contribute to innate immune responses. Expression of the 
TLRs varies dramatically in the mucosal membranes and is detected at both the mRNA and protein 
levels.44 The airway epithelium is perhaps the best studied of the epithelial cell types, and show 
strong expression of both TLR2 and TLR4.45-46 Stimulation of TLRs in airway epithelial cells 
enables engagement of innate immune responses to invading pathogens by directing the expression 
of mucin glycoproteins, a major component of mucus, well as human beta-defensins-1 and -4.47-48 
Epithelial cell TLRs can further amplify the early immune responses through the secretion of many 
inflammatory mediators and chemokines including tumor necrosis factor-alpha (TNF-α), IL-5, IL-
6, IL-8, macrophage inflammatory protein (MIP)-1α, and MIP-1β. This, in turn, leads to the 
recruitment and influx of leukocytes such as DCs, macrophages, monocytes, NK cells, and 
polymorphonuclear cells (PMNs), enabling the clearance of pathogens and facilitating subsequent 
pathogen-specific adaptive immune responses.49-50 Epithelial TLRs, especially TLR2 and TLR4, 
are also believed to play a critical role in the induction and maintenance of asthma and allergy 
through similar mechanisms as the pathogen-specific responses, mentioned above, but with Th2 
skewed responses, leading to disease.48, 51  
 
Chapter 1.3 Vaccines and Vaccine Adjuvants 
Vaccines have proven to be one of the greatest tools available in medicine to prevent infectious 
diseases.52-53 Vaccines have several important functions within the healthcare setting. First, they 
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protect healthy individuals, including those who do not have fully competent immune systems, 
from disease, but also protect those who are unable to receive vaccinations through the process of 
“herd immunity”. Herd immunity is achieved when a majority of the population, usually between 
75-94%, depending on the pathogen, have immunity and prevent colonization of the pathogen 
within the population, which, in turn, protects individuals that are unable to acquire immunity 
against that pathogen.54  
 
The practice of vaccination or inoculation was first shown to be effective by Edward Jenner in 
1798 when he inoculated an 8-year-old boy with pus derived from a cowpox lesion, and then 
infected the boy with the smallpox virus. The boy was ultimately protected from the smallpox 
virus. Vaccines now represent a twenty-four-billion-dollar market covering a wide range of 
pathogens. However, there is still a great unmet need for vaccines to a number of pathogens, such 
as malaria, tuberculosis, HIV, and several flaviviruses, as well as the need for improvement of 
existing vaccines such as the annual influenza vaccine and the acellular pertussis vaccine that 
remain suboptimal.55-56  
 
Chapter 1.3.1 Live Attenuated and Inactivated Vaccines 
Early vaccines were initially derived from whole inactivated or live attenuated pathogens. One of 
the best success stories utilizing both of these strategies has been the near-eradication of the 
poliovirus using the live attenuated oral poliovirus vaccine and the inactivated poliovirus 
vaccine.57 The oral poliovirus vaccine contains all three serotypes of poliovirus that have been 
attenuated by serial passage though African green monkey kidney cells, which resulted in 
significantly reduced pathogenicity.58 Following administration of this replication-competent 
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vaccine, the patient develops a sub-clinical infection in the mucosal membranes, allowing the host 
immune system to develop natural humoral and mucosal immunity to the virus.59 As such, this 
vaccine is widely used in the developing world due to low cost of manufacturing, ease of oral 
administration, and the strong induction of humoral and mucosal immunity. The live-attenuated 
polio vaccine is associated with rare vaccine-associated diseases, such as vaccine-associated 
paralytic poliomyelitis, which is clinically indistinguishable from the poliomyelitis caused by 
wild-type virus.60 Most industrialized countries, including the United States, have adopted the 
inactivated poliovirus vaccine, which differs from the attenuated oral vaccine in that the three 
poliovirus serotypes are inactivated by formalin. While the inactivated poliovirus vaccine is 
significantly safer than the attenuated vaccine, the inactivated vaccine does suffer from reduced 
efficacy at eliciting protective immunity in the lower intestinal tract, relative to the attenuated 
vaccine, and does not prevent intestinal shedding of the virus. The inactivated vaccines does 
however provide protection equal to that of the oral vaccine in pharyngeal membranes.61  
 
Chapter 1.3.2 Subunit Vaccines and Adjuvants 
The tradeoffs between safety and efficacy in the two types of poliovirus vaccines are also relevant 
in several other live-attenuated vaccines. Current trends in vaccine development have focused on 
use of highly purified protein antigens, and such vaccines are termed subunit vaccines. Examples 
are Hepatitis B, Haemophilus influenza type B, pertussis, and human papillomavirus vaccines. 
Although exceedingly safe, the highly purified antigens are frequently poorly immunogenic, and 
rely heavily on adjuvants to enhance immunogenicity and steer adaptive immune responses to the 
antigen.62-63.  
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The role of adjuvants in subunit vaccines is pivotal.  Once referred to as “immunologist’s dirty 
little secret” by Charles Janeway,64 adjuvants now represent a major area of inquiry in immunology 
and vaccinology. Only a small number of adjuvants are currently approved by the FDA. The most 
commonly used vaccine adjuvants to date are the aluminum salts (commonly referred to as ‘alum’), 
which can be found in the vaccines such as those against diphtheria, hepatitis B, pertussis, and 
Haemophilus influenza type B.62 The adjuvantic activity of the aluminum salts were originally 
described by Glenny and coworkers in 1926, in which they suggested antigen alone was too rapidly 
eliminated to induce robust immune responses, and required precipitation with alum in order to 
slow the rate of elimination of antigen.65 Many groups have built upon the work of Glenny and 
have expanded the understanding of the mechanisms of action for the aluminum salts, which can 
be summarized as increasing antigen uptake by DCs, recruiting leukocytes to the injection site, 
activating the innate immune system through the indirect engagement of the NLPR3 
inflammasome.66 Alum is believed to indirectly activate the inflammasome by inducing necrosis 
and causing the release of uric acid, a danger signal. However, there are currently no known 
receptors that are engaged directly by alum.67-68 Additionally, Wang and coworkers observed that 
alum stimulated a population of Grl+, IL-4+ eosinophils in the spleens of mice that primed B cells 
leading to Th2 polarization of the adaptive immune responses.69  
 
While alum-adjuvanted vaccines are generally safe and well tolerated with over one billion doses 
administered world-wide,70 they are not without limitations. Aluminum salt-adjuvanted vaccines 
polarize Th2 immunity, providing limited benefit in vaccines targeting intracellular pathogens that 
rely on either Th1 or Th17 driven immunity for protection and clearance. This was highlighted by 
Warfel et. al. in comparing the whole-cell pertussis vaccine to the alum adjuvanted acellular 
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pertussis vaccine in baboons.71 In this study the authors demonstrate that baboons vaccinated with 
acellular, alum adjuvanted Infanrix® (GlaxoSmithKline) were able to prevent major disease upon 
challenge with B. pertussis in a similar manner to the whole-cell vaccine, but failed to prevent 
either colonization of the bacterium or prevent transmission to naïve animals. They also noted that 
both natural infections and vaccinations with the whole-cell vaccine resulted in memory Th1 and 
Th17 cells, while the acellular vaccine yielded Th1 and Th2 responses. The acellular pertussis 
vaccine was able to protect animals from major disease, but it showed potential limitations in 
enabling “herd immunity”.71  
 
The more recent FDA-approved vaccine adjuvants have focused more closely on biasing adaptive 
immune responses towards Th1 responses. AS04, the first adjuvant to gain approval against human 
papilloma virus types 16 and 18, builds upon the adjuvantic activity of alum immunogenicity 
through the absorption of the TLR4 agonist monophosphoryl lipid A (MPLA) to alum.72-73 
Didierlaurent and colleagues demonstrated that the adjuvantic activity of AS04 was driven 
primarily by the TLR4 component and resulted in enhancement of DC and monocyte antigen 
uptake and cytokine secretion both at the site of injection and draining lymph node, while the alum 
component of AS04 served to prolong the APC stimulation observed at the injection site.74 They 
also demonstrated that AS04 does not directly stimulate T cells through either CD69 upregulation 
or IFN-γ secretion, but only appeared to drive APC activation with strong expression of TNF-α, 
IL-6, and caspase 1-dependent IL-1β.74  
 
The latest generation of adjuvants to gain approval are the oil-in-water emulsions MF59 (squalene 
in water) and AS03 (squalene and α-tocopherol in water) from Novartis and GlaxoSmithKline, 
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respectively. Despite being referred to as antigen delivery systems, these adjuvant systems are able 
to modulate immune responses. Early work on establishing mechanisms of action for these 
adjuvant systems demonstrated that neither of the systems worked through the formation of micro-
depots, but rather through leukocyte recruitment to the site of injection and the draining lymph 
nodes.75-76 The oil-in-water emulsions differ from many TLR agonists, such as MPLA in AS04, in 
that they act by inducing chemokines, such as CCL2 and CCL3, in APCs, which increase the 
number of leukocytes that migrate to the site of injection and increase antigen internalization. 
However, they do not induce strong co-stimulatory molecule upregulation in APCs or activate T 
cells directly.77-79 Within the leukocyte populations that respond to these adjuvants, monocytes 
serve as the primary antigen-internalizing cells at the site of injection, and also appear to transport 
the antigen to draining lymph nodes for B cells and DC presentation of the antigen to cognate T 
cells.78-79  
 
The adjuvants currently under development are generally comprised of ligands of novel targets 
such as the TLRs. AS04 contains the only TLR ligand currently approved by the FDA. However, 
there are several pure TLR agonists in clinical trials and many more, including some of compounds 
described in this work, in preclinical development. Some of the compounds in current clinical trials 
include TLR9 active CpG DNA (phase III), TLR5/NLRC4 ligand flagellin (phase II), and TLR4 
active glucopyranosyl lipid A (phase I).80 Given the important roles that TLRs occupy in bridging 
the innate and adaptive immune systems, targeting these innate immune receptors have been a 
fruitful area of research in the development of novel vaccine adjuvants.  Depending on the TLR 
engaged, downstream responses include leukocyte recruitment, APC activation and maturation, as 
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well as lymphocyte activation. More detail on the specifics of TLR-mediated immune activation 
will be provided in the subsequent chapters. 
 
The premise of the work presented here is to advance the knowledge of TLR mechanisms of 
adjuvantic action across the TLR2 and TLR9 subfamilies of receptors, and establish robust assays 
for assessing innate immune stimulation. Chapters 2 and 3 are dedicated to high-throughput 
screening for novel TLR stimuli and transcriptional profiling of established TLR ligands to enable 
the identification of patterns characteristic of innate immune stimulation. The subsequent chapters 
(4-6) describe our efforts to evaluate the mechanisms of TLR adjuvanticity.  
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Chapter 2. 
 
Identification of Amphotericin B 
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2.1 Introduction 
We set out to identify novel innate immune-active chemical entities and expand the repertoire of 
potential vaccine adjuvants to combat the large number of devastating infectious diseases for 
which no effective vaccines currently exist. The major causes of mortality in pediatric populations 
in the developing world are attributable to lower respiratory infections, infectious diarrhea, malaria 
and measles,81 all of which are preventable illnesses. However, a significant impediment in the 
effective delivery of vaccines in the developing world is the requirement for most vaccines of 
multiple, booster doses for successful immunization. Methods of safely enhancing 
immunogenicity of vaccines would be an important step toward realizing the bold,82-83 but 
faltering84 vision of the Children's Vaccine Initiative: an affordable, heat-stable, orally 
administered, multiple-antigen, single immunization to be given at birth. As mentioned in Chapter 
1, in contrast to older vaccines which utilized inactivated whole organisms or attenuated live 
vaccines,85-86 there is an increasing emphasis in contemporary vaccines on the use of subunit 
vaccines which have the distinct advantages of ease of production, quality control, and safety; 
however, such subunit antigens are largely soluble proteins and tend to be poorly immunogenic, 
necessitating the use of adjuvants to induce robust immune responses.  
 
Our focus on the discovery and development of safe and effective vaccine adjuvants has served as 
an impetus for a detailed exploration of structure-activity relationships (SAR) in a variety of innate 
immune stimuli, including small molecule agonists of TLR2,87-89 TLR7,28, 90-97 TLR8,25-26, 97-100 
NOD1,101 as well as C-C chemokine receptor type 1 (CCR1).102 Other than canonical ligands or 
derivatives thereof, defined small molecule agonists are yet to be discovered for a large number of 
PRRs such as TLR3 and TLR9, and it was of interest to us to embark on high-throughput screens 
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with a view to identifying novel immunostimulatory chemotypes.  Desiring a strategy that would 
permit the identification of immunostimulatory molecular classes acting on a very broad range of 
PRRs, we designed and evaluated a multiplexed, reporter gene-based high-throughput assay. 
Among the most prominent of 'hits' in screening 123,943 compounds were the polyene antifungal 
agents amphotericin B (AmpB) and nystatin. Deconvolution and dose-response profiles of the 
polyenes demonstrated TLR2- and TLR4-agonistic activity.  Cytokine and chemokine induction 
profiles of AmpB closely resembled that of MPLA, suggesting a Toll–interleukin-1 receptor 
domain–containing adaptor inducing interferon- (TRIF)-biased signaling. AmpB as an adjuvant 
was comparable to several other candidate adjuvants in rabbit models of immunization. These 
results point to its potential applicability as an adjuvant for human vaccines. 
 
2.2 Results and Discussion 
Small-molecule agonists have been identified for TLR7,90-91, 96, 103-111 TLR8,26, 97, 99-100, 112-113 
TLR4,114-117 and TLR2.118-119  Chemotypes representing structural families other than those of 
canonical ligands are yet to be explored for a number of TLRs such as TLR3, TLR5 and TLR9, as 
well as other PRRs. The discovery of novel immunostimulatory molecules of defined receptor 
specificities would enhance the repertoire of tools available for interrogating innate immune 
effector mechanisms, and provide additional venues for vaccine adjuvant development. Our 
primary goal was, therefore, to identify novel PRR agonists. We envisioned that an efficient 
strategy would be to design and implement an assay that would permit the identification of 
immunostimulatory molecular classes acting on a very broad range of PRRs and, having cast a 
wide net, as it were, to then deconvolute signals and assign receptor specificities. 
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We tested this premise by first examining the responses of a human monocyte-derived THP-1 
reporter cell line; similar constructs have been successfully utilized to identify agonists of 
TLR4.114, 116  These cells responded robustly to TLR2 and TLR4, and feebly to TLR5, TLR8, 
NOD1 and NOD2 stimuli; agonists of TLR3, TLR7 and TLR9, however, failed to elicit any 

































































Figure 1. Responses of THP1-Blue™ NF-κB reporter cells to various TLR and NLR agonists. 




 (TLR2 agonist) and LPS (TLR4 
agonist), and the absence of responsiveness to Poly I:C (TLR3 agonist), C4 (TLR7 agonist), and 
ODN2006 (TLR9 agonist). Attenuated responses were observed for flagellin (TLR5 agonist), 
KHP-3-126 (TLR8 agonist), C
12
-iE-DAP (NOD1 agonist) and Murabutide (NOD2 agonist).  
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We therefore set out to develop a ‘Universal Reporter’ cell line by constructing hybridomas 
derived from the fusion of CD14+ primary human monocytes with human embryonic kidney cells 
(HEK) expressing only the NF-κB-inducible secreted embryonic alkaline phosphatase (sAP) 
reporter gene (HEK-Blue™ Null cells).102 Although we were able to isolate, expand and 
characterize the ploidy of the heterokaryons, these cells were unstable, rapidly regressing back to 
an embryonic, CD14- phenotype (data not shown). 
 
We reasoned that multiplexing (combining) individual reporter cell lines (HEK2, HEK3, HEK4, 
HEK5, HEK7, HEK8, HEK9, NOD1, NOD2 and HEK-Null) would also achieve our objective of 
simultaneously detecting signals from a wide range of PRRs. Utilizing this multiplexing approach, 
we conducted a pilot high-throughput screen of 34,848 compounds (Fig. 2A). Z’ factors120 were 
optimized by varying several parameters (relative proportion of each reporter cell line, total cell 
density per well, incubation period, liquid handling protocols and plating methods). Responses in 
this assay were first characterized using both a ‘Master Mix’ (mixture of individual ligands, Fig. 
3), as well as individual stimuli (a metric for deconvolution) in each of the ninety-nine test plates 
(Fig. 2B). Although excellent Z' values were observed to individual stimuli (Fig. 2C), the relatively 
high baselines in unstimulated control wells (median: 1.5 AU, Fig. 2C), necessitated a cutoff value 
of 2.0 AU, which could potentially limit the dynamic range of the assay and possibly compromise 
the detection of weak signals.  
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Figure 2. Pilot HTS Screen.  
A. Composite heat 
map of 99 384-well 
plates used for the 
pilot screen using the 
full complement of 
10 multiplexed 
reporter cell lines.  
 
B. Heat map of Plate 
39 showing the 
organization of 
controls in the first 













MPLA, Flagellin, C4 
(TLR7 agonist), 
IMDQ (Dual TLR7/8 
agonist), KHP-3-126 (TLR8 agonist), ODN-2006, C
12
-iE-DAP, and  Murabutide at 5 g/mL. Well 
12 corresponds to a 'Master-Mix' combining all stimuli at 0.45 µg/mL of the individual ligands.  
 
C. Distribution of baseline values and signals (a subset is shown for visual clarity). Means and 
standard deviations were computed for replicates from 99 plates from which Z' factors were 
calculated. Shown also are Gaussian fits of the histograms. 
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 We examined the possibility of improving signal-to-noise (S/N) ratios and dynamic range of the 
assay by eliminating possible redundancy in signaling in the individual reporter cell lines.  We 
tested the responses of each individual reporter cell line to well-characterized innate immune 
stimuli. We observed considerable redundancy and degeneracy within these reporter cells (Fig. 
4A).  
 
Virtually all of the reporter cell lines responded to Poly(I:C), a TLR3 ligand which also signals via 
the RIG-I-like receptors, RIG-I, Melanoma Differentiation-Associated protein 5 (MDA5), or the 
RIG-I-like RNA helicase LGP2.121-123 HEK2 cells responded, as expected, to canonical TLR2 
ligands (PAM2CSK4,
124 LTA,125 and the monoacyl human TLR2-specific lipopeptide, DBS-2-
217C), but also to flagellin and C12-iE-DAP,
101 TLR5 and NOD1 agonists, respectively; HEK5 
cells responded, in reciprocal fashion, to flagellin and the TLR2 agonists, as well as C12-iE-DAP. 
Flagellin also activates, apparently ectopically, HEK3, HEK4, HEK7, HEK8, HEK9 and NOD1 
cells, presumably by alternate sensing via Naip5.126-127 HEK7 cells responded to pure TLR7 
agonists C4,91 EY-3-254B111 and to the dual TLR7/8 agonist IMDQ92, 96 (in addition to, as 
Figure 3. Structures of positive controls used in the HTS. 
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mentioned earlier, poly(I:C) and flagellin),  as well as to C12-iE-DAP. HEK8 cells showed 
responses to TLR8 agonists KHP-3-126,26 MB-152,100 and to the dual TLR7/8 agonist IMDQ; 
poly(I:C), flagellin and C12-iE-DAP also elicited NF-κB induction in these cells. An analysis of 
the redundancies indicated that a subset comprising HEK2, HEK4, HEK7, HEK8 and HEK9, when 
multiplexed, responded to all of the innate immune stimuli (Fig. 4B), while showing a markedly 
reduced baseline absorbance of 0.25 AU.  
 
 
    
Figure 4.  Responses of individual reporter cell lines to innate immune stimuli. A. Heat map 
of responses of individual reporter cell lines to a variety of TLR/NLR stimuli (see Fig 3 for 
structures of compounds), showing redundancy in PRR engagement. B. Multiplexing TLR2, 
TLR4, TLR7, TLR8, and TLR9 cells is sufficient and necessary for robust detection of signals. 
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This multiplexed platform was implemented in screening to screen 123,943 compounds and, as in 
the pilot screen, the inclusion of individual controls in each of the 354 assay plates (Fig. 2B) 
allowed the examination of S/N ratios and Z' factors for individual stimuli, which ranged from 
0.74 (HEK7) to > 0.85 for poly(I:C) and flagellin (Fig. 5). A cutoff value of 4 above in-plate 
absorbance mean yielded 552 provisional hits (Fig. 6). Among the most prominent of signals were 
those originating from the polyene antifungal agents AmpB and nystatin; both these compounds 
were identified as prominent hits in the Selleck as well as the Prestwick libraries (Fig. 6).  
 
Simultaneous deconvolution and dose-response profiles in individual reporter cell lines (HEK2, 
HEK3, HEK4, HEK5, HEK7, HEK8, HEK9, NOD1 and HEK-Null) were performed for all 
provisional hits. AmpB and nystatin showed dose-dependent NF-κB induction in human TLR2- 
and TLR4-specific reporter cell lines (Fig. 7), consistent with previous reports demonstrating 
TLR2 and TLR4 activation by these antifungal agents.128-130 
 
Figure 5. Distribution of negative and individual positive controls obtained in the modified 
multiplexed HTS screen. 
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AmpB has remained the frontline chemotherapeutic agent for serious systemic fungal infections 
for more than a half-century.131-132 AmpB is, as the name suggests, amphoteric which, compounded 
by its pronounced amphipathic nature (due to the asymmetric distribution of polar hydroxyl groups 
on one face of the molecule and a markedly hydrophobic, conjugated polyene on the other), has a 
marked propensity to self-associate with a critical aggregation concentration of ~ 0.2 µg/mL. 
Consequently, the drug is very sparingly soluble in water (< 1 µg/mL).133 AmpB was more potent 
than nystatin (Fig. 7), is an FDA-approved drug for parenteral use (which nystatin is not), and we 
had previously reported a practical and convenient  method for obtaining highly water-soluble 
(>100 mg/mL) formulations of AmpB using pyridoxal phosphate (vitamin B6) as a complexing 
Figure 6. HTS data on 123,943 compounds showing prominent signals originating from AmpB 
and nystatin. Hits were defined as signals > 4 σ (in-plate standard deviations for test compounds 
above negative control means). 
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agent.134 For these reasons, we chose to evaluate the adjuvantic properties of AmpB.  
 
Given the dose-dependent TLR2- and TLR4-agonistic properties128-130 of AmpB (Fig. 7), we 
compared cytokine and chemokine induction  by AmpB to the TLR2-specifi  c diacyl and triacyl 
lipopeptides PAM2CSK4 and PAM3CSK4 (which signal via TLR2/6 and TLR2/1 
heterodimerization , respectively135-136), MPLA, a TLR4 agonist which is a component of the 
FDA-approved AS04 adjuvant, 137-139 as well as LPS, a highly proinflammatory TLR4 agonist, in 













































































Figure 7. Deconvolution and dose-response of AmpB and nystatin showing human TLR2 and 
TLR4-agonistic activities. 
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A high degree of congruence in the pattern of cytokine and chemokine induction between AmpB 
and MPLA was observed (Fig. 8), suggesting a TRIF-biased signaling for AmpB, as has been 
observed for MPLA.140-142 In particular, both AmpB and MPLA, relative to LPS, induce significant 
levels of Myd88-dependent TNF-α and IFN-γ secretion140 only at high concentrations, whereas 
both AmpB and MPLA strongly induce MDC (Fig. 8) and RANTES responses at low 
concentrations, consistent with TRIF-dominant signaling of AmpB.140-142 A possible clinical 











































































































Figure 8. Cytokine and chemokine induction of AmpB in human PBMCs. Aliquots of human 
PBMCs (10
5
 cells in 100 µL/well) were stimulated for 16 h with graded concentrations (two-fold 
dilutions starting at 25 µg/mL) of test compounds. Supernatants were isolated by centrifugation, 
and were assayed in triplicates (from individual donors) using analyte-specific multiplexed 
cytokine/chemokine bead array assays. The cytokine profile of AmpB closely resembles that of 
MPLA, suggestive of TRIF-biased signaling.  
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relatively low levels of proinflammatory mediator in circulation, is the occurrence of infusion-
related febrile reactions131, 143 at therapeutic doses of up to 1 mg/kg per day; in contrast, febrile 





















































































Figure 9. Adjuvanticity of AmpB in a standardized rabbit model of immunization. Cohorts of 
adult female New Zealand white rabbits (n = 4) were immunized intramuscularly in the flank 
region with 10 µg of CRM197 in 0.2 mL of saline (unadjuvanted control) or 10 µg of CRM197 in 
0.2 mL of saline plus 100 µg of AmpB-pyridoxal phosphate adduct without any other excipients. 
Other TLR-active candidate adjuvants were used as comparators. Preimmune test-bleeds were 
obtained on day 0, and animals were immunized on days 1, 15, and 28. A final bleed was obtained 
on day 38. CRM197-specific ELISAs were performed using automated liquid handling methods 
and are depicted as log
10
 (immune/preimmune) titers. 
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The in vitro signatures of a TRIF-biased cytokine induction profile that portend low, if any, local 
or systemic reactogenicity, coupled with the fact that parenteral AmpB has been in the clinic for 
several decades prompted the evaluation of its adjuvanticity in highly standardized rabbit models 
(51, 62) that we have been using to benchmark candidate vaccine adjuvants using CRM197 (10 
µg/dose) as antigen (92). CRM197 is a non-toxic mutant of diphtheria toxin, containing a single 
amino acid substitution (G52E), and is used as a carrier protein in conjugate vaccines for 
polysaccharide antigens, which are frequently T cell-dependent antigens, requiring T cell helpfor 
humoral responses.147 The adjuvantic effects of the highly water-soluble and stable AmpB-
pyridoxal phosphate complex (100 µg/dose) was compared to that of ODN 2006 (TLR9), MB-564 
(TLR8), C4 (TLR7) and DBS-2-217c (TLR2), all of which are also fully water-soluble and were 
also used at 100 µg/dose.  AmpB as an adjuvant elicited comparable anti-CRM197 IgG titers 
relative to the other candidate adjuvants (Fig. 9) in rabbits with no detectable local inflammation. 
 
2.3 Conclusions 
As mentioned earlier, AmpB has had a long track-record in the clinic, with a well-documented 
adverse effect profile; the very low doses of AmpB required for adjuvanting vaccines emphasizes 
its potential use as an adjuvant for human vaccines. Furthermore, the development of a novel 
multiplexed innate immune detection platform described herein has led to the identification of 
several immunostimulatory chemotypes, structure-activity relationship studies of which are 
currently in progress, and will be reported elsewhere.  
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2.4 Materials and Methods 
Compounds for HTS screens  
Curated compound collections from the University of Kansas High Throughput Screening 
laboratory which include Life Chemicals (15,040), ChemBridge (43,736), ChemDiv (56,232), 
Selleck Bioactives (1649), TimTec (5000), and FDA Repurposed Library (2,286) were used. 
Compound transfers from source (80 nL of 10 mM stocks) to assay plates were performed using 
an Echo 550 acoustic liquid handler (Labcyte, Sunnyvale, CA). For most libraries, a target final 
concentration of 10 µM of compound (in a final volume of 80 µL for the multiplexed reporter 
gene-based assay described below) was achieved; the FDA Repurposed Library compounds were 
plated to obtain final concentrations of 2.5 µM. Assay plates were hermetically sealed and stored 
at -80 oC until used. AmpB and nystatin were purchased from Sigma-Aldrich (St. Louis, MO). 
Synthetic MPLA, lipoteichoic acid (LTA) from S. aureus, PAM2CSK4, Poly(I:C), ultrapure LPS 
from E. coli K12, flagellin from S. typhimurium, ODN-2006 (Vaccigrade), C12-iE-DAP, and 
Murabutide were procured from InvivoGen (San Diego, CA). The structures of small molecule 
PRR agonists synthesized by us are shown in Fig. 3. Responses to a variety of TLR and NLR 
agonists were first examined using THP1-Blue™ NF-κB reporter cells (InvivoGen, San Diego, 
CA). 
 
Multiplexed human TLR-2/-3/-4/-5/-7/-8/-9/Null and NOD-1/NOD-2 reporter gene assays (NF-κB 
induction)  
Human TLR-2/-3/-4/-5/-7/-8/-9/Null and NOD-1/NOD-2-specific reporter cells (InvivoGen, San 
Diego, CA; referred to hereafter as HEK2, HEK3 ... HEK9 cells) were used for the multiplexed 
screen.91, 101-102 HEK293 cells stably co-transfected with the appropriate hTLR (or NOD) and 
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secreted alkaline phosphatase (sAP) genes were maintained in HEK-Blue™ Selection medium 
(InvivoGen, San Diego, CA). Expression of sAP under control of NF-κB/AP-1 promoters is 
inducible by appropriate TLR/NOD agonists, and extracellular sAP in the supernatant is 
proportional to NF-κB induction.   
 
For the pilot screen, all ten individual reporter cells were used. Cells were harvested by 
trypsinization from T75 tissue culture flasks, washed once with pyrogen-free phosphate-buffered 
saline (PBS), and resuspended in HEK-Blue Detection Media at a density of 106 cells/mL. 
Combining equal proportions of the ten different cell lines yielded a density of ~105 cells/mL of 
each cell type. The first two columns of each assay plate were reserved for controls (see Fig 2B); 
alternate wells received DMSO or HEK-Blue Detection Media alone (unstimulated, negative 
controls), or individual, TLR/NOD-specific stimuli (see legend to Fig 2B). Structures of small-
molecule TLR/NOD-specific compounds are shown in Fig. 3.  80 µl/well of the multiplexed cell 
mixture was added to 384-well, flat-bottomed, cell culture-treated assay plates, and incubated 
overnight in cell culture incubators. sAP was assayed spectrophotometrically using an alkaline 
phosphatase-specific chromogen (present in HEK-detection medium as supplied by InvivoGen) at 
620 nm using a SpectraMax M2 multimode microplate reader (Molecular Devices, Sunnyvale, 
CA). Z' factors120 were computed for each TLR/NOD-specific signal from 99 assay plates (Fig. 
2C). The modified multiplexed assay used in the final screen included a subset comprising human 
TLR2, TLR4, TLR7, TLR8 and TLR9-specific reporter cells. The following individual stimuli 
were used to quantify signal-to-noise characteristics: PAM2CSK4 (TLR2), DBS-2-217c (TLR2), 
lipoteichoic acid (LTA, TLR2), Poly(I:C) (TLR3), LPS (TLR4), flagellin (TLR5), C4 (pure 
TLR7),91 EY-3-254B (pure TLR7),111 IMDQ (TLR7/8),92, 96 KHP-3-126 (pure TLR8),26 MB-152 
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(pure TLR8),100 ODN-2006 (TLR9), C12-iE-DAP (NOD1), and Murabutide (NOD2). Performance 
metrics for the controls used in the final screen are shown in Fig 5. 
 
All hits (n = 552), defined as signals > 4 σ (in-plate standard deviations for test compounds above 
negative control means), were deconvoluted in full dose-response assays in human TLR-2/-3/-4/-
5/-7/-8/-9 and NOD-1/NOD-2-specific reporter cells in liquid handler-assisted assay formats as 
described by us previously.91, 101-102 
 
Synthesis of pyridoxal phosphate adducts of AmpB and nystatin   
AmpB (20.0 mg) was dissolved in 2 mL of dimethylformamide, to which was added a solution of 
20 mg of pyridoxal phosphate in 2 mL of water (adjusted to pH 7.4 with Na2CO3). The mixture 
was lyophilized, and the resultant fully water-soluble adduct was characterized by liquid 
chromatography-mass spectrometry as described previously.133 
 
Immunoassays for cytokines 
Fresh human peripheral blood mononuclear cells (PBMCs) were isolated from human blood 
obtained by venipuncture (approved by the University of Minnesota institutional review board, 
Protocol ID: 1506-32702H). Written informed consent was obtained as per University guidelines.  
PBMCs were isolated using Vacutainer® CPT™ Cell Preparation Tubes (Beckton-Dickinson, 
New Jersey, NJ). Aliquots of human PBMCs (105 cells in 100 µL/well) were stimulated for 16 h 
with graded concentrations (two-fold dilutions starting at 25 µg/mL) of test compounds. 
Supernatants were isolated by centrifugation, and were assayed in triplicates (from individual 
donors) using analyte-specific multiplexed cytokine/chemokine bead array assays (Milliplex 
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HCYTOMAG-60K, EMD Millipore, Billerica, MA) as reported by us previously 100. The analytes 
examined include: sCD40L, VEGF, TNF-, TNF-α, TGF-α, RANTES, PDGF-AB/BB, PDGF-
AA, MIP-1, MIP-1α, MDC (CCL22), MCP-3, MCP-1, IP-10, IL-17A, IL-15, IL-13, IL-12 (p70), 
IL-12 (p40), IL-10, IL-9, IL-8, IL-7, IL-6, IL-5, IL-4, IL-3, IL-2, IL-1ra, IL-1, IL-1α, IFN-γ, IFN-
α2, GRO, GM-CSF, G-CSF, Fractalkine, Flt-3 ligand, FGF-2, Eotaxin, EGF. 
 
Rabbit immunization and CRM197-specific immunoassays  
All experiments were performed at Harlan Laboratories (Indianapolis, IN) in accordance with 
institutional guidelines (Protocol Number: 150416HBS73DAYSTD). The Harlan IACUC 
Committee approved this study. Small bore needles (24-gauge) were used to minimize distress to 
the animals during intramuscular administration. Following termination of the study, animals were 
first anesthetized using ketamine (0.5 mL of 100 mg/mL for average 6 lb. rabbit) and xylazine (0.5 
mL of 20 mg/mL for average 6 lb. rabbit), and then euthanized by carbon dioxide inhalation. All 
antigen/adjuvant preparations were entirely aqueous; no liposomal or emulsifying agents were 
used. Cohorts of adult female New Zealand White rabbits (n = 4) were immunized intramuscularly 
in the flank region with (a) 10 µg of CRM197148 in 0.2 mL saline (unadjuvanted control), or (b) 
10 µg of CRM197 in 0.2 mL saline plus 100 µg of either AmpB or TLR agonist. Pre-immune test-
bleeds were first obtained via venipuncture of the marginal vein of the ear. Animals were 
immunized on Days 1, 15 and 28. A final test-bleed was performed via the marginal vein of the 
ear on Day 38. Sera were stored at −80 °C until used. CRM197-specific ELISAs were performed 
in 384-well format using automated liquid handling methods as described by us elsewhere 96. A 
Precision 2000 liquid handler (Bio-Tek, Winooski, VT) was used for all serial dilution and reagent 
addition steps, and a Bio-Tek ELx405 384-well plate washer was employed for plate washes. 
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Nunc-ImmunoMaxiSorp (384-well) plates were coated with 80 µL of CRM197 (10 µg/mL) in 100 
mM carbonate buffer, pH 9.0 overnight at 4 °C. After 3 washes in 100 mM phosphate-buffered 
saline (PBS) pH 7.4, containing 0.1% Tween-20, the plates were blocked with 3% bovine serum 
albumin (in PBS, pH 7.4) for 1 h at rt. Serum samples (in quadruplicate) were serially diluted in a 
separate 384-well plate using the liquid handler; 40 µL of the serum dilutions were transferred 
using the liquid handler, and the plate incubated at 37 °C for 1 h. The assay plate was washed three 
times, and 40 µl of 1: 10,000 diluted appropriate anti-rabbit immunoglobulin (IgG, γ-chain) 
conjugated with horseradish peroxidase was added to all wells. Following an incubation step at 37 
°C for 1 h, and three washes, tetramethylbenzidine substrate was added at concentrations 
recommended by vendor (Sigma). The chromogenic reaction was terminated at 30 min by the 
addition of 2M H2SO4. Plates were then read at 450 nm using a SpectraMax M2 device (Molecular 
Devices, Sunnyvale, CA). 
 




Transcriptomal Signatures of 
Innate Immune Stimuli and 
Accessory Immunostimulation 
of Fibroblasts by TLR2 Agonists 
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3.1 Introduction 
Following the success of high-throughput screening using transfected reporter cells (Chapter 2), 
we sought methods of better identifying and authenticating novel innate immune stimuli for 
examination as vaccine adjuvants. Given the enormous diversity of signals recognized by the 
TLRs, which are present both in the extracellular and intracellular compartments, and the potential 
for Th cell polarization by TLRs, we sought to address three questions: (i) are there any 
‘signatures’ that are diagnostic of innate immune activation, regardless of the innate immune 
sensor involved, (ii) which of the many TLR ligands that we have characterized induce strong 
humoral responses to subunit antigens, and (iii) the mechanistic basis for the superior adjuvantic 
activity of such ligands.  Whole transcriptome next-generation RNA sequencing of human 
peripheral blood mononuclear cells exposed to 23 compounds encompassing almost the entire 
repertoire of TLR ligands indicate prominent upregulation of CC and CXC chemokines, 
independent of the chemotype. In a standardized rabbit model of immunization with a diphtheria 
toxin mutein CRM197.148-149 we observed that TLR2 agonists outperformed all other TLR-active 
compounds. Non-hematopoietic cells such as fibroblasts express TLR2, and therefore respond 
uniquely to TLR2 stimuli, resulting in the induction of chemokines, and manifesting in the 
chemotaxis of several major human lymphocytic subsets. These results point to the utility of 
chemokine induction as a ‘signature’ of adjuvantic activity, and provides mechanistic insight into 
the potential utility of harnessing TLR2 agonists as vaccine adjuvants. 
 
3.2 Results and Discussion 
A main goal of this work was to examine if there are any transcriptional signatures common to the 
broad range of TLR/NLR-active compounds that we have evaluated as vaccine adjuvants. These 
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compounds are shown in Fig. 1, and include both canonical and novel small-molecule agonists of 
TLR2 (PAM2CSK4, PAM3CSK4, DBS-2-217C, and lipoteichoic acid), TLR3/MDA5 (Poly I:C), 
TLR4 (LPS from E. coli, MPLA), TLR5/NLRC4 (flagellin), TLR7 (C4, CL307, EY-2-40), TLR8 
(KHP-3-126, MB-569, MB-152), dual TLR7/TLR8 (XG-2-136, Meta-amine and IMDQ), TLR9 
(ODNs 2006, 2216, 2395, and C274), NOD1 (C12-iE-DAP) and NOD2 (Murabutide). We had 
previously characterized the transcriptional responses to a small subset of innate immune 
stimulatory compounds using microarrays.150  
 
Figure 1. Structures of TLR agonists arranged by receptor target. TLR2 agonists are shown in 
blue, pure TLR7 agonists are shown in maroon, dual TLR7/8 agonists are shown in red, and pure 
TLR8 agonists are shown in magenta. 
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In this study, we utilized next-generation sequencing of total RNA isolated from human PBMCs 
stimulated with for 3.5 h with 1 µg/mL of each of the agonists to assess early transcriptional 
responses. A total of 26,363 annotated genes for each of the 23 test samples were compared in 
duplicate against unstimulated (or vehicle-alone, mock-stimulated) control samples.  
 
As we had previously reported, diagnostic transcriptional signatures such as proinflammatory 
cytokine (TLR4), interferon, and interferon-inducible genes (TLR7) were strongly upregulated in 


















































































Figure 2. All TLR and NLR agonists upregulate genes associated primarily with three gene 
families. Root mean square deviations of fold change highlight the upregulation of three gene 
families: CC chemokines (red), CXC chemokines (red), and interferons (blue). Genes that were 
upregulated outside of these families are shown in green. 
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the samples. In order to discern global signatures in an unbiased manner, we compared root mean 
square deviations of fold change (from control values) in expression of each of the genes across 
the 24 test samples (Fig. 2). We observed pronounced deviations in three gene families: the CXC 
and CC chemokines, and Type I interferons (Fig. 2); additionally, we noted significant change in 
a subset of genes including TNFSF15 (TNF superfamily ligand, member 15), TFPI2 (tissue factor 
pathway inhibitor 2), RSAD2 (radical S-adenosyl methionine domain containing 2), PDGFRL 
(platelet derived growth factor receptor like), LEP (leptin), IL6 (interleukin-6), IL12B (interleukin-
12B), IL1A (interleukin-1α) IL36G (interleukin-36γ), IRG1 (immunoresponsive gene 1), INHBA 
(inhibin beta A subunit), IFIT1 (interferon induced protein with tetratricopeptide repeats 1), 
DNAAF1 (dynein axonemal assembly factor 1), DEFB1 (defensin β-1), CFB (complement factor 
B), and LOC100506178 (uncharacterized).  
 
We next quantified changes in the CC and CXC chemokines, as well as IFN genes for each of the 
agonists. Strong signals for the CC chemokines 1, 2, 3, 4, 7, 8, 17, 18, 20, and 23 were observed 
for TLR2, TLR3, TLR4, TLR5, TLR7, TLR7/8, TLR8, NOD1, and NOD2 agonists (Fig. 3). The 
signals for TLR9 were significantly weaker, likely on account of the oligonucleotides requiring 















































































































































































































Figure 3. ‘Signatures’ of innate immune stimulation in CC chemokines. Many of the TLRs 

































































































































Figure 4. Discrimination between extracellular and intracellular innate immune receptors by 
CXC chemokine profiles. The extracellular TLRs 2, 4, and 5 showed strong upregulation of 
CXCL5, CXCL6 and CXCL8, while the endolyososomal TLRs 3, 7, and 8 were characterized by 
upregulation of CXCL11 and CXCL12. 
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A clear demarcation of extracellular versus intracellular TLR/NLR activation was apparent in the 
analysis of gene expression levels for the CXC chemokines. The engagement of the extracellular 
TLRs 2, 4, and 5 resulted in strong upregulation of CXCL5, CXCL6 and CXCL8 genes. In 
contrast, stimulation of the intracellular receptors TLR3, 7, and 8 manifested in upregulation of 
CXCL11 and CXCL12 (Fig. 4). Signals for CXCL1, CXCL2, and CXCL3 were also observed to 
be strongly enhanced but, like the CC chemokines, were found to be common for almost all 
agonists (Fig. 4). Interferon-α responses, as expected were almost exclusively restricted to TLR7 
(and TLR7/8 activation), and it is noteworthy that interferon-ω signals were also evoked by TLR7 

















































































































































Figure 5. TLR7 upregulation of IFN-α and IFN-ω. Pure TLR7 and dual TLR7/8 agonists 
dramatically upregulated all IFN-α genes and IFN-ω. 
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These data point to the potential utility of chemokine readouts as surrogate markers of innate 
immune activation, irrespective of the nature of stimulation. Indeed, both alum,151-152 as well as 
MF59, a squalene-in-water emulsion containing the surfactants polysorbate 80 and sorbitan 
trioleate153-154 are FDA-approved vaccine adjuvants that do not activate any of the TLRs, but 
induce chemokine secretion in hematopoietic cells.155 
 
We next compared the adjuvantic activity of the various classes of TLR agonists in a standardized 
























































































































































































Figure 6. TLR agonists in rank order of adjuvantic potency in a rabbit immunization model, 
organized by target receptor. TLR agonists were compared head-to-head in a standardized 
rabbit immunization model with CRM197 as antigen. TLR2 agonists are shown in blue, TLR7 
agonists are shown in maroon, dual TLR7/8 agonists are shown in red, pure TLR8 agonists are 
shown in magenta, and TLR9 agonists are shown in green. 
TLR2 TLR7 TLR7/8 TLR8 TLR9 
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full human dose of Infanrix® was used as a comparator (Fig. 6).  Animals (n=4/cohort) received 
two boosts following a priming dose, spaced 15 days apart. As anticipated,  the potent dual TLR7/8 
agonists IMDQ and meta-amine,92 were found to possess prominent adjuvantic activity (Fig. 6). 
Somewhat unexpectedly, we observed that almost all of the TLR2 agonists were also strongly 
adjuvantic, with the adjuvantic potency correlating with in vitro potency: (R)-PAM2CSK4 > (RS)-
PAM2CSK4 > (S)-PAM2CSK4
89; the mono-acyl DBS-2-217C is human TLR2-specific agonist,156 
and therefore, as expected found to be weaker (Fig. 6).  
 
We sought to understand why TLR2-active compounds displayed strong adjuvantic activity. 
Transcriptomal profiling (Figs. 3 and 4) pointed to strong CXCL and CCL chemokine induction 
which we confirmed in human PBMCs (data not shown). However, it has been suggested that 
adventitial cells such as fibroblasts have immunoregulatory functions, and should therefore be 
considered as sentinel cells.157-158  Human fibroblasts from disparate anatomical sites have been 
shown to synthesize CC and CXC chemokines.159-164 Using multiplexed cytokine and chemokine 
assays, we initially examined the effect of almost the entire set of TLR agonists on cytokine and 
chemokine secretion in human foreskin fibroblasts (HFFs) and in human bronchial 
adenocarcinoma A549 cells, and found that, in both cell lines, the TLR2-active compounds 
PAM2CSK4 and DBS-2-217C induced both CC and CXC chemokines, including CXCL6/GCP2, 
CCL20/MIP-3α, CCL8/IL-8, CCL2/MCP-1 and MCP-3/CCL7; shown in Fig 7A is the dose-
dependent induction of CXCL6, CCL20 and CCL8 in HFFs.  



















































































































Figure 7. TLR2 agonists induce chemokines in human foreskin fibroblasts. A. TLR2 agonists 
were screened for activity in HFFs using multiplexed cytokine (MagPix™) assays and showed 
CXCL6, CCL20 and CCL8 induction. B. CCL20 and CXCL6 induction by TLR2 agonists in 
HFFs were confirmed by ELISA. The TLR2/6 agonist Pam2CSK4 induced chemokine responses 
in HFFs, but the TLR1/2 agonists Pam3CSK4 failed to induce chemokine responses in HFFs. 
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Seeking to confirm the data using alternative immunoassay platforms, we extended the range of 
TLR2 agonists. We noted an unexpected selectivity in that only the diacyl and monoacyl TLR2/6 
agonists PAM2CSK4 and DBS-2-217C, but not the triacyl TLR1/2 agonist PAM3CSK4,
165-166 
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M rg  D  I    x  F uor 488 
Figure 8. TLR2 and TLR6 are expressed in human foreskin fibroblasts. HFFs stained for TLRs 
1, 2, and 6 were signal amplified using tyramide signal amplification. HFFs showed strong 
staining for TLR2 and TLR6, but stain very weakly for TLR1. 
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cells responded to TLR1/2 and TLR2/6 agonists (data not shown). In human airway epithelium, 
for example, TLR1 expression has been observed preferentially on the luminal surface of the 
tracheal epithelium, while TLR2 and TLR6 appear to be distributed predominantly on basolateral 
surfaces.167 We hypothesized that the apparent selectivity could be a consequence of differential 






























































































 CD56+ NK Cells
Compound Concentration (g/mL)
Figure 9. PBMC chemotactic responses to TLR2/6- stimulated human foreskin fibroblasts. 
TLR2/6 stimulated HFFs produced functional chemotactic responses from lymphocytic 
populations. The TLR1/2 agonist failed to induce chemotaxis. 
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in fibroblasts, employing tyramide signal amplification168-169 for enhancing sensitivity of 
detection. We observed strong expression in fibroblasts of TLR2 and TLR6, but very faint levels 
of TLR1 (Fig. 8), which is consistent with responses elicited by the TLR2/6 agonists PAM2CSK4 
and DBS-2-217C, and not by the TLR1/2 agonist PAM3CSK4. 
 
In order to verify that TLR2/6 occupancy and the consequent secretion of CC and CXC 
chemokines in fibroblasts have functional outcomes, we measured the chemotaxis of human 
PBMCs toward fibroblasts stimulated with TLR2/6 and TLR1/2 ligands. Human SDF-1 was used 
as a positive control in these experiments. We observed dose-dependent migration of PBMCs 
toward fibroblasts stimulated with TLR2/6, but not TLR1/2 ligands (Fig. 9).  
 
Flow cytometric assessment of absolute counts of migrated PBMCs showed that T lymphocytic 
subsets (CD4+ Th cells, CD8+ CTLs, and CD3+ CD56+ cytokine-induced killer cells), but not B 
lymphocytes (CD19+) underwent chemotaxis (Fig. 9). The induction of chemotactic gradients by 
adventital cells and consequent migration of immune cells to the site of injection may likely 
contribute to the strong adjuvantic properties of TLR2/6 agonists. 
 
3.3 Conclusions 
A dominant CC chemokine signature (CC chemokines 1, 2, 3, 4, 7, 8, 17, 18, 20, and 23) appears 
to be a common transcriptional outcome of virtually all immunostimulatory classes of molecules, 
whereas the CXC chemokine patterns allow for the distinction of extracellular (CXCL5, CXCL6 
and CXCL8) vis-à-vis intracellular (CXL11 and CXCL12) TLR/NLR activation.  These findings 
are likely to be useful both in prospectively examining novel compounds for adjuvantic activity, 
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and in understanding structure-activity relationships in such molecules. TLR2/6 agonists 
distinguish themselves in being able to activate adventitial cells such as fibroblasts; local secretion 
of chemokines at the site of immunization, and consequent chemotaxis of immune-competent cells 
to areas where the local concentrations of immunogens are expected to be initially high likely 
contribute to the potent adjuvantic properties in these compounds.  
 
3.4 Materials and Methods 
Reagents 
The following TLR ligands: PAM2CSK4, PAM3CSK4, lipoteichoic acid (LTA), LPS from P. 
gingivalis and E. coli 055:B4, Poly (I:C) (high molecular weight), flagellin, CL307, ODN2216, 
ODN2006, and ODN2395 were purchased (InvivoGen, San Diego, CA). The TLR agonists DBS-
2-217C,156 C4, IMDQ, Meta-amine,91 EY-2-40,111 XG-1-236,97 MB-564, MB-569,113 MB-152,100 
and KHP-3-126112 were synthesized using the routes previously described by us. C274170 was 
graciously provided by Dynavax Technologies (Berkeley, CA).  
 
Culture of human blood and cell lines 
Whole human blood was collected in heparinized vacutainers, and PBMCs were collected and 
isolated in CPT Vacutainers™ (Becton Dickinson, Franklin Lakes, NJ) from healthy volunteers 
providing written informed consent in accordance with the University of Minnesota Institutional 
Review Board approved protocol (IRB Protocol 1506M74641). PBMCs were cultured in RPMI 
1640 supplemented with 10% fetal bovine serum, 2 mM penicillin, and 50 µg/mL streptomycin 
(complete RPMI). Human foreskin fibroblasts (HFFs, ATCC Catalog No. SCRC-1041) were 
cultured in DMEM supplemented with 10% fetal bovine serum, 2 mM penicillin, and 50 µg/mL 
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streptomycin (complete DMEM). Cells were cultured in 96-well plates at 37ºC for 3.5-16 h as 
indicated for that experiment. 
 
Adjuvanticity studies in rabbits 
All immunizations were performed in accordance with University of Minnesota IACUC guidelines 
(Protocol 1601-33398A) by Envigo (Huntington, UK). Cohorts of 4 female New Zealand white 
rabbits were immunized intramuscularly in the flank with 10 µg antigen (diphtheria toxin mutant 
CRM197, List Biological Laboratories, Campbell, CA)147-148 and 100 µg adjuvant in 0.2 mL saline, 
or antigen alone as published previously by us 171. Prebleeds were collected for each animal from 
the marginal vein in the ear. Immunizations were carried out on days 1, 15, and 28 with blood 
collections on days 25 and 38. Sera was isolated immediately following blood collection and stored 
at -80ºC until utilized. CRM197-specific antibody titers were evaluated by ELISA as previously 
reported by us.171  
 
Next-generation sequencing of PBMCs 
PBMCs were stimulated in 96-well plates for 3.5 h with 1 µg/mL TLR/NLR agonist. Total RNA 
was isolated using RNeasy 96 kits according to the manufacturer’s instructions (Qiagen, Hilden, 
Germany). Samples were stored in RNase free 96-well PCR plates at -80ºC until used. RNA 
quality and concentration were determined using Agilent RNA 6000 Nano Kits (Agilent 
Technologies, Santa Clara, CA) and libraries were generated using Clontech SMARTer Standards 
Total-RNA Pico Kits (Clontech Laboratories, Inc., Mountain View, CA). Libraries contained 
inserts of approximately 200 base pairs and averaged quality scores over Q30. Individual TruSeq 
libraries were pooled into 2 and sequenced across 3 lanes. Next-generation sequencing was carried 
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out by the University of Minnesota Genomics Center using a HiSeq 2500 (Illumina, San Diego, 
CA) in high output mode for 13 x 106 reads per sample for 50 base pair paired ends using v4 
chemistry. Data were calculated as fold change over unstimulated control samples using the EDGE 
test.172-173 RNA Seq data is available at the Sequence Read Archive (BioProject ID: 
PRJNA390780; http://www.ncbi.nlm.nih.gov/bioproject/390780). 
 
Multiplexed cytokine analysis in PBMCs and HFFs 
Cytokine and chemokine responses PBMC and HFF were measured using methods previously 
reported by us113, 174-175 with the following Milliplex kits: HCYTMAG-60K-PX41, HCYPMAG-
63K, and HCYP2MAG-62K (EMD Millipore, Billerica MA). PBMCs or HFFs were seeded at a 
density of 105 cells per well and stimulated for 16 h with graded concentrations of stimuli or mock-
stimulated with vehicle (DMSO). Supernatants were collected by Precision 2000 liquid handlers 
(Bio-Tek, Winooski, VT) and diluted 1:3 for each kit. The data was acquired on a MagPix® 
instrument and the data analyzed using Milliplex Analyst (EMD Millipore, Billerica MA). 
 
ELISAs for HFF chemokine secretion 
HFFs were cultured in 96-well plates at 105 cells per well in complete DMEM with graded 
concentrations of TLR ligands for 16 h at 37ºC. Plates were centrifuged to collect supernatants. 
Supernatants were diluted 1:5 for CXCL6 ELISAs (Abcam, Cambridge, MA., Catalog number 
AB155431) and 1:2 for CCL20 ELISAs (Abcam, Cambridge, MA., Catalog number AB100599). 
The manufacturer’s procedures were followed for both types of ELISA and acquired on a 
SpectraMax M2 (Molecular Devices, Sunnyvale, CA). Concentrations were quantified from four-
parameter logistic fits of standard curves for each analyte.  
 49  
Imaging for TLR1, -2, and -6 in HFFs 
HFFs were plated at 104 per well in a tissue culture-treated 96-well plate and incubated overnight. 
Each well was washed 3 times in PBS and then fixed for 10 min at room temperature in 4% 
paraformaldehyde followed by blocking with 10% goat serum in PBS (recommended blocking 
buffer for the Tyramide Superboost kit described below) for 1 h at room temperature. Polyclonal 
anti-TLR1, -2, and -6 antibodies (Abcam, Cambridge, MA., Catalog numbers AB189337, 
AB191458, AB37072, respectively) were utilized at 1:100 dilutions in 100 µL blocking buffer to 
stain cells for 1 h at room temperature, followed by 1 h of incubation with goat-anti-rabbit-HRP 
antibody conjugate. Tyramide signal amplification was carried out for 5 min according to the 
Tyramide SuperBoost kit’s manufacturer (Invitrogen, Carlsbad, CA., Catalog number B40922). 
Samples were counterstained with 100 ng of DAPI and imaged at the University of Minnesota 
Imaging Center using a Nikon A1R confocal microscope with a 60X water immersion objective 
with a numerical aperture of 1.20. 
 
PBMC Chemotaxis with HFFs 
HFFs were plated at 106 per well in an IncuCyte ClearView 96-well reservoir plate (Essen 
Bioscience, Ann Arbor, MI) in complete DMEM and cultured for 16 hours. Following incubation, 
the cells were stimulated with graded concentrations of TLR agonists for 24 h. An IncuCyte 
ClearView chemotaxis plate was coated with 0.5 mg/mL Matrigel (Corning Life Sciences, 
Corning, NY., Catalog number 354248) in complete RPMI on ice. Matrigel polymerization was 
carried out for 30 minutes at 37ºC, and then the chemotaxis plate was cooled to room temperature 
for 1 h. PBMCs were plated in 60 µL of complete RPMI in the top well of the chemotaxis plate. 
The top of the chemotaxis plate was placed on the reservoir plate containing HFFs and cultured 
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for 16 h at 37ºC. After the incubation, the bottom reservoir plate was stained with CD3-PE and 
CD56-APC (eBioscience, San Diego, CA., Catalog numbers 12-0037-42 and 17-0566-42, 
respectively), CD4-V450, CD8-V500, CD14-FITC, and CD19-PE-Cy7 (Becton Dickinson, 
Franklin Lakes, NJ., Catalog numbers 560345, 560774, 555397, 557835, respectively). 
Erythrocytes were lysed and leukocytes fixed by transferring 200 µL of PBMCs to 800 µL of warm 
Lyse/Fix buffer (Becton Dickinson, Franklin Lakes, NJ) in a 96-deep well plate by liquid handler 
for 10 min at 37ºC. The fixing process was carried out one additional time before washing with 
800 µL complete RPMI. Samples were resuspended in 200 µL of complete RPMI, and acquired 
on a FACSVerse flow cytometer (Becton Dickinson, Franklin Lakes, NJ) for 250,000 gated events.  
Absolute counts were recorded by an inline flow sensor for lymphocytes (FSC, SSC), T cells 
(CD3+ CD56-), Th cells CD3+ CD4+ CD8- CD56-), CTLs (CD3+ CD4- CD8+ CD56-), NK cells 
(CD3- CD56+), B cells (CD3- CD19+ CD56-), cytokine-induced killer cells (CIK) (CD3+ CD56+), 
and monocytes (CD14+). 
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Chapter 4. 
 
Protective Responses against 
Mycobacterium tuberculosis 
Induced by ESAT-6 
Immunization with a Toll-like 
Receptor 2/7 Hybrid Agonist 
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4.1 Introduction 
Tuberculosis (TB) is one of the most prevalent infections worldwide, with an estimated one-third 
of the world’s population infected and 1.3 million TB-related deaths per year.176 The threat posed 
by TB has been compounded in recent years by the emergence of multidrug-resistant tuberculosis 
for which few promising candidate drugs have been identified in the development pipeline.177 As 
with the majority of transmissible infectious diseases, vaccination may be a cost-effective and 
practical strategy to reduce the global burden of TB.  
 
The live attenuated M. bovis-derived Bacille Calmette-Guérin (BCG) is the only currently 
approved vaccine for TB. While BCG was shown to be effective in preventing up to 70% of miliary 
TB and TB meningitis when administered within several days of birth,178 the efficacy of BCG 
appears to be highly variable in preventing pulmonary TB in adult populations, with clinical trials 
ranging from 0-80% success.179-182 The limitations of the BCG vaccine and a renewed need for 
vaccines providing durable protection against pulmonary disease have spurred the exploration of 
new vaccine constructs, many of which are subunit vaccines.176 As mentioned in Chapter 1, 
modern subunit vaccines utilize highly purified immunogens of defined composition, facilitating 
the ease of production and quality control. However, such immunogens are often poorly 
immunogenic and fail to induce strong, protective memory responses, necessitating the inclusion 
of vaccine adjuvants to induce robust, long-lived immunological memory.183-185   
 
Despite the widespread use of BCG in developing countries aimed at reducing the burden of extra-
pulmonary disease, the correlates of protection for TB in humans are poorly understood.186-187 It 
is believed that TB-specific CD4+ T helper cell-mediated immune responses (Th1),188-189 and not 
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antibody-mediated humoral immunity is essential for the control of TB. There is, however, 
evidence that TB directly engages TLR2190 which, as was discussed previously (Chapter 3), is still 
under investigation to determine the nature of T cell polarization (Th1 or Th2), and could 
potentially result in Th2 polarization during natural infections.191  
 
We hypothesized that mimicking the TLR2 engagement observed for TB, and additionally 
enhancing the immunostimulation by the addition of Th1-biasing TLR7/8 agonist, could yield a 
hybrid poly-TLR vaccine adjuvant for TB possessing TLR2/7/8 activity. Furthermore, of the 
several hundred compounds that we have examined to date, we have found that TLR2 agonists,87-
88, 192-193 as well as TLR7/8 agonists,39, 91, 93, 96-97, 194-195 were highly potent in immunogenicity 
screens in rabbits. We therefore elected to focus on ‘hybrids’ of TLR2 and TLR7 agonists. Proof-
of-concept studies with such a TLR2/7 hybrid molecule indicated potent adjuvantic activity. 
Epitope mapping experiments showed that the hybrid adjuvant induced immunoreactivity to more 
contiguous peptide epitopes in a model antigen.  Immunization of mice with the M. tuberculosis 
antigen ESAT-6 adjuvanted with a water-soluble analogue of the hybrid elicited reductions in 
pulmonary mycobacterial loads.  
 
4.2 Results and Discussion 
Poly-TLR adjuvants have been explored recently in studies which showed that combining a TRIF-
biased TLR4 agonist (MPLA)196 and a TLR7 agonist (imidazoquinoline) enhanced antibody and 
T cell responses.197 Concurrent engagement of a TRIF-coupled TLR in combination with an 
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endosomal TLR appears to be pivotal in synergistically upregulating IL-12p70 production in 
dendritic cells; this synergy is lost when the two individual stimuli are delivered 24 hours apart.198 
These and other studies199-201 suggest that particular combinations of TLR agonists are more 
effective than others and, importantly, highlight the need for efficient, simultaneous delivery of 
the individual innate immune stimuli to the antigen-presenting cell.  
 
Recently, Gutjahr and coworkers demonstrated synergistic activity using a covalently linked TLR2 
and TLR7 agonists.202 We therefore set out to build upon the studies of poly-TLRs conducted by 
other groups,199-201 and we selected a best-in-class imidazoquinoline (compound 1, IMDQ), which 
possess potent TLR7/8 activity, and the TLR2 agonist PAM2CS (compound 6) to covalently link 
together and form a hybrid poly-TLR agonist, as is shown in Scheme 1).    
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Initially, a Boc-protected polyoxyethylene linker with a free carboxylic acid was appended to the 
benzylic amine of IMDQ using an amide-bond coupling reagent HBTU. Following Boc-
deprotection, the resulting primary amine was reacted sequentially with carbon disulfide and di-
tert-butyl dicarbonate in the presence of catalytic amounts of DMAP to yield the isothiocyanate 
compound 5. Compound 5 was directly reacted with PAM2CS under mildly basic conditions to 
yield compound 7 (Hybrid-1). The water soluble analog Hybrid-2 was synthesized from compound 
5 and a tris-Boc-protected trilysine analog of PAM2CS (synthesized as shown in Scheme 2) under 
identical conditions, involving an additional mild Boc-deprotection protocol using Tin(II) choride 
(synthesis was conducted by Dr. Nikunj Shukla). 
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Following the successful conjugation of IMDQ and PAM2CS, we examined the TLR activity 
profiles of Hybrid-1 and Hybrid-2 in human-specific TLR reporter cell lines to ensure that there 
was retention of TLR2 and TLR7 activity. The TLR2-active PAM2CS has an EC50 (half-maximal 
effective concentration) of 1 nM in TLR2 reporter cells, and IMDQ exhibits EC50 values of 10 nM 


































































Figure 1. TLR activity profile of Hybrid-1 in human-specific TLR reporter assays. Hybrid-1 
and Hybrid-2 were active in TLR2- and TLR7-specific human TLR reporter cells, but with a loss 
of potency at both targets relative to the parent compounds, IMDQ and PAM
2
CS. All activity was 
lost in TLR8 for both hybrids. Mean and standard deviations of quadruplicates are shown. 
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in TLR2 and TLR7, but with reduced potencies of 100 nM and 10 μM, respectively; Hybrid-2 was 
slightly less potent than Hybrid-1 with potencies of 300 nM and 20 µM in TLR2 and TLR7, 
respectively. The losses in activity at TLR2 and TLR7 for the hybrid compounds could be derived 
from the substantial increases in the size of the molecules resulting in reduced membrane 
permeability and possible steric hindrance at the receptors. Previously, we had shown that the 
benzylic amine of IMDQ was required for TLR8 activity92 and, as expected, utilizing  this amine 
of IMDQ for the conjugation to the TLR2 agonists resulted in the complete loss of all TLR8 
activity in the conjugates (Fig. 1).  
 
IMDQ and PAM2CS were previously shown to be potent adjuvants individually during the course 
of their respective structure-activity relationship studies, but the TLR agonists were not evaluated 
during those studies in combination for synergistic adjuvanticity. We therefore examined the TLR 
agonists individually and in combination for adjuvanticity in a standardized rabbit immunization 
model. Each cohort of rabbits was primed and boosted twice at 15 day intervals with 10 μg of 
bovine α-lactalbumin antigen and 100 μg of adjuvant. As we anticipated, IMDQ and PAM2CS 
both elicited high anti-α-lactalbumin-specific IgG titers individually (Fig. 2A). A 1:1 mixture of 
IMDQ and PAM2CS also resulted in high antibody titers, but with more variability than the 
individual TLR agonists. Hybrid-1 was equipotent to either of the individual TLR agonists with 
respect to humoral responses, but showed increased variability similar to the mixture of IMDQ 
and PAM2CS (Fig. 2A).  
 
We were not able to determine clear differences between the various TLR agonists by only 
examining α-lactalbumin-specific antibody titers (Fig. 2A), so we examined the quality of the 
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antibodies generated by each adjuvant using surface plasmon resonance (SPR). The protein antigen 
α-lactalbumin was immobilized on the chip and the various immune sera were washed over the 
immobilized antigen. Dissociation ratios were calculated from the ratio of the responses at 15 
seconds and 500 seconds. Sera from Hybrid-1 yielded high dissociation ratios and sensorgram 


























































































































Figure 2. Hybrid-1 induced strong humoral responses in rabbits immunized with α-
lactalbumin. A. Cohorts of 3 rabbits were primed and boosted twice at 15 day intervals with 10 
µg/dose of bovine α-lactalbumin and 100 µg/dose adjuvant. Sera was isolated from the rabbits 
prior to immunization (Pre-immune) and on day 38 (Immune 2). IMDQ, PAM
2
CS, and Hybrid-
1, along with the mixture of IMDQ and PAM
2
CS, were equally adjuvantic at 100 µg/dose in 
rabbits. B. Bovine α-lactalbumin was immobilized on SPR chips to determine the quality of the 
Immune 2 sera elicited by the various TLR agonists. Evaluation of the antibody quality revealed 
that Hybrid-1 induced high quality antibodies to bovine α-lactalbumin with high dissociation 
ratios and sensorgram responses. Mean and standard deviations of the three rabbits in each 
cohort are shown.  
A B 
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antibodies of intermediate quality relative to Hybrid-1 with high dissociation ratios, but lower 
sensorgram responses, while PAM2CS resulted in antibodies with the lowest dissociation ratios 
and sensorgram responses. Hybrid-1 appeared to drive the highest quality of antibody to the model 
antigen α-lactalbumin.  
 
We continued to examine the antibodies generated against α-lactalbumin by the TLR2/7 hybrid 
against the mixture of IMDQ and PAM2CS by conducting linear epitope mapping of the immune 
sera. Thirteen-mer peptides with overlaps of 12 amino acids covering the entire sequence of α-
lactalbumin were printed in duplicate on chips. Alternating Flag and hemagglutinin control 
peptides were printed in a boarder surrounding the α-lactalbumin peptides. Chips were then 
incubated with immune sera followed by fluorescent secondary antibodies to evaluate linear 
epitopes to α-lactalbumin. Five representative fluorescence images are shown in Fig. 3A, with 
control Fusion Tag (Flag, DYKDDDDKGG) peptides in green and hemagglutinin peptides 
(YPYDVPDYAG) in red bordering the peptide arrays. Sera from rabbits immunized with α-
lactalbumin alone failed to show any signals above baseline, while sera from all cohorts adjuvanted 
with Hybrid-1 or IMDQ and PAM2CS, either individually, or in combination, recognized linear 
peptide epitopes (Fig. 3A). A comparison of Hybrid-1 adjuvanted samples with the mixture of 
IMDQ and PAM2CS revealed that Hybrid-1 induced immunoreactivity to more contiguous 
epitopes of α-lactalbumin, with epitope spreading observed through amino acids 50-58 and 62-75 
relative to sera from rabbits adjuvanted with the IMDQ and PAM2CS mixture (Fig. 3B). The 
induction of epitope spreading by vaccine adjuvants has been shown to be important in eliciting 
cross-protective responses to viruses, such as influenza and the human papillomavirus.203-204 
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Epitope spreading has also been observed in M. tuberculosis antigens,205 but remains of unknown 
value for TB vaccines, as there have been no successful subunit vaccines approved for TB.  
 
The high quality of the antibodies generated with the TLR2/7 hybrid molecule (Fig. 2) and the 
exposure of cryptic epitopes (Fig. 3) pointed to the potential superiority of the covalently linked 
TLR stimuli at inducing humor responses. One possibility for the superior humoral responses 
elicited by the covalently linked TLR2/7 hybrid over the mixture of TLR ligands is direct 
Figure 3. Hybrid-1 induced linear epitope spreading. A. 13-mer overlapping peptides covering 
the full sequence of α-lactalbumin were printed on chips in duplicates with boarders of Flag and 
hemagglutinin peptides as controls. Immune Sera from the 3 rabbits in each cohort was 
incubated with the chips. Green and red fluorescent borders for each chip represent control Flag 
peptide and hemagglutinin peptide, respectively. Representative raw fluorescence images are 
shown for sera from IMDQ, PAM
2
CS, Hybrid-1, mixtures of IMDQ and PAM
2
CS, and 
unadjuvanted control immunized rabbits. B. Rabbits immunized with α-lactalbumin reacted to 
more linear epitopes when adjuvanted with Hybrid-1 compared to any of the other cohorts. 
Representative data from 1 rabbit immunized with Hybrid-1, and 1 rabbit immunized with the 
mixture of IMDQ and PAM
2
CS are shown. 
A B 
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activation of both TLR2 and TLR7 within the same cell. While TLR2 and TLR7 possess distinct 
localization patterns on the plasma membrane and within endosomes, respectively,206 there is 
growing evidence of  TLR2 internalization and trafficking to endosomes following ligation.207-209  
Given the superior activity of the TLR2/7 hybrids at eliciting humoral responses in rabbits using a 
model antigen, we sought to evaluate their potential as vaccine adjuvants using models more 
relevant to M. tuberculosis. MPLA formulated in dimethyldioctadecyl-ammonium bromide 
(DDA) liposomes was previously shown to induce protective adaptive immune responses when 
administered as an adjuvant with the secreted M. tuberculosis antigens ESAT-6 and Antigen-
85.210-213 Furthermore, previous work by others revealed the immunostimulation derived from this 
adjuvantic formulation induced balanced Th1/Th2 responses.212-213 With this in mind, we aimed 
to determine if our TLR2/7 hybrid was able to mimic the immunostimulatory profile of the MPLA 
DDA liposome formulation, and ultimately induce protective responses to M. tuberculosis. 
Cohorts of three C57BL/6 mice were immunized three times at two-week intervals with 10 μg of 
ESAT-6 as antigen and 20 μg of adjuvant, which was found to be optimal from pilot experiments 
conducted by the lab of Dr. Marc Jenkins (data not shown). MPLA formulated in DDA liposomes 
was used as a reference control. We selected the water-soluble Hybrid-2 for these studies to 
eliminate potential confounding effects of AddaVax, which Hybrid-1 had to be formulated in.  
 
Four weeks following the final immunization the axillary lymph nodes and spleens were harvested 
for ESAT-6-specific tetramer enrichment of T helper cells. Singlet cells were selected by FSC-
A/FSC-W and SSC-A/SSC-W and, from the singlet cells, effector memory T helper cells were 
further defined as CD90.2+ CD4+ CD44+. ESAT-6-specific effector memory T cells were 
identified by tetramer staining and categorized as T regulatory (Treg), Th1, Th17, and T follicular  
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Figure 4. ESAT-6-
specific T cell 
analysis of 
polarization. A. 
Mice (n = 3 per 
cohort) were 
primed and 
boosted twice at 
two week intervals 
with 10 µg/dose of 
ESAT-6 antigen 
and 20 µg/dose 
adjuvant. Mice 
were sacrificed four 
weeks following the 
final immunization 
and the spleen and 
lymph nodes were 
harvested to 
examine ESAT-6-
specific T cell 
populations. Singlet 




memory T helper 








. ESAT-6-specific effector memory T cells were identified by tetramer staining and 
categorized as T regulatory (Treg), Th1, Th17, and T follicular helper (Tfh) ce lls based on the 
expression of FoxP3, T-bet, RORγt, and Bcl-6, respectively. B. None of the adjuvants examined 
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helper (Tfh) cells based on the expression of FoxP3, T-bet, RORγt, and Bcl-6, respectively (Fig. 
4A). However, our efforts to gain insight into ESAT-6-specific T cells were hampered by small 
cohort sizes, and we were not able to observe statistically significant differences between the 
cohorts in any of the cell populations (Fig. 4B).   
 
In parallel to the T cell analysis, we attempted to examine immune sera collected from the mice 
immunized above to examine ESAT-6-specific antibody isotypes for characterization of the 
Th1/Th2 polarization induced by the various TLR agonists. IgG1, IgG2a, IgG2b, IgG3, and IgM 
ESAT-6-specific titers were evaluated by ELISA. While there appeared to be distinctions between 
the Th2-driven IgG1 titers,214 and the Th1-driven IgG2a and IgG2b titers,215 the small cohort size 
Figure 5. ESAT-6-specific antibody isotypes. Blood was collected by cardiac puncture from the 
mice immunized with ESAT-6 and various adjuvants mentioned above, and was analyzed by 
ELISA for ESAT-6-specific antibody isotypes. The same limited cohort sizes and animal variability 
resulted in non-significant data. 
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and variability between the individual mice within the cohorts resulted in data that failed to reach 



































































































Figure 6. Functional responses in mice immunized with ESAT-6. Mice (n = 10 per cohort) were 
primed and boosted twice at two week intervals with 10 µg/dose of ESAT-6 antigen and 20 µg/dose 
adjuvant. A. Five mice from each cohort were sacrificed four weeks following the final boost. 
Lungs, spleen, and lymph nodes were harvested to examine ESAT-6-specific T cells in the tissues 
by ELISpot. MPLA DDA liposomes and Hybrid-2 both induced significant numbers of ESAT-6-
specific IFN-γ SFUs in the lungs of mice. B. The remaining five mice per cohort were infected with 
approximately 100 bacilli of M. tuberculosis H37Rv each by aerosol. Four weeks following 
challenge, the mice were sacrificed and the lungs and spleens were analyzed for colony forming 
units (CFUs) of M. tuberculosis. BCG, MPLA DDA liposomes, and Hybrid-2 all reduced 
mycobacterial loads in the lungs of the mice. BCG and MPLA DDA liposomes additionally reduced 
CFUs in the spleen of the mice. IMDQ failed to show any reduction in mycobacterial loads. Mean 
and standard deviations are shown for each of the 5 mice. (* P<0.05) 
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While we were unable to gain insight into ESAT-6-specific cellular and humoral immunity, 
because of small sample sizes, we opted to examine functional responses of Hybrid-2-adjuvanted 
ESAT-6 immunizations in a TB challenge study in collaboration with Dr. Angelo Izzo. Mice were 
immunized with 10 μg ESAT-6 and 20 μg adjuvant three times at two-week intervals. Four weeks 
following the final immunization the mice were either sacrificed to examine ESAT-6-specific IFN-
γ spot-forming units (SFU) in lungs, spleen, and lymph nodes, or were challenged with aerosolized 
M. tuberculosis and sacrificed four weeks later to evaluate M. tuberculosis colony-forming units 
(CFU) in the lungs and spleen. BCG was used as a positive control and MPLA DDA liposomes 
were used as a reference control. Saline was used as a negative control. MPLA DDA liposomes 
increased the SFUs in the lungs to 120 SFUs per 4x105 cells (Fig. 6A). The heavy bias to the lungs 
that was observed for the MPLA DDA liposomes was also observed for Hybrid-2. Hybrid-2 
increased the SFUs in the lungs to identical levels as the MPLA DDA liposomes. BCG and IMDQ 
failed to elicit significant SFUs in any of the tissues. 
 
 
There appeared to be a connection between the increases in SFUs in the lungs induced by MPLA 
DDA liposomes and Hybrid-2, but not BCG, with functional reductions in mycobacterial loads in 
the lungs following challenge with M. tuberculosis H37Rv (Fig. 6B). Hybrid-2 adjuvanted mice 
showed significant reductions in the lungs of 5-fold, while MPLA DDA liposomes reduced the 
CFUs in the lungs by 15-fold, with additional reductions in the spleen of 4-fold. BCG, on the other 
hand, showed balanced reductions in CFUs in both the lungs and spleen of mice, with reductions 
of 6-fold and 8-fold, respectively. The TLR7/8 agonist IMDQ failed to induce protective responses 
in the mice, and reduced the CFUs in neither the lungs nor the spleen (Fig. 6B). The reductions in 
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mycobacterial load in the lungs of mice adjuvanted with Hybrid-2 are comparable to that elicited 
by BCG, and merits further investigation.  
 
4.3 Conclusions 
In conclusion, poly-TLR agonists can be synthesized from the repertoire of existing small-
molecule TLR agonists. The resulting hybrid molecules we synthesized retained TLR2/7 activity, 
but at the expense of all TLR8 activity. Using model antigens, Hybrid-1 was able to induce 
antibody titers equivalent to either individual TLR agonists, but at a higher quality. The water-
soluble Hybrid-2 was able to elicit reductions in mycobacterial burdens when administered 
prophylactically with ESAT-6. However, our attempts to gain insight into the mechanisms of 
adjuvanticity were stymied by small cohort sizes and variability within the animals. More robust 
studies with larger cohorts will need to be conducted before correlations between protection and 
immunogenicity can be observed. 
 
4.4 Materials and Methods 
Chemistry Reagents 
Synthesis was conducted by Dr. Nikunj Shukla. All of the solvents and reagents used were 
obtained commercially and used as such, unless noted otherwise. Moisture- or air-sensitive 
reactions were conducted under nitrogen atmosphere in oven-dried (120 ºC) glass apparatus. The 
solvents were removed under reduced pressure using standard rotary evaporators. Flash column 
chromatography was carried out using RediSep Rf ‘Gold’ high performance silica columns on 
CombiFlash® Rf instrument (Teledyne Isco Inc, Lincoln, NE) unless otherwise mentioned, while 
thin-layer chromatography was carried out on silica gel (200 μm) CCM pre-coated aluminum 
sheets. Purity for all final compounds was confirmed to be greater than 97% by LC-MS using a 
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Zorbax Eclipse Plus 4.6 mm x 150 mm, 5 μm analytical reverse phase C18 column with H2O-
CH3CN gradient on either Shimadzu LC (Shimadzu Corp., Kyoto, Japan) or Agilent LC combined 
with an Agilent ESI-TOF mass spectrometer (Agilent Technologies, Santa Clara, CA; mass 
accuracy of 10 ppm) operating in the positive ion acquisition mode. 
 
Synthesis of Compound 1 (IMDQ) 
Compound 1 (1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine) was 
synthesized as described previously.91 
 
Synthesis of Compound 4 
To a solution of compound 2 (purchased from Matrix Science, Columbia, SC; 500 mg, 2.3 mmol) 
in anhydrous dichloromethane was added, di-tert-butyl dicarbonate (454 mg, 2.08 mmol) and the 
reaction was stirred for 1 hour, followed by removal of the solvent under vacuum. The residue was 
then dissolved in anhydrous THF and triethylamine (52 mg, 5.2 mmol) and glutaric anhydride (445 
mg, 3.9 mmol) were added. The reaction mixture was stirred for 2 hours followed by removal of 
the solvent under vacuum to obtain the crude residue which was purified using column 
chromatography (20% MeOH/dichloromethane) to yield compound 3 (400 mg, 41%). To a 
solution of 3 (125 mg, 0.23 mmol) in anhydrous DMF were added, triethylamine (60 mg, 0.59 
mmol), HBTU (98 mg, 0.26 mmol) and the imidazoquinoline 1 (100 mg, 0.23 mmol). The reaction 
mixture was stirred for 12 hours followed by removal of the solvent under vacuum. The residue 
was purified using flash chromatography (20% MeOH/CH2Cl2) to obtain the N-Boc protected 
intermediate. N-Boc deprotection was carried out by stirring in 1 mL of 4M HCl/dioxane solution 
for 6 hours followed by removal of the solvent under vacuum to obtain hydrochloride salt of 
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compound 4, N1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N5-(3-(2-
(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)glutaramide (140 mg, 80%). 1H NMR (500 MHz, 
MeOD) δ 7.96 (dd, J = 8.4, 0.7 Hz, 1H), 7.75 (dd, J = 8.4, 0.8 Hz, 1H), 7.63 (ddd, J = 8.4, 7.3, 1.2 
Hz, 1H), 7.36 (ddd, J = 8.4, 7.3, 1.1 Hz, 1H), 7.27 (d, J = 8.3 Hz, 2H), 7.05 (d, J = 8.2 Hz, 2H), 
5.93 (s, 2H), 4.32 (s, 2H), 3.67 – 3.59 (m, 8H), 3.59 – 3.54 (m, 2H), 3.49 (t, J = 6.1 Hz, 2H), 3.22 
(t, J = 7.0 Hz, 2H), 3.08 (t, J = 6.4 Hz, 2H), 3.02 – 2.96 (m, 2H), 2.21 (dt, J = 21.1, 7.6 Hz, 4H), 
1.94 – 1.80 (m, 6H), 1.73 (dd, J = 13.4, 6.5 Hz, 2H), 1.45 (dd, J = 15.0, 7.5 Hz, 2H), 0.94 (t, J = 
7.4 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 175.35, 175.26, 159.05, 150.46, 140.34, 137.61, 
135.34, 135.23, 130.95, 129.50, 126.84, 126.42, 125.88, 122.97, 119.60, 114.22, 71.39, 71.09, 
71.05, 71.00, 70.39, 69.65, 49.83, 43.54, 40.17, 37.66, 36.31, 36.20, 30.50, 30.34, 28.05, 27.76, 
23.32, 23.28, 14.10. MS (ESI-TOF) for C37H53N7O5 [M + H]
+ found 676.4270, calculated m/z 
676.4181; [M + 2H]+2 found 338.7178, calculated 338.7127. 
 
Synthesis of Compound 5 
To a solution of compound 4 (140 mg, 0.19 mmol) in anhydrous dichloromethane, were added 
carbon disulfide (143 mg, 1.89 mmol) and triethylamine (47 mg, 0.469 mmol). The reaction 
mixture was stirred for an hour. Di-tert-butyl dicarbonate (41 mg, 0.19 mmol) and a catalytic 
amount of DMAP were added to the reaction mixture. The reaction mixture was stirred for 18 
hours and then the solvent was removed under vacuum. The residue was purified using column 
chromatography (20% MeOH/CH2Cl2) to obtain the compound 5 (N1-(4-((4-amino-2-butyl-1H-
imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-N5-(3-(2-(2-(3-isothiocyanatopropoxy)ethoxy) 
ethoxy)propyl)glutaramide) (55 mg, 40 %). MS (ESI-TOF) for C38H51N7O5S [M + H]
+ found 
718.3578, calculated 718.3745. 
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Synthesis of Compound 6 (PAM2CS) 
Compound 6 ((R)-3-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-
oxopropyl)thio)propane-1,2-diyl dipalmitate) was synthesized as described previously.89 
 
Synthesis of Compound 7 (Hybrid-1) 
To a solution of compound 5 (50 mg, 0.07 mmol) in anhydrous pyridine was added compound 6 
(54 mg, 0.07 mmol). The reaction mixture was heated at 45 ºC for 24 hours, followed by removal 
of the solvent under vacuum. The residue was then purified using column chromatography (12% 
MeOH/CH2Cl2) to obtain compound 7 ((25S,29R)-1-(4-((4-amino-2-butyl-1H-imidazo[4,5-
c]quinolin-1-yl)methyl)phenyl)-25-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)carbamoyl)-
3,7-dioxo-23-thioxo-12,15,18-trioxa-27-thia-2,8,22,24-tetraazatriacontane-29,30-diyl 
dipalmitate, 55 mg, 53%). 1H NMR (500 MHz, MeOD) δ 7.84 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 8.0 
Hz, 1H), 7.48 – 7.44 (m, 1H), 7.26 (d, J = 8.2 Hz, 2H), 7.18 – 7.14 (m, 1H), 7.04 (d, J = 8.2 Hz, 
2H), 5.87 (s, 2H), 5.23 (bs, 2H), 4.53 (t, J = 4.4 Hz, 1H), 4.38 (dd, J = 11.9, 3.0 Hz, 1H), 4.33 (s, 
2H), 4.14 (dd, J = 12.0, 6.5 Hz, 1H), 3.91 (dd, J = 11.3, 4.6 Hz, 1H), 3.80 (dd, J = 11.3, 4.1 Hz, 
1H), 3.73 (s, 3H), 3.61 (dd, J = 5.9, 3.0 Hz, 4H), 3.56 (dd, J = 5.7, 2.7 Hz, 4H), 3.53 – 3.47 (m, 
4H), 3.22 (t, J = 6.8 Hz, 2H), 3.14 – 3.07 (m, 1H), 3.04 – 2.92 (m, 3H), 2.88 (dd, J = 14.1, 6.1 Hz, 
1H), 2.80 (dd, J = 14.2, 7.3 Hz, 1H), 2.35 – 2.28 (m, 4H), 2.21 (dt, J = 21.8, 7.4 Hz, 4H), 1.91 – 
1.76 (m, 6H), 1.72 (p, J = 6.5 Hz, 2H), 1.64 – 1.53 (m, 4H), 1.44 (dt, J = 14.7, 7.4 Hz, 2H), 1.27 
(s, 50H), 0.94 (t, J = 7.4 Hz, 3H), 0.89 (t, J = 7.0 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 175.24, 
174.95, 174.76, 171.98, 156.76, 152.19, 140.07, 136.02, 135.90, 129.48, 129.10, 126.94, 126.79, 
124.11, 121.90, 115.50, 79.56, 79.30, 79.04, 71.97, 71.54, 71.52, 71.20, 71.15, 69.97, 65.02, 62.83, 
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56.34, 56.29, 52.95, 49.72, 43.66, 37.92, 36.34, 36.21, 35.26, 35.02, 33.72, 33.13, 30.88, 30.84, 
30.81, 30.73, 30.71, 30.55, 30.52, 30.33, 30.26, 30.24, 27.89, 26.12, 26.09, 23.80, 23.47, 23.28, 
14.55, 14.21. MS (ESI-TOF) for C80H131N9O13S2, [M + H]
+ found 1490.9570, calculated 
1490.9381. 
 
Synthesis of Compound 9 (Hybrid-2) 
Compound 9 was synthesized in three steps involving the synthesis of a tri-lysine synthon, 
coupling of the tri-lysine to the serine carboxyl group of PAM2CS-OH, followed by coupling of 
the isothiocyanate-bearing imidazoquinoline derivative 5.  
 
First, a tri-lysine synthon was synthesized as follows (Fig. S1). To a solution of Fmoc-L-Lys(Boc)-
OH (1.6 g, 3.37 mmol, Bachem, Bubendorf, Switzerland) in 1:1 solvent mixture of anhydrous 
DMF and pyridine were added, HBTU (1.9 g, 5.05 mmol) and H-L-Lys(Boc)-OMe (1 g, 3.37 
mmol, Bachem). The reaction mixture was stirred for 1 hour followed by removal of the solvent 
under vacuum to obtain the crude residue which was dissolved in ethyl acetate, washed 
sequentially with water and brine, and concentrated under vacuum to obtain the intermediate N-
Fmoc-protected bis-lysine compound (2.46 g). The N-Fmoc group was then removed by dissolving 
the compound in neat piperidine (2.3 mL) and stirring for 5 minutes, followed by quenching the 
reaction using excess of water and extracting the compound in ethyl acetate. The ethyl acetate 
fraction was then washed several times with water and dried over sodium sulfate and purified by 
column chromatography (8% MeOH/CH2Cl2) to obtain compound K2 (1.3 g, 79%). The third 
lysine unit was coupled by adding K2 (1.3 g, 2.66 mmol) to a solution of compound Fmoc-L-
Lys(Boc)-OH (791 mg, 2.66 mmol) in a 1:1 solvent mixture of anhydrous DMF and pyridine 
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containing HBTU (1.5 g, 3.99 mmol). The reaction mixture was stirred for 1 hour, followed by 
removal of the solvent under vacuum to obtain the crude residue which was dissolved in ethyl 
acetate, washed with water and brine and concentrated under vacuum to obtain the intermediate 
N-Fmoc protected tri-lysine compound. The N-Fmoc group was then removed by dissolving the 
compound in neat piperidine and stirring for 5 minutes, followed by quenching the reaction using 
excess of water, and extracting the compound in ethyl acetate. The ethyl acetate fraction was 
washed several times with water and dried over sodium sulfate and purified by column 
chromatography (8% MeOH/CH2Cl2) to obtain the tri-lysine synthon K3 (1.6 g, 84%). 
1H NMR 
(500 MHz, CDCl3) δ 7.78 (d, J = 6.3 Hz, 1H), 6.82 (d, J = 7.7 Hz, 1H), 4.80 (s, 3H), 4.53 (d, J = 
4.8 Hz, 1H), 4.37 (d, J = 6.5 Hz, 1H), 3.74 (s, 3H), 3.38 (dd, J = 7.9, 4.4 Hz, 1H), 3.18 – 3.00 (m, 
6H), 1.96 – 1.77 (m, 3H), 1.70 (dd, J = 15.1, 7.5 Hz, 5H), 1.62 – 1.28 (m, 39H). 13C NMR (126 
MHz, CDCl3) δ 175.59, 172.62, 171.57, 156.17, 156.11, 79.15, 79.05, 54.90, 52.68, 52.44, 52.05, 
40.05, 34.56, 31.56, 31.44, 29.86, 29.52, 29.44, 28.44, 22.76, 22.61, 22.44. MS (ESI-TOF) for 
C34H64N6O10 [M + Na
+] found 739.4592, calculated 739.4576. 
 
Second, the tri-lysine synthon was coupled to the PAM2CS moiety as follows. NH-Fmoc-
PAM2CS-OH was synthesized as described earlier,
192 and was dissolved (27 mg, 0.028 mol) in a 
1:1 solvent mixture of DMF and pyridine to which was added HBTU (16 mg, 0.041 mmol) and 
compound K3 (20 mg, 0.028 mmol). The reaction mixture was stirred for 4 hours followed by 
removal of solvent under vacuum to obtain the N-Fmoc protected intermediate (17 mg). The N-
Fmoc group was then removed by dissolving the compound in neat piperidine and stirring for 5 
minutes, followed by quenching the reaction using excess of water and extracting the compound 
in ethyl acetate (12 mg). The ethyl acetate fraction was washed several times with water and dried 
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over sodium sulfate to obtain crude intermediate which was purified using column 
chromatography to obtain compound 8 (12 mg, 0.008 mmol). 
 
Finally, the tri-lysine bearing, water-soluble PAM2CS-IMDQ hybrid adjuvant 9 was synthesized 
as follows: compound 8 (12 mg, 0.008 mmol) was dissolved in pyridine and compound 5 (6 mg, 
0.008 mmol) was added. The reaction mixture was stirred for 4 hours followed by removal of 
solvent under vacuum to obtain the residue which was purified using column chromatography to 
obtain tris-Boc-protected compound (12 mg). To a solution of tris-Boc-protected compound (10 
mg, 0.005 mmol) in anhydrous dichloromethane was added SnCl4 (0.137 mmol, 36 mg) and the 
reaction mixture was stirred for 30 minutes.216 The solvent was then removed under vacuum to 
obtain the residue which was purified using semi-preparative reverse phase HPLC to obtain the 
compound 9 ((25S,29R)-1-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl) 
phenyl)-3,7-dioxo-23-thioxo-25-(((4R,7R,10R,13S)-4,7,10-tris(4-aminobutyl)-14-hydroxy-
3,6,9,12-tetraoxo-2-oxa-5,8,11-triazatetradecan-13-yl)carbamoyl)-12,15,18-trioxa-27-thia-
2,8,22,24-tetraazatriacontane-29,30-diyl dipalmitate, 6 mg). MS (ESI-TOF) for C98H167N15O16S2 
[M + H+] found 1875.2112, calculated 1875.2229; [M + Na+] found 1897.1929, calculated 
1897.2049; [M + 2H+] found 938.1115, calculated 938.1151; [M + 3H+] found 625.7434, 
calculated 625.7458; [M + 4H+] found 469.5592, calculated 469.5612. 
 
Biology Reagents 
PAM2CSK4 and AddaVax™ (oil (squalene)-in-water nano-emulsion) were purchased from 
InvivoGen (San Diego, CA). ESAT-6 was obtained from BEI resources (catalog number NR-
14868). The following antibodies were purchased: B220-APC-eFluor780, CD11b-APC-
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eFluor780, CD11c-APC-eFluor780, CD8α-APC-eFluor780 (eBioscience, San Diego, CA; catalog 
numbers 47-0452-80, 47-0112-82, 47-0114-82, 47-0081-82, respectively), CD4-BV786, CD90.2-
BUV395, Bcl-6-FITC, FoxP3-PerCP-Cy5.5, RORγt-BV421, CXCR5-BV650, and T-bet-PE-Cy7 
(Becton Dickinson, Franklin Lakes, NJ.; catalog numbers 563331, 565257, 561525, 563902, 
562894, 563981, and 561265, respectively). The following goat-anti-mouse antibodies were 
purchased for ELISA: anti-IgG1, -IgG2a, -IgG2b, -IgG3, -IgM, and -IgA (Sigma Aldrich, St. 
Louis, MO; catalog numbers M8770, M4434, M8067, M8270, A8786, A4789, respectively). 
Goat-anti-rabbit IgG-HRP and rabbit-anti-goat IgG-HRP were also procured from Sigma (catalog 
numbers AP307P and A8919, respectively). PE- and APC-labeled I-Ab tetramers containing 
ESAT-6 amino acids 4-17, were graciously provided by Marc Jenkins.217 
 
Human TLR2/-7/-8 Reporter Gene Assays (NF-κB induction) 
The induction of NF-κB was quantified using human TLR2, TLR7 and TLR8-specific HEK-
Blue™ reporter gene assays (InvivoGen, San Diego, CA;  cell line catalog numbers hkb-htlr2, 
hkb-htlr7, and hkb-htlr8, respectively) as previously described by us.88, 90 The reporter cells were 
incubated at a density of 105 cells/mL in a volume of 80 µL/well, in 384-well, flat-bottomed, cell 
culture-treated microtiter plates, and subsequently stimulated with graded concentrations of 
stimuli. Secreted alkaline phosphatase was assayed spectrophotometrically using an alkaline 
phosphatase-specific chromogen (present in HEK-detection medium as supplied by the vendor) at 
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Rabbit Immunizations 
All rabbit immunization experiments were performed by Envigo (Huntington, UK) in accordance 
with institutional guidelines (University of Kansas IACUC protocol # 119-06) which specifically 
approved the studies. Hybrid-1 was not water soluble and required formulation in the squalene-
based oil-in-water nano-emulsion, AddaVax™. Cohorts of adult female New Zealand White 
rabbits (n = 3) were immunized intramuscularly in the flank region with (a) 10 µg of bovine α-
lactalbumin plus 100 µg of test compounds in 0.2 mL AddaVax, or (b) 10 µg of bovine α-
lactalbumin plus 50 µg of IMDQ and 50 µg of PAM2CS in 0.2 mL AddaVax. Prior to 
immunization pre-immune test-bleeds were first obtained via venipuncture of the marginal vein of 
the ear. Animals were immunized on days 1, 15 and 28. Immune sera were harvested on day 25 
(Immune 1), and day 38 (Immune 2). Sera were stored at −80°C until used.  
 
Enzyme-linked Immunosorbent Assays (ELISA) 
Bovine α-lactalbumin-specific ELISAs were performed in 384-well format using automated liquid 
handling methods as described by us.88 A Precision 2000 liquid handler (BioTek, Winooski, VT) 
was used for all serial dilution and reagent addition steps, and a BioTek ELx405 384-well plate 
washer was employed for plate washing; 100 mM phosphate-buffered saline (PBS) pH 7.4, 
containing 0.1% Tween-20 was used as wash buffer. Nunc-Immuno MaxiSorp (384-well) plates 
were coated with 40 µL of 10 µg/mL α-lactalbumin in 100 µM carbonate buffer, pH 9.0 overnight 
at 4°C. After 3 washes, the plates were blocked with 3% bovine serum albumin (in PBS, pH 7.4) 
for 1 hour at room temperature. Serum samples (in quadruplicate) were serially diluted in a 
separate 384-well plate using the liquid handler. After three additional washes of the assay plate, 
40 µL of the serum dilutions were transferred using the liquid handler, and the plate incubated at 
 75  
37°C for 1 hour. The assay plate was washed three times, and 40 µL of 1:10,000 diluted anti-rabbit 
immunoglobulin (IgG [γ chain]) conjugated with horseradish peroxidase was added to all wells. 
Following an incubation step at 37°C for 1 hour, and three washes, 40 µL tetramethylbenzidine 
substrate was added. The chromogenic reaction was terminated at 30 min by the addition of 2M 
H2SO4. Plates were then read at 450 nm using a SpectraMax M2 device (Molecular Devices, 
Sunnyvale, CA). 
 
Surface Plasmon Resonance Experiment 
Surface plasmon resonance experiments were performed as described earlier.102 Bovine α-
lactalbumin was immobilized onto the CM5 sensor chip of a BIAcore 3000 instrument (GE 
Healthcare, Little Chalfont, UK) using EDCI/NHS chemistry (~900 response units/channel). 
Rabbit serum samples at a 1:50 dilution in PBS were injected at 10 µL/min for 5 minutes. HEPES-
buffered saline (40 µL/min) was used during the dissociation stage. The binding surface was 
regenerated with a short pulse of 25 mM NaOH. For sensorgram analyses, data points were taken 
at 15 seconds and 500 seconds of post-injection, and dissociation rates were calculated as a ratio 
of late-to-early binding response over 500 seconds. 
 
Linear Epitope Mapping  
Linear peptide epitope mapping was performed utilizing PEPperMAP® technology 
(PEPperPRINT GmbH, Heidelberg, Germany) as described earlier.96 Immune-2 sera (Day 38, 
following the second boost) from three animals in each cohort were used. The C- and N-termini 
of the bovine α-lactalbumin were first elongated by neutral GSGSGSG sequences to avoid 
truncated peptides. The protein sequence was then translated into 13-mer peptides with a peptide-
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peptide overlap of 12 amino acids. Arrays of 129 peptides were printed in duplicate spots; four 
such arrays were printed on each glass slide. Each array was framed by a fusion tag (Flag) peptide 
(DYKDDDDKGG, 72 spots) and influenza virus hemagglutinin (HA) epitope tag peptide 
(YPYDVPDYAG, 72 spots) as controls. After pre-soaking the arrays for 10 min in standard buffer 
(phosphate-buffered saline [PBS], pH 7.4 + 0.05% Tween 20) and 60 min in Rockland blocking 
buffer (Rockland Immunochemicals, Inc., Gilbertsville, PA), the peptide microarrays were 
initially incubated with the secondary goat anti-rabbit IgG (H+L) conjugated with DyLight680 
antibody at a dilution of 1:5000 for 60 min at room temperature to verify that no significant 
background interactions occurred with the peptide arrays. The microarrays were washed twice and 
incubated for an additional 30 min in standard buffer. The peptide arrays were then incubated 
overnight at 4°C with rabbit sera diluted to 1:1000. After multiple washes in standard buffer, the 
slides were incubated for 30 min with the secondary goat anti-rabbit IgG (H+L) conjugated with 
DyLight680 antibody at a dilution of 1:5000 at room temperature. After two additional washes in 
standard buffer, the microarrays were rinsed with ultrapure water and dried in a stream of air. 
Green/red fluorescence intensities were acquired on an Odyssey Imager (Lincoln, NE) at a spatial 
resolution of 21 µm. Staining of Flag and HA control peptides that frame the arrays gave rise to 
high and homogeneous spot intensities with a coefficient of variation of <2%. The PEPSlide 
Analyzer algorithm deconvolutes raw fluorescence intensities of each spot into foreground and 
background signal. Intensity maps were generated based on corrected foreground intensities 
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ESAT-6-specific T Cell and Antibody Isotype Analysis 
Six-8 week old C57BL/6 mice were housed in specific-pathogen-free conditions according to the 
University of Minnesota IACUC protocol #1703-34657A. Cohorts of 3 mice were vaccinated 
subcutaneously 3 times at two-week intervals with 10 µg ESAT-6 adjuvanted with IMDQ, Hybrid-
2, or PAM2CSK4. Monophosphoryl lipid a (MPLA) formulated in dimethyldioctadecyl-
ammonium bromide (DDA) liposomes218 was used as reference adjuvant.213 Unadjuvanted ESAT-
6 in phosphate-buffered saline was used for the control cohort. Mice were sacrificed 4 weeks 
following the final immunization. Blood was collected by cardiac puncture, and the spleen and 
axillary lymph nodes were harvested for T cell analysis. ESAT-6-specific antibody isotypes were 
analyzed by ELISA as mentioned above, using 10 µg/mL ESAT-6 for coating and goat-anti-mouse 
IgG1, IgG2a, IgG2b, IgG3, IgM, and IgA primary antibodies (Sigma Aldrich, St. Louis, MO). 
ESAT-6-specific T cells were enriched using PE- and APC-labeled I-Ab tetramers containing 
ESAT-6 amino acids 4-17.217 Single cell suspensions were stained at room temperature for 1 hour 
with PE- and APC- tetramers. Tetramer positive cells were enriched using PE- and APC-specific 
antibodies with dextran magnetic beads (Stemcell Technologies, Vancouver, Canada) as was 
previously published by Moon and coworkers.217 Enriched samples were stained with Fixable 
viability dye eFluor780 (eBioscience, San Diego, CA) and the following antibodies: B220-APC-
eFluor780, CD11b-APC-eFluor780, CD11c-APC-eFluor780, CD8α-APC-eFluor780, CD4-
BV786, CD90.2-BUV395, Bcl-6-FITC, FoxP3-PerCP-Cy5.5, RORγt-BV421, CXCR5-BV650, 
and T-bet-PE-Cy7. Samples were acquired on BD LSRFortessa X-20 (BD Bioscience, Franklin 
Lake, NJ) and analyzed using FlowJo version 10 (FlowJo, LLC, Ashland, OR).  
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ESAT-6-specific IFN-γ ELISpot Assays 
Five cohorts of five C57BL/6 mice each were vaccinated via the subcutaneous route 3 times at 
two-week intervals with ESAT-6 (10 µg/dose) admixed with Hybrid-2 (20 µg/dose) or IMDQ (20 
µg/dose). Control cohorts received either a single dose of 5x104 CFU of BCG Pasteur (positive 
control), or MPLA DDA liposomes213 (reference adjuvant), or pyrogen-free saline (negative 
control). An additional two cohorts received only compound Hybrid-2 or IMDQ (20 µg/dose) as 
adjuvant-only controls. Each cohort was analyzed for their immune responses to vaccination at 4 
weeks post-vaccination by ELISpot assay as was previously published by Brandt and coworkers.219  
 
ELISpot was conducted using a MultiScreen 96-well plate (Millipore, Billerica, MA) coated with 
10 μg/mL of rat anti-mouse IFN-γ capture antibody (Becton Dickinson, Franklin Lakes, NJ.; 
Catalog number 554412) and incubated overnight at 4°C. Plates were washed in PBS and blocked 
with RPMI containing 10% fetal calf serum for 1 hour. Spleen, lung, and lymph node cells were 
plated at 105 cells per well in 100 μL followed by ESAT-6 stimulation at 10 μg/mL with 0.2 ng/mL 
of interleukin-2 for 48 hours at 37°C. The plates were washed with PBS containing 0.1% Tween 
and incubated overnight at 4°C with a biotin-conjugated rat anti-mouse IFN-γ secondary antibody 
at 5 μg/mL in PBS containing 0.1% Tween and 0.5% bovine serum albumin. Vectastain ABC 
avidin peroxidase conjugate and Vectastain AEC substrate kits (Vector Laboratories, Burlingame, 
CA.; Catalog number PK6100) were used to develop the filters. The reaction was stopped by 
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M. tuberculosis Challenge Studies 
Five cohorts of five C57BL/6 mice each were vaccinated via the subcutaneous route 3 times at 
two-week intervals with ESAT-6 (10 µg/dose) admixed with Hybrid-2 (20 µg/dose) or IMDQ (20 
µg/dose). Control cohorts received either a single dose of 5x104 CFU of BCG Pasteur (positive 
control), or MPLA DDA liposomes (reference adjuvant), or pyrogen-free saline (negative control). 
An additional two cohorts received only compound Hybrid-2 or IMDQ (20 µg/dose) as adjuvant-
only controls. M. tuberculosis H37Rv were grown from low-passage seed lots in Proskauer-Beck 
liquid medium containing 0.05% Tween 80 to early log phase. Cultures were stored at −70°C until 
used. Thawed aliquots were diluted in distilled sterile water to the desired inoculum 
concentrations. An aerosol generation device (Glas-Col, Terre Haute, Ind.) was used to expose the 
animals to an aerosol of M. tuberculosis and was calibrated to deliver approximately 100 bacilli 
per mouse.219 To assess bacterial loads, individual whole-organ homogenates were plated on 
nutrient Middlebrook 7H11 Bacto agar (Becton Dickinson Microbiology Systems, Cockeysville, 
Md.). Bacterial colonies were counted after 2 to 3 weeks of incubation at 37°C.   
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Chapter 5. 
 
Identification of a Human TLR8-
specific Agonist and a 
Functional Pan-TLR Inhibitor  
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5.1 Introduction 
The promising results of the TLR2/7 hybrids (Chapter 4) brought to light the importance of 
understanding the abilities of various TLR agonists to bias the adaptive immune responses using 
robust assays. We therefore set out to examine mechanisms of adjuvanticity in individual TLR 
agonists. We began our efforts by the SAR of the novel TLR8 agonistic 2-aminoimidazoles.   
In the context of Th1-biased adaptive immune responses, TLR8 is of particular significance. The 
engagement of TLR8, which is expressed predominantly in myeloid dendritic cells, monocytes, 
and monocyte-derived dendritic cells,194, 220 potently enhances the production of Th1-polarizing 
cytokines, TNF-α, IL-12, and IL-18 in APCs.220-223 Our interest in Th1-polarizing small molecule 
agonists of TLR8 has led to the exploration of a variety of dual TLR7/8-active chemotypes (1a-1c 
in Fig. 1),93, 95, 97, 99 as well as pure TLR8 agonists with no detectable activity at TLR7, including 
the 2,3-diamino-furo[2,3-c]pyridines (1d),98 4-amino-furo[2,3-c]quinolines (1e),25 3-alkyl-
quinoline-2-amines (1f),26 1-alkyl-2-aminobenzimidazoles (1g),100 and 2-amino-3-pentyl-5-
alkylaminoquinolines (1h).113 
Figure 1. Structures of the dual TLR7/8-active (1a-1c) and pure TLR8-active (1d-1h) compounds. 
Arrows indicate evolution of chemotypes. 
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Part-structures of the 2-aminobenzimidazole scaffold were examined with a view to identifying 
structural requisites corresponding to the smallest possible fragment of the benzimidazole core that 
would allow for retention of TLR8-agonistic activity, enabling the identification of a TLR8-
specific agonist of low proinflammatory potential, and an analogue with functional pan-TLR 
inhibitory properties, which may prove useful as an anti-inflammatory agent. 
 
5.2 Results and Discussion 
In our earlier exploration of novel TLR8-specific agonists, we had noted distinct differences in 
potencies in the order: 1h>1f26 ≈ 1g100>1e,112 with 1d being TLR8-specific (Fig. 1), but entirely 
devoid of proinflammatory cytokine-inducing properties. The significant enhancement of potency 
for TLR8 observed for 1h was achieved by specifically 'designing in' the 5-pentylamine substituent 
on to 1f to yield 1h, which, based on co-crystal structures, was predicted to afford strong salt-
bridge interactions with Asp545 in TLR8.113 The design of 1e from 1f was also arrived at by 
structure-guided methods derived from co-crystal structures of TLR8 with 1e showing a 
hydrophobic pocket enabling optimal binding of C2 alkyl chains.26 These studies have been 
instructive, and have provided a strong impetus to explore ligand design for PRRs for which small 
molecule ligands have not yet been identified, such as TLR3 and TLR9, for which only canonical 
ligands224 have been described.  
 
Given the structural homology and highly conserved ligand binding sites within the TLR 
family,225-226 one possible approach toward identifying novel small molecule ligands for these 
innate immune receptors is the de novo design of potential ligands227-228 starting from key 
 83  
interactions ('hot spots') at the binding site, and then examining hypothesis-driven, focused 
libraries such as we had successfully undertaken for 1h.113 We therefore reverted back to the 2-
aminobenzimidazole scaffold of 1g, and wished to interrogate structural requisites corresponding 
to the smallest possible part-structure of the benzimidazole core that would allow for retention of 
agonistic activity, our goal being able to utilize the SAR data in the de novo design of ligands.  
 
Noting from our previous SAR studies that an appropriately positioned pentyl substituent confers 
optimal activity, our first target was the synthesis of 1-pentyl-2-aminoimidazole, 4, obtained from 
2-nitroimidazole via N-alkylation, followed by reduction of the nitro group (Scheme 1) (synthesis 
was conducted by Dr. Mallesh Beesu). We noted that, similar to 2-amino-3-alkylindoles,100 the 
free base of 4 was unstable in DMSO. The HCl salt, however, was stable and active in TLR8-
specific primary screens, with a potency about one-twenty-fifth (EC50: 28.4 µM, Table 1) that of 
the parent compound 1g (EC50: 1.13 µM), likely attributable to loss of π-π interactions with 
Phe405.26, 97 In an effort to regain such interactions, we explored aromatic substituents on the 
unusually diminutive imidazole scaffold.  
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The 5-phenyl substituted analogue 7 was synthesized from N-pentylpyrimidin-2-amine and 2-
bromoacetophenone under microwave conditions via the elegant, one-pot, two-step protocol 
developed by Ermolat’ev and colleagues (Scheme 2).229 Compound 7, however, was completely 
inactive, suggesting non-optimal orientation of the 5-phenyl group for adequate π-π interactions. 
The 4,5-diphenyl substituted analogue 10, accessed from 3 via sequential dibromination, Suzuki 
reaction with phenylboronic acid, and reduction of the 2-nitro group (Scheme 3), exhibited very 
weak TLR-8 agonistic activity (Fig. 2), pointing to out-of-plane orientation of the vicinal phenyl 
substituents, owing to steric crowding. The 4-phenyl substituted analogue 17a was synthesized 
from 3 via mono-bromination at C4, sequential Suzuki reaction with phenylboronic acid, followed 
by reduction of the 2-nitro group (Scheme 4). A ten-fold gain in TLR8-agonistic activity was 
observed for 17a (EC50: 2.48 µM; Table 1, Fig. 2) relative to the imidazole 4, likely indicating 
restoration of π-π interactions with Phe405 of human TLR8.  
 
We therefore undertook a detailed exploration of aromatic substituents at C4 (Scheme 4). The 
majority of analogues in this series showed similar EC50 values (1.5-3 µM), but differed 
substantially in the maximal responses induced in the human TLR8-specific reporter gene assays 
(Fig. 2) in a manner similar to what we had observed previously with the 2,3-diamino-furo[2,3-
c]pyridine (1d) class of TLR8 agonists,98 and it should be noted that a discussion of relative 
potency in primary screens is therefore based on maximal responses (shown in Table 1). Optimal 
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compounds identified possess both potent EC50 and high AUCs. The 4-o-tolyl analogue 17b was 
marginally less active in primary, TLR8-specific reporter gene assays (EC50: 2.5 µM; Table 1, Fig. 
2) than 17a, while the homologated 4-(2-ethylphenyl) analogue 17c was significantly weaker, 
signaling poor tolerance of steric bulk at that position. The regioisomeric analogues 17d (4-m-
tolyl), 17e (4-p-tolyl), also showed some attenuation in activity relative to 17b, and the congeners 
17f-17i, bearing 2,3-, 2,4-, 2,5-, and 2,6-dimethylphenyl substituents at C4, respectively (Scheme 
4), showed lowered maximal responses (Fig. 2). Replacing the C4-phenyl with a benzyl group 
(18a), or further homologation to a phenethyl substituent (18b) led to progressive loss in activity 
as evidenced by lowering of TLR8 maximal responses (Fig. 2). Naphthyl (18c, 18d), biphenyl 
(18e), or benzyloxyphenyl (18f) substituents also were deleterious. Compound 19a, with a 3-
pyridyl group at C4 showed a marked shift-to-the-right in its dose-response profile, and the 
dimethylisoxazole-bearing 19b was weaker still (Fig. 2, Table 1). These data, taken together, 
indicated that neither steric bulk, nor the presence of heteroatoms in the aromatic group at C4 were 
well-tolerated.  
 
We specifically examined whether the presence of H-bond-donating or -accepting functional 
groups on the C4-phenyl substituent would enhance activity but found that all such analogues, 
including the 2-phenolic (19c), 2-hydroxymethyl (19d), 4-aminophenyl (19e), 4-benazamide 
(19f), 4-methylbenzoate (19g), 2-methylbenzoate (19h) were weaker than 17a (Fig. 2, Table 1). 
Encouraged by the observation that the 2-methoxyphenyl analogue 20a showed an activity profile 
comparable to that of 17a (Fig. 2, Table 1), we synthesized its regioisomeric compounds 20b-20c, 
the di- and trimethoxyphenyl compounds (20f and 20g, respectively), as well as the 
methoxymethylphenyl congeners 20d and 20e, none of which were more potent than 20a. We also 
evaluated analogues with electron-deficient phenyl groups. The chlorophenyl analogues 21a-21c 
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Figure 2. Agonistic activities of 2-aminoimidazole analogues in human TLR8 reporter gene 
assays. Means + SD on quadruplicates are shown. Also included is 1g, used as a reference TLR8-
active compound. The bimodal nature of agonistic responses resulting in apparent inhibition at 
high ligand concentrations was verified not to be due to cytotoxicity. 
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 were all considerably weaker, whereas of the fluorophenyl compounds (21d-21g), the 4-
fluorophenyl (21f) and 4-fluoro-2-methyl-phenyl (21g) analogue were potent, while the 
trifluoromethylphenyl compounds (21h-21j) were weak. 
 
A crystal structure of the ectodomain of human TLR8 complexed with 17a allows the 
rationalization of several aspects of the SAR that we have observed with this very small (229 
Daltons) TLR8-specific agonist. Compound 17a, similar to other TLR8-binding ligands,26, 97, 113, 
230 occupies the same binding pocket formed by both the TLR8 protomers, with the binding 
geometry of the ligand and interacting residues being virtually identical; bidentate ionic H-bonds 
were observed between the side-chain carboxylate of Asp543 of TLR8 and the N2 and N3 atoms 
of 17a. Aromatic stacking with near-perfect coplanarity is observed between the C4-phenyl ring 
of 17a and Phe405 in TLR8 (Fig. 3) in a pocket that is tightly circumscribed and delimited by the 
hydrophobic residues Tyr353, Val378, Val520 and Gln519 (Fig. 3), explaining why the SAR on 
Figure 3. Crystal structure of 17a bound to the ectodomain of human TLR8. Dashed lines in 
yellow depict direct hydrogen bonds. Dots indicate van der Waals radii of the aromatic rings of 
17a and Phe405. 
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the phenyl ring was fastidious and unyielding. An inspection of dihedral angles and inter-atomic 
distances in the crystal structure also raises the possibility of a halogen bond231-232 between the 
fluorine atom in 21f and the phenolic oxygen of Tyr353. 
 
Figure 4. Cytokine induction (excerpted from a 41 cytokine panel) in human PBMCs. 
Compounds that were found to be active in primary screens were evaluated. Means of a single 
representative experiment is shown. 
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Given that the majority of analogues were weak, we examined the TLR8-agonistic properties of 
all of the compounds for cytokine and chemokine induction in human PBMCs using a 41-analyte 
multiplexed immunoassay platform. Unexpectedly, only 17a and 21f showed cytokine/chemokine 
profiles (TNF-α, IL-1β, IL-6, IL12p40, IFN-γ, MCP-1, MIP-1α and MIP-1β); a subset of the 
secondary screen data is shown in Fig. 4. The potencies of both 17a and 21f were lower than that 
of 1g, used as a comparator (Fig. 4). We attempted to understand the basis of the apparent 
dissociation of activity in primary cell-based reporter assays and secondary screens in human 
PBMCs. The proprietary detection medium used in the reporter gene assay contains a chromogenic 
substrate for alkaline phosphatase in low concentrations of protein (which we verified to be equine 
albumin by peptide MS/MS fingerprinting), whereas the cytokine assays with human PBMCs are 
Figure 5. Intracellular PhosFlow™ flow cytometry for quantifying NF-κB phosphorylation in 
monocytes and polymorphonuclear cells in whole human blood. Dose-response profile for 17a 
and 21f are shown relative to reference TLR8-active comparators, 1f, 1g and 1h. Inset shows 
gating strategy. 
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performed in medium containing either 10% autologous, decomplemented serum, or 10% fetal 
bovine serum. Reporter gene assays adapted to include 10% human serum or 10% fetal bovine 
serum showed no differences in rank-order potencies. Addition of either recombinant human 
serum albumin233-234 or human acid 1-glycoprotein235 (up to concentrations of 1 mg/mL) also did 
not appreciably attenuate signals in TLR8-specific reporter gene assays (data not shown). The data 
cannot be explained adequately in terms of differential compartmentalization in the acidic 
endolysosomal compartment236 due to pKa differences, given that highly similar congeneric pairs 
(17a/17b, 21f/21g, for instance) show complete dissociation in secondary screens. The reasons for 
why only 17a and 21f, and none of the other analogues retain TLR8-agonistic activity in secondary 
screens remain enigmatic, and highlights possible shortcomings in strickly using reporter cells for 












































































































Figure 6. A. Inhibitory activity of 7 and 18f as well as a panel of cell signaling inhibitors in 
human TLR8 reporter cells. A 5 µg/mL concentration of 1f was used as stimulus. TLR inhibitory 
activities of 18f. The following stimuli (and reporter cells) were used: PAM2CS (10 ng/mL; TLR2), 
Poly(I:C) (50 ng/mL; TLR3), LPS (1 µg/mL; TLR4), flagellin from S. typhimurium (1 µg/mL, 
TLR5), TLR7-specific imidazoquinoline (1 µg/mL, TLR7), 1f (5µg/mL; TLR8), Oligonucleotide 
ODN2006 (15 µg/mL; TLR9). 
A B 
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We had previously reported a clear dependence between antigen-specific IgG titers and in vitro 
TLR8-agonistic potency. In a standardized rabbit model using the diphtheria toxin mutein 
CRM197148 as a model antigen and admixed with 100 µg/dose of TLR8-specific agonist, we 
observed that adjuvantic activity in vivo mirrored in vitro potency: 1h>1f>1e.113 Because 17a and 
21f are considerably weaker than 1e, that these aminoimidazoles would be less adjuvantic than 
previously-characterized compounds could be reliably predicted, and animal experiments were 
therefore not warranted.  
 
Compound 1h, the most potent TLR8-specific lead adjuvant that we have characterized thus far, 











































































Figure 7. A. Inhibitory screen of 18f against 365 wild-type kinases. Compound 18f was used at 
a single concentration of 10 µM. Mean of duplicates are shown. CAM: calmodulin kinase. 
TSSK3: testes-specific serine kinase-3; TrkA: tropomyosin kinase. B. Dose-response profiles of 
inhibition of calmodulin kinases by 18f. 
A B 
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soluble compound with properties that predict a high volume of distribution is likely to result in 
some degree of 'wasted' (systemic) inflammation,237 and we are currently addressing this potential 
drawback by devising strategies to target its delivery to secondary lymphoid tissue. Compounds 
17a and 21f are, conversely, considerably weaker and, consequently, larger doses would become 
necessary which would likely also increase systemic exposure of the molecule. Indeed, a potential 
strength of a molecule such as 17a may well lie in its weakness, and it seemed possible that 17a 
could be better suited for other indications such as mucosal immunotherapy for atopic rhinitis. 
Clinical trials of aqueous formulation of monophosphoryl lipid A (CRX-675; a TLR4 agonist)238 
and methyl2-(3-(((3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl)(3-
morpholinopropyl) amino)methyl)phenyl)acetate (AZD8848; a TLR7 agonist)239 have proven 
promising, but have been associated with systemic side effects,240-242 and it would be desirable and 
advantageous for these indications to limit systemic exposure. In order to test the premise that 17a 
would display significantly lower proinflammatory properties, we sought to directly compare the 
phosphorylation of p38 mitogen-activated protein kinase (p38MAPK), extracellular-signal-
regulated kinase 1/2 (ERK1/2) and NF-κB243-244 induced by 17a and 21f relative to 1f, 1g, and 1h, 
in whole human blood. Prominent, dose-dependent phosphorylation of NF-κB was evident within 
15 min of stimulation in monocytic and polymorphonuclear populations for 1f, 1g, and 1h (Fig. 
5), whereas 17a and 21f were found to be significantly less potent in inducing phosphorylation of 
the p65 subunit (transactivation domain) of NF-κB (Fig. 5). Taken together with cytokine 
induction profiles (Fig. 4), these data strengthen the premise for evaluating the effects of mucosal 
application of 17a and 21f, and experiments designed to probe lamina propria lymphocytic 
responses in nasal and bronchial mucosa are being planned.  
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Figure 8. Dose-dependent inhibition of 1f-stimulated cytokine release inhuman PBMCs by 
18f. 1f (stimulus) was at a fixed concentration of 10 µg/mL. A subset of cytokine responses are 
shown highlighting apparent selectivity for IL-1β release. Means of duplicates for one of two 
independent experiments are shown. 
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All compounds were counter-screened for activity in human TLR2, TLR3, TLR4, TLR5, TLR7 
and TLR9 reporter gene assays, and were found not to have off-target innate immune receptor-
stimulatory activities (data not shown). In addition, we examined all inactive 2-aminoimidazole 
derivatives for possible receptor antagonistic activity such as we had previously described for 
TLR7.90, 94-95 We observed that 7 and 18f inhibited, in a dose-dependent manner, TLR8 responses 
induced by 1f (Fig. 6A). We chose to characterize 18f in detail due to its greater apparent 
antagonistic potency (Fig. 6A). We noted that 18f also inhibited TLR2, TLR3, TLR4, TLR5, 
TLR7, and TLR9 responses with very similar (0.8-3 µg/mL; 2.4-9 µM) IC50 values (Fig. 6B), 
which suggested a mechanism of inhibition other than by competitive binding at TLR8. We 
compared the activity of 18f with a variety of cell signaling inhibitors including chloroquine245 
(endosomal acidification inhibitor), N-(3-((5-iodo-4-((3-(thiophene-2-carboxamido)propyl) 
amino)pyrimidin-2-yl)amino)phenyl)pyrrolidine-1-carboxamide, 22 (BX-795; an inhibitor of 3-
phosphoinositide-dependent kinase-1,246 TANK-binding kinase 1 and IκB kinase-ε),247 
glibenclamide248 (inhibitor of ATP-sensitive potassium channels), and 2-aminopurine249 (inhibitor 
of double-stranded RNA (dsRNA)-activated protein kinase), and gefitinib250 (epidermal growth 
factor receptor inhibitor). The inhibitory profile of 18f closely resembled that of 22 and gefitinib 
not only in TLR8 screens (Fig. 6A), but also in other reporter cell lines (data not shown), prompting 
us to explore possible kinase inhibitory activities of 18f. Compound 18f was screened at a fixed 
concentration (10 µM) against 365 wild-type kinases using a commercial screening service 
(Reaction Biology, Malvern, PA). IC50 values for individual kinases were established with either 
staurosporine or appropriate control compounds (data not shown). Significant inhibition of several 
calmodulin kinase isoforms, as well as testis-specific serine kinase (TSSKK3), and tropomyosin 
receptor kinase (TrkA) was observed at 10 µM concentration of 18f (Fig. 7A). We confirmed the 
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inhibitory activity of this compound against a panel of calmodulin kinases in follow-up dose-
response experiments (Fig. 7B).  
 
Compound 18f displayed rather weak kinase inhibitory potencies with IC50 values ranging from 
3-11 µM (Fig. 7B), and it was important to ascertain whether the in vitro kinase activities of 18f 
would be of any potential pharmacological significance in ex vivo assays performed under near-
physiological conditions. We first examined dose-dependent cytokine inhibition in human PBMCs 
stimulated with the TLR8-specific agonist 1f at 5 µg/mL (23.36 µM) using the 41-analyte 
multiplexed immunoassay.  
 
Figure 9. Dose-dependent suppression by 18f of CD86 expression in CD14
+
 monocytic subsets 
in whole human blood. A 5 µg/mL concentration of 1f was used as stimulus. 
 104  
We observed a clear, dose-dependent inhibition by 18f of cytokines and chemokines that were 
upregulated by the TLR8; the IC50 values for the vast majority of analytes were highly concordant 
(3-5 µg/mL), with the sole exception of IL-1β, which was inhibited substantially at much lower 
concentrations of 18f (Fig. 8). Similar profiles were observed with pure TLR4 and TLR7 
stimulation (data not shown).  
 
We sought to further confirm inhibition by 18f of TLR signaling in whole human blood assays. 
We had recently reported, using multicolor flow cytometry, that TLR8 agonism, in particular, 
markedly upregulates antigen presentation markers in monocytes.113 We quantified the effect of 
18f on expression levels of CD80 and CD86 in whole human blood stimulated with 1f, LPS, and 
two TLR7-specific agonist that we had previously characterized.91, 111 Depicted in Fig. 9 is the 
dose-dependent down-regulation of CD86 by 18f in CD14+ monocytes. Near-identical responses 
were also observed for CD80 (data not shown). Compound 18f also inhibited TLR8, TLR7, and 
TLR4 stimuli with similar IC50 values (2.5 µg/mL; 7.46 µM), suggesting that this compound may 
be a useful starting point for further evaluation as an anti-inflammatory agent. 
 
5.3 Conclusions 
Our exploration of the 2-aminoimidazole scaffold has led us, rather unexpectedly, first to the 
identification of a TLR8-specific agonist of low potency (and low proinflammatory potential), and 
then to an analogue with functional pan-TLR inhibitory properties. As mentioned earlier, the 
highly attenuated proinflammatory properties of 17a could be useful for indications such as 
mucosal immunotherapy for atopic rhinitis. A fitting coda for 18f is yet to be reached, and studies 
designed to characterize its pharmacology in greater detail are in progress. We do not yet 
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understand the basis of selective suppression of IL-1β secretion, and the significance of its apparent 
inhibitory activity on testis-specific serine kinase is being explored.  
 
 
5.4 Materials and Methods 
Chemistry 
All compounds were synthesized by Dr. Mallesh Beesu. All of the solvents and reagents used were 
obtained commercially and used as such unless noted otherwise. Moisture- or air-sensitive 
reactions were conducted under nitrogen atmosphere in oven-dried (120 ºC) glass apparatus. 
Solvents were removed under reduced pressure using standard rotary evaporators. Flash column 
chromatography was carried out using RediSep Rf ‘Gold’ high performance silica columns on 
CombiFlash Rf instruments unless otherwise mentioned, while thin-layer chromatography was 
carried out on silica gel CCM pre-coated aluminum sheets. Purity for all final compounds was 
confirmed to be greater than 98% by LC-MS using a Zorbax Eclipse Plus 4.6 mm x 150 mm, 5 
µm analytical reverse phase C18 column with H2O-CH3CN and H2O-MeOH gradients and an 
Agilent 6520 ESI-QTOF Accurate Mass spectrometer (mass accuracy of 5 ppm) operating in the 
positive ion acquisition mode. 
 
2-Nitro-1-pentyl-1H-imidazole (3) 
To a solution of 2-nitroimidazole (2) (113 mg, 1 mmol) in DMF (5 mL) were added K2CO3 (276 
mg, 2 mmol) and 1-iodopentane (156.6 µL, 1.2 mmol). The reaction mixture was stirred for 12 h 
then the solvent was removed under reduced pressure. The reaction mixture was diluted with water 
and extracted with EtOAc (3 x 10 mL). The combined organic layer was dried over Na2SO4, 
concentrated under reduced pressure, and the crude material was purified by silica gel column 
chromatography (20% EtOAc/hexanes) to obtain the compound 3 as a pale yellow oil (150 mg, 
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82%). 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 1.1 Hz, 1H), 7.08 (d, J = 1.1 Hz, 1H), 4.39 (t, J 
= 7.4 Hz, 2H), 1.87 – 1.81 (m, 2H), 1.38 – 1.30 (m, 4H), 0.90 (t, J = 7.1 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 144.88, 128.41, 125.96, 50.49, 30.35, 28.58, 22.23, 13.96. MS (ESI-TOF) for 
C8H13N3O2[M + H]
+ calculated 184.1081, found 184.1076. 
 
1-Pentyl-1H-imidazol-2-amine hydrochloride (4)  
To a solution of compound 3 (18.3 mg, 0.1 mmol) in anhydrous EtOAc (10 mL) was added a 
catalytic amount of Pt/C, and the reaction mixture was subjected to hydrogenation at 30 psi for 1 
h. The reaction mixture was filtered, and the filtrate concentrated under reduced pressure. The 
crude material was purified using silica gel column chromatography (10% MeOH/CH2Cl2) then 
treated with 2N HCl/Et2O to obtain 4 as white solid (15 mg, 79%). 
1H NMR (500 MHz, MeOD) δ 
6.89 (d, J = 2.5 Hz, 1H), 6.84 (d, J = 2.4 Hz, 1H), 3.85 (t, J = 7.3 Hz, 2H), 1.79 – 1.72 (m, 2H), 
1.42 – 1.31 (m, 4H), 0.94 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 147.64, 117.47, 
113.68, 46.41, 29.55, 29.52, 23.29, 14.24. MS (ESI-TOF) for C8H15N3 [M + H]
+ calculated 
154.1339, found 154.1318. 
 
N-Pentylpyrimidin-2-amine (6)  
To a solution of 2-chloropyrimidine (115 mg, 1 mmol) in MeOH (2 mL), was added DIPEA (174 
µL, 1 mmol) and amyl amine (116 µL, 1 mmol). The reaction mixture was stirred for 12 h at 75 
ºC. The reaction mixture was cooled to room temperature and the solvent was removed under 
reduced pressure. The reaction mixture was diluted with water and extracted with EtOAc (3 x 20 
mL). The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure, 
and the crude material was purified by flash chromatography (10% MeOH/CH2Cl2) to afford the 
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compound 6 as a pale oil (125 mg, 75%). 1H NMR (500 MHz, CDCl3) δ 8.26 (d, J = 4.8 Hz, 2H), 
6.49 (t, J = 4.8 Hz, 1H), 5.17 (s, 1H), 3.38 (td, J = 5.7, 7.2 Hz, 2H), 1.64 – 1.57 (m, 2H), 1.38 – 
1.34 (m, 4H), 0.90 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 162.56, 158.15, 110.42, 
41.62, 29.41, 29.26, 22.59, 14.17. MS (ESI-TOF) for C9H15N3 [M + H]
+ calculated 166.1339, 
found 166.1436. 
 
1-Pentyl-5-phenyl-1H-imidazol-2-amine hydrochloride (7)  
To a solution of compound 6 (66 mg, 0.4 mmol) in anhydrous acetonitrile (2 mL) was added 2-
bromoacetophenone (107.4 mg, 0.54 mmol). The reaction mixture was then heated under 
microwave conditions (150 W, 150 ºC) in a sealed vial for 20 min. The reaction mixture was cooled 
to room temperature, hydrazine hydrate (0.1 mL, 64% solution) was added, and heated under 
microwave conditions (100 W, 100 ºC) for another 5 min. The reaction mixture was diluted with 
water and extracted with dichloromethane (3 x 20 mL). The combined organic layer was dried 
over Na2SO4 and concentrated under reduced pressure, crude material was purified by flash 
chromatography (10% MeOH/CH2Cl2) then treated with 2N HCl/Et2O to obtain the compound 7 
as a white solid (74 mg, 70%). 1H NMR (500 MHz, MeOD) δ 7.53 – 7.52 (m, 3H), 7.47 – 7.45 (m, 
2H), 6.90 (s, 1H), 3.90 (t, J = 7.6 Hz, 2H), 1.56 – 1.50 (m, 2H), 1.19 – 1.08 (m, 4H), 0.78 (t, J = 
7.1 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 148.27, 130.81, 130.79, 130.70, 130.22, 128.55, 
111.70, 44.03, 29.23, 28.86, 22.95, 14.07. MS (ESI-TOF) for C14H19N3 [M + H]
+ calculated 
230.1652, found 230.1669. 
 
4,5-Dibromo-2-nitro-1-pentyl-1H-imidazole (8)  
To a solution of compound 3 (91.6 mg, 0.5 mmol) in anhydrous DMF (5 mL) was added NBS 
(180 mg, 1 mmol), and the reaction mixture was stirred for 12 h at 75 ºC. The reaction mixture 
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was cooled to room temperature and the solvent was removed under reduced pressure. The reaction 
mixture was diluted with water and extracted with EtOAc (3 x 10 mL). The combined organic 
layer was dried over Na2SO4, concentrated under reduced pressure, and the crude material was 
purified by flash chromatography (10% EtOAc/hexanes) to obtain the compound 8 as a pale yellow 
solid (102 mg, 60 %). 1H NMR (500 MHz, CDCl3) δ 4.50 (t, J = 7.8 Hz, 2H), 1.84 – 1.78 (m, 2H), 
1.40 – 1.36 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 143.92, 118.01, 
112.75, 50.65, 29.59, 28.54, 22.24, 13.96. MS (ESI-TOF) for C8H11Br2N3O2 [M + H]
+ calculated 
339.9291, found 339.9252. 
 
2-Nitro-1-pentyl-4,5-diphenyl-1H-imidazole (9)  
To a stirred solution of compound 8 (68.2 mg, 0.2 mmol) in 1,4-dioxane (3 mL) were added 
phenylboronic acid (97.6 mg, 0.8 mmol), Pd(dppf)Cl2 (29.2 mg, 0.04 mmol) and K2CO3 (221 mg, 
1.6 mmol). The resulting reaction mixture was stirred at 90 ºC under nitrogen atmosphere for 12 
h. The reaction mixture was diluted with water and extracted with EtOAc (3 x 20 mL). The 
combined organic layer was dried over Na2SO4 and concentrated under reduced pressure, crude 
material was purified by flash chromatography (20% EtOAc/hexanes) to obtain the compound 9 
as a yellow solid (37 mg, 55%). 1H NMR (500 MHz, CDCl3) δ 7.59 – 7.51 (m, 3H), 7.46 – 7.44 
(m, 2H), 7.39 – 7.37 (m, 2H), 7.22 – 7.21 (m, 3H), 4.20 (t, J = 7.9 Hz, 2H), 1.73 – 1.67 (m, 2H), 
1.21 – 1.14 (m, 4H), 0.80 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.75, 138.33, 
134.33, 132.19, 130.95, 130.38, 129.64, 128.64, 128.42, 128.02, 127.35, 47.56, 30.39, 28.61, 
21.99, 13.88. MS (ESI-TOF) for C20H21N3O2 [M + H]
+ calculated 336.1707, found 336.1814.  
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Compound 10 was synthesized similarly as compound 4. 
 
1-Pentyl-4,5-diphenyl-1H-imidazol-2-amine hydrochloride (10)  
Compound 9 was used as reagent. Off-white solid (28 mg, 82%). 1H NMR (500 MHz, MeOD) δ 
7.57 – 7.52 (m, 3H), 7.45 – 7.42 (m, 2H), 7.30 – 7.28 (m, 3H), 7.24 – 7.21 (m, 2H), 3.77 (t, J = 
7.7 Hz, 2H), 1.57 – 1.50 (m, 2H), 1.18 – 1.11 (m, 4H), 0.79 (t, J = 6.7 Hz, 3H). 13C NMR (126 
MHz, MeOD) δ 147.79, 132.53, 131.31, 130.57, 129.86, 129.67, 128.85, 128.43, 127.93, 125.65, 
124.70, 44.09, 29.28, 28.97, 22.93, 14.06. MS (ESI-TOF) for C20H23N3 [M + H]
+ calculated 
306.1965, found 306.1971. 
 
4-Bromo-2-nitro-1-pentyl-1H-imidazole (11)  
To a solution of compound 3 (183 mg, 1 mmol) in anhydrous DMF (10 mL) was added NBS (178 
mg, 1 mmol), and the reaction mixture was stirred for 24 h at 50 ºC. The reaction mixture was 
cooled to room temperature and the solvent was removed under reduced pressure. The reaction 
mixture was diluted with water and extracted with EtOAc (3 x 10 mL). The combined organic 
layer was dried over Na2SO4, concentrated under reduced pressure, and the crude material was 
purified by silica gel column chromatography (10% EtOAc/hexanes) to obtain the compound 11 
as a yellow oil (196 mg, 75%). 1H NMR (500 MHz, CDCl3) δ 7.08 (s, 1H), 4.39 (t, J = 7.4 Hz, 
2H), 1.88 – 1.82 (m, 2H), 1.39 – 1.31 (m, 4H), 0.91 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 143.45, 125.44, 115.13, 50.95, 30.27, 28.55, 22.23, 13.95. MS (ESI-TOF) for 
C8H12BrN3O2 [M + H]
+ calculated 262.0186, found 262.0149. 
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2-Nitro-1-pentyl-4-phenyl-1H-imidazole (12a)  
To a stirred solution of compound 11 (52 mg, 0.2 mmol) in 1,4-dioxane (2 mL) were added 
phenylboronic acid (48.8 mg, 0.4 mmol), Pd(dppf)Cl2 (14.6 mg, 0.02 mmol) and K2CO3 (110 mg, 
0.8 mmol). The resulting reaction mixture was stirred at 85 ºC under nitrogen atmosphere for 8 h. 
The reaction mixture was diluted with water and extracted with EtOAc (3 x 20 mL). The combined 
organic layer was dried over Na2SO4 and concentrated under reduced pressure, crude material was 
purified by flash chromatography (15% EtOAc/hexanes) to obtain the compound 12a as a yellow 
oil (45 mg, 87%). 1H NMR (500 MHz, CDCl3) δ 7.83 – 7.80 (m, 2H), 7.43 – 7.40 (m, 2H), 7.36 – 
7.32 (m, 2H), 4.44 (t, J = 7.4 Hz, 2H),1.94 – 1.87 (m, 2H), 1.40 – 1.36 (m, 4H), 0.92 (t, J = 6.9 
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.61, 140.85, 131.68, 128.94, 128.64, 125.46, 121.49, 
50.84, 30.41, 28.68, 22.31, 14.01. MS (ESI-TOF) for C14H17N3O2 [M + H]
+ calculated 260.1394, 
found 260.1470. 
 
Compounds 12b-i, 13a-f, 14a-b, 14d-h, 15a-g,and 16a-j were synthesized similarly as compound 
12a. 
 
2-Nitro-1-pentyl-4-(o-tolyl)-1H-imidazole (12b)  
o-Tolylboronic acid was used as reagent. Yellow solid (42 mg, 77%). 1H NMR (500 MHz, CDCl3) 
δ 7.76 – 7.73 (m, 1H), 7.25 – 7.23 (m, 3H), 7.19 (s, 1H), 4.44 (t, J = 7.4 Hz, 2H), 2.49 (s, 3H), 
1.93 – 1.87 (m, 2H), 1.40 – 1.34 (m, 4H), 0.91 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
144.08, 140.56, 135.53, 131.20, 131.09, 129.10, 128.50, 126.30, 124.00, 50.66, 30.44, 28.69, 
22.30, 21.64, 14.02. MS (ESI-TOF) for C15H19N3O2 [M + H]
+ calculated 274.1550, found 
274.1581. 
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4-(2-Ethylphenyl)-2-nitro-1-pentyl-1H-imidazole (12c)  
2-Ethylphenylboronic acid was used as reagent. Yellow oil (50 mg, 87%). 1H NMR (500 MHz, 
CDCl3) δ 7.60 (dd, J = 1.2, 7.5 Hz, 1H), 7.34 – 7.28 (m, 2H), 7.25 – 7.22 (m, 1H), 7.16 (s, 1H), 
4.46 (t, J = 7.3 Hz, 2H), 2.85 (q, J = 7.5 Hz, 2H), 1.95 – 1.88 (m, 2H), 1.41 – 1.36 (m, 4H), 1.22 
(t, J = 7.5 Hz, 3H), 0.93 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.10, 142.11, 140.69, 
130.82, 129.74, 129.16, 128.84, 126.12, 123.78, 50.63, 30.41, 28.69, 26.75, 22.31, 15.43, 14.04. 
MS (ESI-TOF) for C16H21N3O2 [M + H]
+ calculated 288.1707, found 288.1700. 
 
2-Nitro-1-pentyl-4-(m-tolyl)-1H-imidazole (12d)  
m-Tolylboronic acid was used as reagent. Yellow solid (46 mg, 84%). 1H NMR (500 MHz, CDCl3) 
δ 7.69 (s, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.35 (s, 1H), 7.30 (t, J = 7.6 Hz, 1H), 7.16 (d, J = 7.5 Hz, 
1H), 4.44 (t, J = 7.5 Hz, 2H), 2.39 (s, 3H), 1.94 – 1.87 (m, 2H), 1.40 – 1.35 (m, 4H), 0.92 (t, J = 
6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.55, 141.00, 138.76, 131.53, 129.45, 128.81, 
126.16, 122.50, 121.52, 50.84, 30.41, 28.68, 22.31, 21.53, 14.02. MS (ESI-TOF) for C15H19N3O2 
[M + H]+ calculated 274.1550, found 274.1578. 
 
2-Nitro-1-pentyl-4-(p-tolyl)-1H-imidazole (12e)  
p-Tolylboronic acid was used as reagent. Yellow solid (44 mg, 80%). 1H NMR (500 MHz, CDCl3) 
δ 7.70 (d, J = 8.0 Hz, 2H), 7.31 (s, 1H), 7.22 (d, J = 8.0 Hz, 2H), 4.43 (t, J = 7.4 Hz, 2H), 2.37 (s, 
3H), 1.93 – 1.85 (m, 2H), 1.42 – 1.33 (m, 4H), 0.92 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 144.49, 141.02, 138.60, 129.62, 128.87, 125.37, 121.20, 50.80, 30.40, 28.68, 22.30, 
21.45, 14.01. MS (ESI-TOF) for C15H19N3O2 [M + H]
+ calculated 274.1550, found 274.1579. 
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4-(2,3-Dimethylphenyl)-2-nitro-1-pentyl-1H-imidazole (12f)  
2,3-Dimethylphenylboronic acid was used as reagent. Yellow oil (50 mg, 87%). 1H NMR (500 
MHz, CDCl3) δ 7.42 (dd, J = 1.7, 7.4 Hz, 1H), 7.20 – 7.12 (m, 3H), 4.46 (t, J = 7.4 Hz, 2H), 2.37 
(s, 3H), 2.34 (s, 3H), 1.95 – 1.88 (m, 2H), 1.42 – 1.36 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 143.98, 141.38, 137.60, 134.68, 131.71, 130.27, 127.63, 125.70, 124.21, 
50.62, 30.42, 28.71, 22.30, 20.89, 17.07, 14.03. MS (ESI-TOF) for C16H21N3O2 [M + H]
+ 
calculated 288.1707, found 288.1802. 
 
4-(2,4-Dimethylphenyl)-2-nitro-1-pentyl-1H-imidazole (12g)  
2,4-Dimethylphenylboronic acid was used as reagent. Yellow oil (45 mg, 78%). 1H NMR (500 
MHz, CDCl3) δ 7.65 (d, J = 7.7 Hz, 1H), 7.17 (s, 1H), 7.10 – 7.04 (m, 2H), 4.45 (t, J = 7.4 Hz, 
2H), 2.46 (s, 3H), 2.34 (s, 3H), 1.94 – 1.87 (m, 2H), 1.40 – 1.36 (m, 4H), 0.92 (t, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 144.01, 140.70, 138.35, 135.29, 131.86, 129.02, 128.35, 127.06, 
123.79, 50.63, 30.44, 28.70, 22.30, 21.58, 21.27, 14.03. MS (ESI-TOF) for C16H21N3O2 [M + H]
+ 
calculated 288.1707, found 288.1771. 
 
4-(2,5-Dimethylphenyl)-2-nitro-1-pentyl-1H-imidazole (12h)  
2,5-Dimethylphenylboronic acid was used as reagent. Yellow solid (50 mg, 87%). 1H NMR (500 
MHz, CDCl3) δ 7.61 (s, 1H), 7.19 (s, 1H), 7.13 (d, J = 7.7 Hz, 1H), 7.07 (dd, J = 1.9, 7.7 Hz, 1H), 
4.45 (t, J = 7.4 Hz, 2H), 2.45 (s, 3H), 2.35 (s, 3H), 1.95 – 1.87 (m, 2H), 1.40 – 1.35 (m, 4H), 0.93 
(t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.05, 140.61, 135.90, 132.24, 131.05, 130.89, 
129.56, 129.28, 124.06, 50.67, 30.44, 28.69, 22.30, 21.25, 21.03, 14.03. MS (ESI-TOF) for 
C16H21N3O2 [M + H]
+ calculated 288.1707, found 288.1677. 
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4-(2,6-Dimethylphenyl)-2-nitro-1-pentyl-1H-imidazole (12i)  
2,6-Dimethylphenylboronic acid was used as reagent. Yellow oil (48 mg, 84%). 1H NMR (500 
MHz, CDCl3) δ 7.20 – 7.16 (m, 1H), 7.11 – 7.05 (m, 2H), 6.98 (s, 1H), 4.48 (t, J = 7.2 Hz, 2H), 
2.17 (s, 6H), 1.96 – 1.89 (m, 2H), 1.42 – 1.33 (m, 4H), 0.92 (t, J = 7.0 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 144.33, 139.57, 137.88, 131.75, 128.69, 127.63, 124.74, 50.56, 30.31, 28.65, 
22.28, 20.89, 14.05. MS (ESI-TOF) for C16H21N3O2 [M + H]
+ calculated 288.1707, found 
288.1735. 
 
4-Benzyl-2-nitro-1-pentyl-1H-imidazole (13a)  
Benzylboronic acid pinacol ester was used as reagent. Yellow oil (30 mg, 55%). 1H NMR (500 
MHz, CDCl3) δ 7.34 – 7.30 (m, 2H), 7.27 – 7.23 (m, 3H), 6.65 (s, 1H), 4.29 (t, J = 7.5 Hz, 2H), 
3.96 (s, 2H), 1.83 – 1.75 (m, 2H), 1.38 – 1.23 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 143.87, 142.16, 138.41, 129.04, 128.86, 126.85, 123.40, 50.43, 35.14, 30.37, 
28.64, 22.24, 13.99. MS (ESI-TOF) for C15H19N3O2 [M + H]
+ calculated 274.1550, found 
274.1587. 
 
(E)-2-Nitro-1-pentyl-4-styryl-1H-imidazole (13b)  
Trans-2-Phenylvinylboronic acid was used as reagent. Yellow solid (40 mg, 70%). 1H NMR (500 
MHz, CDCl3) δ 7.50 – 7.48 (m, 2H), 7.41 – 7.34 (m, 3H), 7.29 – 7.27 (m, 1H), 7.12 (s, 1H), 6.92 
(d, J = 16.2 Hz, 1H), 4.40 (t, J = 7.3 Hz, 2H), 1.92 – 1.84 (m, 2H), 1.40 – 1.32 (m, 4H), 0.92 (t, J 
= 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.41, 139.45, 136.61, 131.35, 128.89, 128.29, 
126.76, 123.19, 117.99, 50.74, 30.36, 28.66, 22.30, 14.01. MS (ESI-TOF) for C16H19N3O2 [M + 
H]+ calculated 286.1550, found 286.1584. 
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4-(Naphthalen-1-yl)-2-nitro-1-pentyl-1H-imidazole (13c)  
1-Naphthylboronic acid was used as reagent. Yellow oil (55 mg, 89%). 1H NMR (500 MHz, 
CDCl3) δ 8.43 – 8.39 (m, 1H), 7.91 – 7.88 (m, 2H), 7.74 (dd, J = 1.2, 7.1 Hz, 1H), 7.59 – 7.48 (m, 
3H), 7.38 (s, 1H), 4.52 (t, J = 7.4 Hz, 2H), 2.02 – 1.92 (m, 2H), 1.45 – 1.39 (m, 4H), 0.95 (t, J = 
7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.44, 140.33, 134.02, 131.00, 129.38, 129.32, 
128.74, 127.49, 126.99, 126.18, 125.44, 125.21, 124.52, 50.79, 30.50, 28.77, 22.33, 14.05. MS 
(ESI-TOF) for C18H19N3O2 [M + H]
+ calculated 310.1550, found 310.1611. 
 
4-(Naphthalen-2-yl)-2-nitro-1-pentyl-1H-imidazole (13d)  
2-Naphthylboronic acid was used as reagent. Yellow solid (45 mg, 73%). 1H NMR (400 MHz, 
CDCl3) δ 8.36 (s, 1H), 7.91 – 7.82 (m, 4H), 7.53 – 7.46 (m, 3H), 4.47 (t, J = 7.4 Hz, 2H), 1.97 – 
1.90 (m, 2H), 1.41 – 1.38 (m, 4H), 0.94 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.73, 
140.87, 133.60, 133.41, 128.95, 128.68, 128.42, 127.90, 126.72, 126.50, 124.44, 123.24, 121.84, 
50.92, 30.45, 28.72, 22.33, 14.03. MS (ESI-TOF) for C18H19N3O2 [M + H]
+ calculated 310.1550, 
found 310.1627. 
 
4-([1,1'-Biphenyl]-4-yl)-2-nitro-1-pentyl-1H-imidazole (13e)  
4-Biphenylboronic acid was used as reagent. Yellow solid (56 mg, 83%). 1H NMR (500 MHz, 
CDCl3) δ 7.90 – 7.83 (m, 2H), 7.67 – 7.62 (m, 4H), 7.48 – 7.43 (m, 2H), 7.39 (s, 1H), 7.38 – 7.33 
(m, 1H), 4.46 (t, J = 7.4 Hz, 2H), 1.95 – 1.89 (m, 2H), 1.40 – 1.38 (m, 4H), 0.93 (t, J = 7.0 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 144.66, 141.38, 140.55, 130.63, 128.98, 127.68, 127.60, 
127.12, 125.86, 121.56, 115.78, 50.89, 30.42, 28.69, 22.32, 14.02. MS (ESI-TOF) for C20H21N3O2 
[M + H]+ calculated 336.1707, found 336.1764. 
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4-(2-(Benzyloxy)phenyl)-2-nitro-1-pentyl-1H-imidazole (13f)  
2-(Benzyloxy)phenylboronic acid was used as reagent. Yellow solid (55 mg, 75%). 1H NMR (500 
MHz, CDCl3) δ 8.27 (dd, J = 1.8, 7.7 Hz, 1H), 7.55 (s, 1H), 7.50 – 7.46 (m, 2H), 7.45 – 7.38 (m, 
3H), 7.33 – 7.28 (m, 1H), 7.11 – 7.02 (m, 2H), 5.18 (s, 2H), 4.28 (t, J = 7.3 Hz, 2H), 1.78 – 1.71 
(m, 2H), 1.35 – 1.21 (m, 4H), 0.89 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 155.92, 
143.84, 136.74, 136.70, 129.33, 128.88, 128.57, 128.27, 128.16, 126.26, 121.51, 120.72, 112.00, 
70.81, 50.47, 29.97, 28.52, 22.23, 14.01. MS (ESI-TOF) for C21H23N3O3 [M + H]
+ calculated 
366.1812, found 366.1814. 
 
3-(2-Nitro-1-pentyl-1H-imidazol-4-yl)pyridine (14a)  
3-Pyridinylboronic acid was used as reagent. Gray solid (30 mg, 58%). 1H NMR (500 MHz, 
CDCl3) δ 8.98 (d, J = 1.4 Hz, 1H), 8.58 (dd, J = 1.6, 4.8 Hz, 1H), 8.19 – 8.17 (m, 1H), 7.43 (s, 
1H), 7.40 – 7.30 (m, 1H), 4.47 (t, J = 7.5 Hz, 2H), 1.95 – 1.89 (m, 2H), 1.40 – 1.38 (m, 4H), 0.93 
(t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 149.62, 146.77, 144.93, 137.80, 132.95, 127.86, 
123.89, 121.73, 50.98, 30.43, 28.67, 22.29, 14.00. MS (ESI-TOF) for C13H16N4O2 [M + H]
+ 
calculated 261.1346, found 261.1390. 
 
3,5-Dimethyl-4-(2-nitro-1-pentyl-1H-imidazol-4-yl)isoxazole (14b)  
3,5-Dimethylisoxazol-4-yl-4-boronic acid was used as reagent. Yellow solid (42 mg, 75%). 1H 
NMR (500 MHz, CDCl3) δ 7.08 (s, 1H), 4.44 (t, J = 7.5 Hz, 2H), 2.61 (s, 3H), 2.42 (s, 3H), 1.94 
– 1.87 (m, 2H), 1.42 – 1.33 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
167.32, 158.23, 132.07, 128.46, 122.33, 108.50, 50.72, 30.47, 28.69, 22.28, 14.02, 12.58, 11.67. 
MS (ESI-TOF) for C13H18N4O3 [M + H]
+ calculated 279.1452, found 279.1423. 
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2-(2-Nitro-1-pentyl-1H-imidazol-4-yl)benzaldehyde (14d)  
2-Formylphenylboronic acid was used as reagent. Yellow solid (42 mg, 73%). 1H NMR (500 MHz, 
CDCl3) δ 10.40 (s, 1H), 7.98 (dd, J = 1.4, 7.7 Hz, 1H), 7.75 (dd, J = 1.2, 7.7 Hz, 1H), 7.66 – 7.63 
(m, 1H), 7.53 – 7.49 (m, 1H), 7.40 (s, 1H), 4.48 (t, J = 7.4 Hz, 2H), 1.97 – 1.89 (m, 2H), 1.41 – 
1.37 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 192.29, 144.63, 137.56, 
134.35, 133.95, 133.89, 130.18, 129.48, 128.94, 125.30, 50.88, 30.42, 28.67, 22.27, 14.00. MS 
(ESI-TOF) for C15H17N3O3 [M + H]
+ calculated 288.1343, found 288.1349. 
 
2-Nitro-4-(4-nitrophenyl)-1-pentyl-1H-imidazole (14e)  
4-Nitrophenylboronic acid was used as reagent. Red solid (43 mg, 71%). 1H NMR (500 MHz, 
CDCl3) δ 8.28 (d, J = 8.9 Hz, 2H), 7.98 (d, J = 9.0 Hz, 2H), 7.50 (s, 1H), 4.48 (t, J = 7.5 Hz, 2H), 
1.96 – 1.89 (m, 2H), 1.42 – 1.37 (m, 4H), 0.93 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
147.63, 145.04, 138.25, 137.89, 125.96, 124.43, 122.88, 51.11, 30.43, 28.67, 22.29, 14.00. MS 
(ESI-TOF) for C14H16N4O4 [M + H]
+ calculated 305.1244, found 305.1260. 
 
4-(2-Nitro-1-pentyl-1H-imidazol-4-yl)benzamide (14f)  
4-Aminocarbonylphenylboronic acid was used as reagent. Yellow solid (52 mg, 86%). 1H NMR 
(500 MHz, DMSO-d6) δ 8.34 (s, 1H), 8.01 (s, 1H), 7.95 (d, J = 8.5 Hz, 2H), 7.90 (d, J = 8.5 Hz, 
2H), 7.39 (s, 1H), 4.40 (t, J = 7.4 Hz, 2H), 1.88 – 1.81 (m, 2H), 1.36 – 1.28 (m, 4H), 0.88 (t, J = 
6.9 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 167.40, 144.56, 137.95, 134.56, 133.52, 128.19, 
124.77, 124.40, 49.95, 29.25, 28.02, 21.66, 13.82. MS (ESI-TOF) for C15H18N4O3 [M + H]
+ 
calculated 303.1452, found 303.1446. 
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Methyl 4-(2-nitro-1-pentyl-1H-imidazol-4-yl)benzoate (14g)  
4-Methoxycarbonylphenylboronic acid was used as reagent. Yellow solid (50 mg, 79%). 1H NMR 
(500 MHz, CDCl3) δ 8.09 (d, J = 8.7 Hz, 2H), 7.89 (d, J = 8.5 Hz, 2H), 7.45 (s, 1H), 4.46 (t, J = 
7.6 Hz, 2H), 3.94 (s, 3H), 1.96 – 1.87 (m, 2H), 1.42 – 1.36 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 166.85, 144.82, 139.59, 135.94, 130.31, 129.98, 125.26, 122.36, 52.35, 
50.98, 30.43, 28.67, 22.30, 14.00. MS (ESI-TOF) for C16H19N3O4 [M + H]
+ calculated 318.1448, 
found 318.1430. 
 
Methyl 2-(2-nitro-1-pentyl-1H-imidazol-4-yl)benzoate (14h)  
2-Methoxycarbonylphenylboronic acid was used as reagent. Yellow oil (55 mg, 87%). 1H NMR 
(500 MHz, CDCl3) δ 7.78 – 7.74 (m, 2H), 7.55 – 7.52 (m, 1H), 7.42 (dd, J = 1.3, 7.6 Hz, 1H), 7.39 
(s, 1H), 4.44 (t, J = 7.4 Hz, 2H), 3.86 (s, 3H), 1.94 – 1.86 (m, 2H), 1.41 – 1.35 (m, 4H), 0.93 (t, J 
= 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.03, 144.02, 138.79, 131.70, 131.50, 130.46, 
130.13, 129.70, 128.36, 124.70, 52.58, 50.74, 30.41, 28.66, 22.31, 14.03. MS (ESI-TOF) for 
C16H19N3O4 [M + H]
+ calculated 318.1448, found 318.1544. 
 
4-(2-Methoxyphenyl)-2-nitro-1-pentyl-1H-imidazole (15a)  
2-Methoxyphenylboronic acid was used as reagent. Yellow solid (45 mg, 78%). 1H NMR (500 
MHz, CDCl3) δ 8.24 (dd, J = 1.8, 7.7 Hz, 1H), 7.66 (s, 1H), 7.36 – 7.27 (m, 1H), 7.07 – 7.04 (m, 
1H), 6.97 (dd, J = 1.0, 8.3 Hz, 1H), 4.43 (t, J = 7.4 Hz, 2H), 3.97 (s, 3H), 1.93 – 1.86 (m, 2H), 1.41 
– 1.36 (m, 4H), 0.92 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 156.67, 143.84, 136.90, 
129.38, 128.27, 126.07, 121.20, 120.38, 110.85, 55.54, 50.60, 30.46, 28.66, 22.31, 14.03. MS 
(ESI-TOF) for C15H19N3O3 [M + H]
+ calculated 290.1499, found 290.1494. 
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4-(3-Methoxyphenyl)-2-nitro-1-pentyl-1H-imidazole (15b)  
3-Methoxyphenylboronic acid was used as reagent. Yellow solid (48 mg, 83%). 1H NMR (500 
MHz, CDCl3) δ 7.38 (dd, J = 1.5, 2.6 Hz, 1H), 7.37 – 7.33 (m, 2H), 7.31 (t, J = 7.8 Hz, 1H), 6.91 
– 6.86 (m, 1H), 4.43 (t, J = 7.4 Hz, 2H), 3.87 (s, 3H), 1.93 – 1.85 (m, 2H), 1.41 – 1.33 (m, 4H), 
0.92 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 160.21, 144.50, 140.71, 133.06, 129.95, 
121.75, 117.83, 114.70, 110.57, 55.58, 50.85, 30.39, 28.66, 22.30, 14.00. MS (ESI-TOF) for 
C15H19N3O3 [M + H]
+ calculated 290.1499, found 290.1503. 
4-(4-Methoxyphenyl)-2-nitro-1-pentyl-1H-imidazole (15c)  
4-Methoxyphenylboronic acid was used as reagent. Yellow oil (44 mg, 76%). 1H NMR (500 MHz, 
CDCl3) δ 7.74 (d, J = 8.9 Hz, 2H), 7.26 (s, 1H), 6.94 (d, J = 8.8 Hz, 2H), 4.43 (t, J = 7.3 Hz, 2H), 
3.84 (s, 3H), 1.93 – 1.85 (m, 2H), 1.41 – 1.34 (m, 4H), 0.92 (t, J = 7.0 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 160.06, 144.46, 140.93, 126.86, 124.41, 120.72, 114.33, 55.50, 50.79, 30.42, 
28.69, 22.32, 14.02. MS (ESI-TOF) for C15H19N3O3 [M + H]
+ calculated 290.1499, found 
290.1505. 
 
4-(4-Methoxy-2-methylphenyl)-2-nitro-1-pentyl-1H-imidazole (15d)  
4-Methoxy-2-methylphenylboronic acid was used as reagent. Yellow solid (45 mg, 74%). 1H NMR 
(500 MHz, CDCl3) δ 7.68 (d, J = 8.4 Hz, 1H), 7.13 (s, 1H), 6.82 – 6.77 (m, 2H), 4.44 (t, J = 7.4 
Hz, 2H), 3.82 (s, 3H), 2.47 (s, 3H), 1.95 – 1.86 (m, 2H), 1.41 – 1.36 (m, 4H), 0.92 (t, J = 6.9 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 159.63, 143.96, 140.56, 137.14, 130.47, 124.00, 123.45, 
116.45, 111.57, 55.39, 50.61, 30.44, 28.70, 22.31, 21.86, 14.03. MS (ESI-TOF) for C16H21N3O3 
[M + H]+ calculated 304.1656, found 304.1655. 
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4-(2-Methoxy-3-methylphenyl)-2-nitro-1-pentyl-1H-imidazole (15e)  
(2-Methoxy-3-methylphenyl)boronic acid was used as reagent. Yellow solid (42 mg, 69%). 1H 
NMR (500 MHz, CDCl3) δ 7.97 (dd, J = 1.3, 7.5 Hz, 1H), 7.69 (s, 1H), 7.17 (dd, J = 1.2, 7.4 Hz, 
1H), 7.11 (t, J = 7.6 Hz, 1H), 4.46 (t, J = 7.3 Hz, 2H), 3.69 (s, 3H), 2.35 (s, 3H), 1.94 – 1.86 (m, 
2H), 1.40 – 1.36 (m, 4H), 0.92 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 156.01, 144.04, 
137.13, 131.58, 131.45, 126.53, 125.56, 124.97, 124.78, 59.68, 50.70, 30.37, 28.67, 22.31, 16.14, 
14.03. MS (ESI-TOF) for C16H21N3O3 [M + H]
+ calculated 304.1656, found 304.1651. 
4-(2,3-Dimethoxyphenyl)-2-nitro-1-pentyl-1H-imidazole (15f)  
2,3-Dimethoxyphenylboronic acid was used as reagent. Yellow solid (50 mg, 78%). 1H NMR (500 
MHz, CDCl3) δ 7.75 (dd, J = 1.5, 8.0 Hz, 1H), 7.70 (s, 1H), 7.13 (t, J = 8.1 Hz, 1H), 6.90 (dd, J = 
1.5, 8.1 Hz, 1H), 4.45 (t, J = 7.3 Hz, 2H), 3.91 (s, 3H), 3.85 (s, 3H), 1.93 – 1.86 (m, 2H), 1.41 – 
1.33 (m, 4H), 0.91 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 152.96, 146.62, 143.99, 
136.75, 125.93, 125.65, 124.66, 120.01, 112.32, 59.98, 56.02, 50.68, 30.37, 28.64, 22.30, 14.03. 
MS (ESI-TOF) for C16H21N3O4 [M + H]
+ calculated 320.1605, found 320.1597. 
 
2-Nitro-1-pentyl-4-(3,4,5-trimethoxyphenyl)-1H-imidazole (15g)  
3,4,5-Trimethoxyphenyl-boronic acid was used as reagent. Yellow solid (60 mg, 86%). 1H NMR 
(500 MHz, CDCl3) δ 7.32 (s, 1H), 7.02 (s, 2H), 4.45 (t, J = 7.4 Hz, 2H), 3.94 (s, 6H), 3.88 (s, 3H), 
1.94 – 1.87 (m, 2H), 1.41 – 1.35 (m, 4H), 0.93 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
153.79, 144.44, 140.83, 138.66, 127.39, 121.35, 102.71, 61.13, 56.49, 50.89, 30.45, 28.69, 22.32, 
14.02. MS (ESI-TOF) for C17H23N3O5 [M + H]
+ calculated 350.1710, found 350.1685. 
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4-(2-Chlorophenyl)-2-nitro-1-pentyl-1H-imidazole (16a)  
2-Chlorophenylboronic acid was used as reagent. Yellow oil (42 mg, 72%). 1H NMR (500 MHz, 
CDCl3) δ 8.16 (dd, J = 1.7, 7.9 Hz, 1H), 7.81 (s, 1H), 7.43 (dd, J = 1.3, 8.0 Hz, 1H), 7.38 – 7.34 
(m, 1H), 7.29 – 7.25 (m, 1H), 4.47 (t, J = 7.4 Hz, 2H), 1.95 – 1.89 (m, 2H), 1.42 – 1.36 (m, 4H), 
0.93 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.00, 137.05, 131.36, 130.40, 130.34, 
130.24, 129.37, 127.37, 125.78, 50.82, 30.42, 28.64, 22.29, 14.02. MS (ESI-TOF) for 
C14H16ClN3O2 [M + H]
+ calculated 294.1004, found 294.0970. 
 
4-(3-Chlorophenyl)-2-nitro-1-pentyl-1H-imidazole (16b)  
3-Chlorophenylboronic acid was used as reagent. Yellow oil (42 mg, 72%). 1H NMR (500 MHz, 
CDCl3) δ 7.82 (t, J = 1.7 Hz, 1H), 7.69 (dt, J = 1.5, 7.5 Hz, 1H), 7.36 (s, 1H), 7.34 – 7.29 (m, 2H), 
4.45 (t, J = 7.4 Hz, 2H), 1.94 – 1.87 (m, 2H), 1.41 – 1.36 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 144.68, 139.41, 135.05, 133.48, 130.23, 128.61, 125.54, 123.52, 
121.76, 50.94, 30.40, 28.67, 22.30, 14.01. MS (ESI-TOF) for C14H16ClN3O2 [M + H]
+ calculated 
294.1004, found 294.0961. 
 
4-(4-Chlorophenyl)-2-nitro-1-pentyl-1H-imidazole (16c)  
4-Chlorophenylboronic acid was used as reagent. Yellow solid (49 mg, 84%). 1H NMR (500 MHz, 
CDCl3) δ 7.74 (d, J = 8.7 Hz, 2H), 7.38 (d, J = 8.6 Hz, 2H), 7.34 (s, 1H), 4.44 (t, J = 7.4 Hz, 2H), 
1.93 – 1.86 (m, 2H), 1.41 – 1.35 (m, 4H), 0.92 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
144.61, 139.73, 134.45, 130.22, 129.15, 126.72, 121.46, 50.89, 30.41, 28.67, 22.30, 14.00. MS 
(ESI-TOF) for C14H16ClN3O2 [M + H]
+ calculated 294.1004, found 294.0981. 
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4-(2-Fluorophenyl)-2-nitro-1-pentyl-1H-imidazole (16d)  
2-Fluorophenylboronic acid was used as reagent. Yellow solid (38 mg, 68%). 1H NMR (500 MHz, 
CDCl3) δ 8.20 (td, J = 1.9, 7.8 Hz, 1H), 7.53 (d, J = 3.5 Hz, 1H), 7.33 – 7.28 (m, 1H), 7.25 – 7.22 
(m, 1H), 7.15 – 7.10 (m, 1H), 4.45 (t, J = 7.4 Hz, 2H), 1.94 – 1.88 (m, 2H), 1.42 – 1.35 (m, 4H), 
0.93 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 160.26 (d, J = 248.4 Hz), 144.28, 134.78 
(d, J = 1.7 Hz), 129.73 (d, J = 8.5 Hz), 128.30 (d, J = 3.4 Hz), 125.39 (d, J = 14.9 Hz), 124.77 (d, 
J = 3.2 Hz), 119.63 (d, J = 12.2 Hz), 115.76 (d, J = 21.6 Hz), 50.81, 30.41, 28.64, 22.29, 14.00. 
MS (ESI-TOF) for C14H16FN3O2 [M + H]
+ calculated 278.1299, found 278.1256. 
 
4-(3-Fluorophenyl)-2-nitro-1-pentyl-1H-imidazole (16e)  
3-Fluorophenylboronic acid was used as reagent. Yellow oil (42 mg, 76%). 1H NMR (500 MHz, 
CDCl3) δ 7.59 – 7.56 (m, 1H), 7.55 – 7.50 (m, 1H), 7.40 – 7.35 (m, 2H), 7.05 – 7.00 (m, 1H), 4.45 
(t, J = 7.4 Hz, 2H), 1.94 – 1.87 (m, 2H), 1.42 – 1.34 (m, 4H), 0.93 (t, J = 6.9 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 163.34 (d, J = 246.0 Hz), 144.61, 139.62 (d, J = 2.8 Hz), 133.92 (d, J = 8.3 
Hz), 130.54 (d, J = 8.4 Hz), 121.75, 121.04 (d, J = 2.9 Hz), 115.47 (d, J = 21.2 Hz), 112.47 (d, J 
= 23.1 Hz), 50.92, 30.41, 28.67, 22.30, 14.00. MS (ESI-TOF) for C14H16FN3O2 [M + H]
+ calculated 
278.1299, found 278.1251. 
 
4-(4-Fluorophenyl)-2-nitro-1-pentyl-1H-imidazole (16f)  
4-Fluorophenylboronic acid was used as reagent. Yellow oil (44 mg, 79%). 1H NMR (500 MHz, 
CDCl3) δ 7.79 (dd, J = 5.3, 8.9 Hz, 2H), 7.30 (s, 1H), 7.12 – 7.08 (m, 2H), 4.44 (t, J = 7.4 Hz, 2H), 
1.94 – 1.87 (m, 2H), 1.40 – 1.36 (m, 4H), 0.93 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
163.04 (d, J = 248.0 Hz), 144.56, 140.01, 127.94 (d, J = 3.2 Hz), 127.28 (d, J = 8.2 Hz), 121.10, 
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115.96 (d, J = 21.8 Hz), 50.85, 30.42, 28.68, 22.31, 14.01. MS (ESI-TOF) for C14H16FN3O2 [M + 
H]+ calculated 278.1299, found 278.1252. 
 
4-(4-Fluoro-2-methylphenyl)-2-nitro-1-pentyl-1H-imidazole (16g)  
4-Fluoro-2-methyl-phenylboronic acid was used as reagent. Yellow oil (50 mg, 86%). 1H NMR 
(500 MHz, CDCl3) δ 7.70 (dd, J = 5.9, 9.4 Hz, 1H), 7.16 (s, 1H), 7.00 – 6.90 (m, 2H), 4.45 (t, J = 
7.4 Hz, 2H), 2.48 (s, 3H), 1.95 – 1.88 (m, 2H), 1.41 – 1.35 (m, 4H), 0.93 (t, J = 6.9 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 162.47 (d, J = 247.5 Hz), 143.93, 139.59, 137.98 (d, J = 7.7 Hz), 
130.84 (d, J = 8.6 Hz), 127.30 (d, J = 3.2 Hz), 123.55, 117.49 (d, J = 21.3 Hz), 113.12 (d, J = 21.3 
Hz), 50.54, 30.30, 28.56, 22.16, 21.47, 13.88. MS (ESI-TOF) for C15H18FN3O2 [M + H]
+ calculated 
292.1456, found 292.1463. 
 
2-Nitro-1-pentyl-4-(2-(trifluoromethyl)phenyl)-1H-imidazole (16h)  
2-(Trifluoromethyl) phenylboronic acid was used as reagent. Yellow oil (50 mg, 76%). 1H NMR 
(500 MHz, CDCl3) δ 7.92 (d, J = 7.8 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.62 (t, J = 7.9 Hz, 1H), 
7.48 (t, J = 7.7 Hz, 1H), 7.32 (s, 1H), 4.47 (t, J = 7.3 Hz, 2H), 1.95 – 1.87 (m, 2H), 1.43 – 1.33 (m, 
4H), 0.93 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.20, 137.26, 132.20, 132.11, 
130.97, 128.57, 127.38 (q, J = 30.4 Hz), 126.25 (q, J = 5.8 Hz), 124.91 (q, J = 5.8 Hz), 124.18 (q, 
J = 273.4 Hz), 50.80, 30.31, 28.52, 22.27, 13.98. MS (ESI-TOF) for C15H16F3N3O2 [M + H]
+ 
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2-Nitro-1-pentyl-4-(3-(trifluoromethyl)phenyl)-1H-imidazole (16i)  
3-(Trifluoromethyl) phenylboronic acid was used as reagent. Yellow solid (45 mg, 69%). 1H NMR 
(500 MHz, CDCl3) δ 8.04 (s, 1H), 8.02 (d, J = 7.7 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.54 (t, J = 
7.7 Hz, 1H), 7.43 (s, 1H), 4.46 (t, J = 7.5 Hz, 2H), 1.96 – 1.88 (m, 2H), 1.41 – 1.36 (m, 4H), 0.93 
(t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 144.74, 139.32, 132.56, 131.43 (q, J = 32.4 
Hz), 129.50, 128.65, 125.17 (q, J = 3.8 Hz), 124.07 (q, J = 301.9 Hz), 122.21 (q, J = 3.9 Hz), 
121.85, 50.99, 30.43, 28.68, 22.30, 14.00. MS (ESI-TOF) for C15H16F3N3O2 [M + H]
+ calculated 
328.1267, found 328.1230. 
 
2-Nitro-1-pentyl-4-(4-(trifluoromethyl)phenyl)-1H-imidazole (16j)  
4-(Trifluoromethyl) phenylboronic acid was used as reagent. Yellow oil (52 mg, 79%). 1H NMR 
(500 MHz, CDCl3) δ 7.93 (d, J = 7.9 Hz, 2H), 7.67 (d, J = 7.9 Hz, 2H), 7.43 (s, 1H), 4.46 (t, J = 
7.4 Hz, 2H), 1.96 – 1.87 (m, 2H), 1.41 – 1.36 (m, 4H), 0.93 (t, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 144.80, 139.23, 135.10, 130.41 (q, J = 32.6 Hz), 125.96 (q, J = 3.7 Hz), 125.61, 
124.03 (q, J = 272.1 Hz), 122.14, 50.99, 30.43, 28.68, 22.30, 14.01. MS (ESI-TOF) for 
C15H16F3N3O2 [M + H]
+ calculated 328.1267, found 328.1223. 
 
Compounds 17a-i, 18a-f, 19a-h, 20a-g, and 21a-j were synthesized similarly as compound 4. 
 
1-Pentyl-4-phenyl-1H-imidazol-2-amine hydrochloride (17a)  
Compound 12a was used as reagent. White solid (22 mg, 83%). 1H NMR (500 MHz, MeOD) δ 
7.60 – 7.54 (m, 2H), 7.47 – 7.43 (m, 2H), 7.39 – 7.36 (m, 1H), 7.29 (s, 1H), 3.90 (t, J = 7.4 Hz, 
2H), 1.85 – 1.79 (m, 2H), 1.45 – 1.35 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
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MeOD) δ 148.22, 130.26, 129.77, 128.69, 128.40, 125.56, 113.18, 46.64, 29.59, 29.57, 23.32, 
14.26. MS (ESI-TOF) for C14H19N3 [M + H]
+ calculated 230.1652, found 230.1677. 
 
1-Pentyl-4-(o-tolyl)-1H-imidazol-2-amine hydrochloride (17b)  
Compound 12b was used as reagent. White solid (20 mg, 71%). 1H NMR (400 MHz, MeOD) δ 
7.39 – 7.37 (m, 1H), 7.36 – 7.25 (m, 3H), 7.02 (s, 1H), 3.92 (t, J = 7.3 Hz, 2H), 2.41 (s, 3H), 1.85 
– 1.79 (m, 2H), 1.47 – 1.38 (m, 4H), 0.96 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 
147.68, 137.43, 132.15, 130.22, 129.46, 128.12, 127.41, 127.04, 115.45, 46.55, 29.62, 29.61, 
23.33, 20.91, 14.29. MS (ESI-TOF) for C15H21N3 [M + H]
+ calculated 244.1808, found 244.1836. 
 
4-(2-Ethylphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (17c)  
Compound 12c was used as reagent. White solid (20 mg, 68%). 1H NMR (500 MHz, MeOD) δ 
7.41 – 7.33 (m, 3H), 7.31 – 7.26 (m, 1H), 6.97 (s, 1H), 3.92 (t, J = 7.3 Hz, 2H), 2.74 (q, J = 7.6 
Hz, 2H), 1.86 – 1.78 (m, 2H), 1.45 – 1.36 (m, 4H), 1.19 (t, J = 7.6 Hz, 3H), 0.96 (t, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, MeOD) δ 147.63, 144.12, 130.77, 130.72, 130.27, 127.64, 127.31, 
126.86, 115.12, 46.50, 29.59, 29.57, 27.38, 23.32, 15.64, 14.29. MS (ESI-TOF) for C16H23N3 [M 
+ H]+ calculated 258.1965, found 258.1959. 
 
1-Pentyl-4-(m-tolyl)-1H-imidazol-2-amine hydrochloride (17d)  
Compound 12d was used as reagent. White solid (22 mg, 79%). 1H NMR (500 MHz, MeOD) δ 
7.41 (s, 1H), 7.37 – 7.31 (m, 2H), 7.27 (s, 1H), 7.20 (d, J = 7.4 Hz, 1H), 3.89 (t, J = 7.3 Hz, 2H), 
2.39 (s, 3H), 1.85 – 1.77 (m, 2H), 1.45 – 1.35 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H). 13C NMR (126 
MHz, MeOD) δ 148.13, 140.26, 130.48, 130.18, 128.58, 128.51, 126.06, 122.67, 113.02, 46.61, 
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29.60, 29.59, 23.33, 21.41, 14.27. MS (ESI-TOF) for C15H21N3 [M + H]
+ calculated 244.1808, 
found 244.1837. 
 
1-Pentyl-4-(p-tolyl)-1H-imidazol-2-amine hydrochloride (17e)  
Compound 12e was used as reagent. White solid (20 mg, 71%). 1H NMR (500 MHz, MeOD) δ 
7.45 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 7.7 Hz, 2H), 7.22 (s, 1H), 3.88 (t, J = 7.4 Hz, 2H), 2.37 (s, 
3H), 1.84 – 1.77 (m, 2H), 1.45 – 1.35 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
MeOD) δ 148.05, 140.09, 130.84, 128.54, 125.86, 125.53, 112.54, 46.57, 29.60, 29.59, 23.33, 
21.25, 14.27. MS (ESI-TOF) for C15H21N3 [M + H]
+ calculated 244.1808, found 244.1839. 
 
4-(2,3-Dimethylphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (17f)  
Compound 12f was used as reagent. White solid (22 mg, 75%). 1H NMR (500 MHz, MeOD) δ 
7.27 – 7.24 (m, 1H), 7.20 – 7.15 (m, 2H), 6.93 (s, 1H), 3.91 (t, J = 7.4 Hz, 2H), 2.35 (s, 3H), 2.29 
(s, 3H), 1.86 – 1.79 (m, 2H), 1.45 – 1.37 (m, 4H), 0.96 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
MeOD) δ 147.52, 139.06, 136.38, 131.99, 128.48, 128.37, 127.73, 126.93, 115.21, 46.50, 29.61, 
29.60, 23.32, 20.65, 16.92, 14.28. MS (ESI-TOF) for C16H23N3 [M + H]
+ calculated 258.1965, 
found 258.1932. 
 
4-(2,4-Dimethylphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (17g)  
Compound 12g was used as reagent. White solid (22 mg, 75%). 1H NMR (500 MHz, MeOD) δ 
7.26 (d, J = 7.8 Hz, 1H), 7.16 (s, 1H), 7.11 (d, J = 7.6 Hz, 1H), 6.96 (s, 1H), 3.91 (t, J = 7.3 Hz, 
2H), 2.37 (s, 3H), 2.34 (s, 3H), 1.85 – 1.78 (m, 2H), 1.44 – 1.36 (m, 4H), 0.96 (t, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, MeOD) δ 147.54, 140.42, 137.20, 132.82, 129.36, 128.03, 127.16, 125.23, 
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115.05, 46.51, 29.62, 29.60, 23.33, 21.17, 20.85, 14.29. MS (ESI-TOF) for C16H23N3 [M + H]
+ 
calculated 258.1965, found 258.1959. 
 
4-(2,5-Dimethylphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (17h)  
Compound 12h was used as reagent. White solid (20 mg, 68%). 1H NMR (500 MHz, MeOD) δ 
7.23 – 7.18 (m, 2H), 7.14 (dd, J = 1.5, 8.3 Hz, 1H), 6.99 (s, 1H), 3.91 (t, J = 7.4 Hz, 2H), 2.36 (s, 
3H), 2.35 (s, 3H), 1.85 – 1.78 (m, 2H), 1.45 – 1.36 (m, 4H), 0.96 (t, J = 7.0 Hz, 3H). 13C NMR 
(126 MHz, MeOD) δ 147.61, 137.15, 134.18, 132.14, 130.86, 129.83, 127.87, 127.23, 115.32, 
46.53, 29.62, 29.60, 23.32, 20.89, 20.46, 14.28. MS (ESI-TOF) for C16H23N3 [M + H]
+ calculated 
258.1965, found 258.1939. 
4-(2,6-Dimethylphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (17i)  
Compound 12i was used as reagent. White solid (22 mg, 75%). 1H NMR (500 MHz, MeOD) δ 
7.25 (t, J = 7.9 Hz, 1H), 7.15 (d, J = 7.6 Hz, 2H), 6.84 (s, 1H), 3.93 (t, J = 7.2 Hz, 2H), 2.22 (s, 
6H), 1.86 – 1.80 (m, 2H), 1.47 – 1.34 (m, 4H), 0.96 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
MeOD) δ 147.67, 139.85, 130.84, 128.74, 128.13, 125.18, 115.58, 46.42, 29.58, 29.53, 23.30, 
20.47, 14.31. MS (ESI-TOF) for C16H23N3 [M + H]
+ calculated 258.1965, found 258.1967. 
 
4-Benzyl-1-pentyl-1H-imidazol-2-amine hydrochloride (18a)  
Compound 13a was used as reagent. White solid (18 mg, 64%). 1H NMR (500 MHz, MeOD) δ 
7.33 (t, J = 7.5 Hz, 2H), 7.27 – 7.24 (m, 3H), 6.59 (s, 1H), 3.83 (s, 2H), 3.78 (t, J = 7.2 Hz, 2H), 
1.77 – 1.68 (m, 2H), 1.42 – 1.26 (m, 4H), 0.93 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, MeOD) 
δ 147.67, 138.25, 129.84, 129.60, 128.12, 127.73, 114.16, 46.27, 31.59, 29.55, 29.53, 23.28, 14.26. 
MS (ESI-TOF) for C15H21N3 [M + H]
+ calculated 244.1808, found 244.1789. 
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1-Pentyl-4-phenethyl-1H-imidazol-2-amine hydrochloride (18b)  
Compound 13b was used as reagent. White solid (19 mg, 65%). 1H NMR (500 MHz, MeOD) δ 
7.29 – 7.25 (m, 2H), 7.20 – 7.17 (m, 3H), 6.48 (s, 1H), 3.74 (t, J = 7.2 Hz, 2H), 2.90 (t, J = 7.5 Hz, 
2H), 2.81 – 2.77 (m, 2H), 1.70 – 1.64 (m, 2H), 1.38 – 1.32 (m, 2H), 1.29 – 1.20 (m, 2H), 0.92 (t, 
J = 7.3 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 147.25, 141.53, 129.52, 129.44, 127.64, 127.42, 
113.57, 46.12, 35.33, 29.53, 29.44, 27.46, 23.28, 14.24. MS (ESI-TOF) for C16H23N3 [M + H]
+ 
calculated 258.1965, found 258.1917. 
 
4-(Naphthalen-1-yl)-1-pentyl-1H-imidazol-2-amine hydrochloride (18c)  
Compound 13c was used as reagent. White solid (25 mg, 79%). 1H NMR (500 MHz, MeOD) δ 
8.09 – 8.07 (m, 1H), 8.02 – 7.95 (m, 2H), 7.61 – 7.55 (m, 4H), 7.20 (s, 1H), 3.98 (t, J = 7.4 Hz, 
2H), 1.93 – 1.84 (m, 2H), 1.48 – 1.41 (m, 4H), 0.98 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
MeOD) δ 147.96, 135.35, 132.33, 131.03, 129.83, 128.70, 128.31, 127.61, 126.36, 126.24, 125.47, 
115.97, 46.65, 29.66, 29.64, 23.36, 14.31. MS (ESI-TOF) for C18H21N3 [M + H]
+ calculated 
280.1808, found 280.1830. 
 
4-(Naphthalen-2-yl)-1-pentyl-1H-imidazol-2-amine hydrochloride (18d)  
Compound 13d was used as reagent. White solid (22 mg, 70%). 1H NMR (500 MHz, MeOD) δ 
8.04 (s, 1H), 7.95 – 7.87 (m, 3H), 7.68 (dd, J = 1.8, 8.6 Hz, 1H), 7.57 – 7.50 (m, 2H), 7.43 (s, 1H), 
3.93 (t, J = 7.4 Hz, 2H), 1.88 – 1.82 (m, 2H), 1.46 – 1.39 (m, 4H), 0.97 (t, J = 6.9 Hz, 3H). 13C 
NMR (126 MHz, MeOD) δ 148.38, 134.78, 134.55, 130.13, 129.07, 128.87, 128.45, 128.10, 
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127.84, 125.99, 123.97, 123.36, 113.74, 46.70, 29.61, 29.60, 23.34, 14.28. MS (ESI-TOF) for 
C18H21N3 [M + H]
+ calculated 280.1808, found 280.1790. 
 
4-([1,1'-Biphenyl]-4-yl)-1-pentyl-1H-imidazol-2-amine hydrochloride (18e)  
Compound 13e was used as reagent. White solid (25 mg, 73%). 1H NMR (500 MHz, MeOD) δ 
7.72 (d, J = 8.3 Hz, 2H), 7.67 – 7.65 (m, 4H), 7.46 (t, J = 7.6 Hz, 2H), 7.38 – 7.35 (m, 1H), 7.34 
(s, 1H), 3.91 (t, J = 7.4 Hz, 2H), 1.85 – 1.80 (m, 2H), 1.46 – 1.36 (m, 4H), 0.96 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, MeOD) δ 148.26, 142.70, 141.28, 130.02, 128.84, 128.67, 128.11, 127.83, 
127.58, 126.00, 113.26, 46.67, 29.60, 29.58, 23.33, 14.27. MS (ESI-TOF) for C20H23N3 [M + H]
+ 
calculated 306.1965, found 306.1963. 
 
4-(2-(Benzyloxy)phenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (18f)  
Compound 13f was used as reagent. White solid (24 mg, 64%). 1H NMR (500 MHz, MeOD) δ 
7.52 (dd, J = 1.6, 7.8 Hz, 1H), 7.49 – 7.46 (m, 2H), 7.44 – 7.39 (m, 2H), 7.37 – 7.32 (m, 2H), 7.20 
(dd, J = 1.0, 8.4 Hz, 1H), 7.15 (s, 1H), 7.09 – 7.01 (m, 1H), 5.27 (s, 2H), 3.81 (t, J = 7.3 Hz, 2H), 
1.75 – 1.67 (m, 2H), 1.40 – 1.28 (m, 4H), 0.93 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, MeOD) 
δ 156.56, 147.42, 138.08, 130.78, 129.77, 129.35, 128.95, 126.90, 124.50, 122.32, 117.41, 115.94, 
114.29, 71.78, 46.41, 29.52, 29.40, 23.26, 14.26. MS (ESI-TOF) for C21H25N3O[M + H]
+ 
calculated 336.2070, found 336.2019. 
 
1-Pentyl-4-(pyridin-3-yl)-1H-imidazol-2-amine hydrochloride (19a)  
Compound 14a was used as reagent. White solid (18 mg, 68%). 1H NMR (500 MHz, MeOD) δ 
8.80 (s, 1H), 8.45 – 8.44 (m, 1H), 8.06 – 8.02 (m, 1H), 7.49 – 7.46 (m, 1H), 7.37 (s, 1H), 3.87 (t, 
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J = 7.3 Hz, 2H), 1.84 – 1.78 (m, 2H), 1.44 – 1.36 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H). 13C NMR (126 
MHz, MeOD) δ 149.89, 148.71, 146.10, 133.66, 128.52, 128.31, 125.46, 114.45, 46.43, 29.93, 
29.67, 23.35, 14.29. MS (ESI-TOF) for C13H18N4 [M + H]
+ calculated 231.1604, found 231.1570. 
 
4-(3,5-Dimethylisoxazol-4-yl)-1-pentyl-1H-imidazol-2-amine hydrochloride (19b) 
Compound 14b was used as reagent. White solid (20 mg, 70%). 1H NMR (500 MHz, MeOD) δ 
7.06 (s, 1H), 3.90 (t, J = 7.4 Hz, 2H), 2.45 (s, 3H), 2.27 (s, 3H), 1.86 – 1.76 (m, 2H), 1.45 – 1.36 
(m, 4H), 0.96 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 169.82, 160.07, 148.33, 116.89, 
116.51, 105.77, 46.66, 29.59, 29.49, 23.30, 14.27, 11.48, 10.32. MS (ESI-TOF) for C13H20N4O[M 
+ H]+ calculated 249.1710, found 249.1689. 
 
2-(2-Amino-1-pentyl-1H-imidazol-4-yl)phenol hydrochloride (19c)  
Compound 13f and 5% Pd/C were used as reagents. White solid (18 mg, 64%). 1H NMR (500 
MHz, MeOD) δ 7.48 (dd, J = 1.6, 7.8 Hz, 1H), 7.31 (s, 1H), 7.19 (ddd, J = 1.6, 7.3, 8.2 Hz, 1H), 
6.96 – 6.85 (m, 2H), 3.90 (t, J = 7.4 Hz, 2H), 1.85 – 1.77 (m, 2H), 1.45 – 1.35 (m, 4H), 0.95 (t, J 
= 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 155.26, 147.12, 130.63, 126.79, 125.65, 121.06, 
117.11, 115.09, 114.34, 46.51, 29.64, 29.58, 23.32, 14.26. MS (ESI-TOF) for C14H19N3O[M + H]
+ 
calculated 246.1601, found 246.1550. 
 
(2-(2-Amino-1-pentyl-1H-imidazol-4-yl)phenyl)methanol hydrochloride (19d)  
Compound 14d was used as reagent. White solid (21 mg, 71%). 1H NMR (500 MHz, MeOD) δ 
7.55 – 7.48 (m, 2H), 7.46 – 7.38 (m, 2H), 7.20 (s, 1H), 4.61 (s, 2H), 3.92 (t, J = 7.4 Hz, 2H), 1.87 
– 1.80 (m, 2H), 1.45 – 1.37 (m, 4H), 0.96 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 
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147.79, 139.28, 131.40, 130.22, 129.59, 129.46, 128.60, 126.90, 115.18, 63.86, 46.61, 29.61, 
29.59, 23.32, 14.27. MS (ESI-TOF) for C15H21N3O[M + H]
+ calculated 260.1757, found 260.1748. 
 
4-(4-Aminophenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (19e)  
Compound 14e was used as reagent. White solid (19 mg, 68%). 1H NMR (500 MHz, MeOD) δ 
7.73 (d, J = 8.6 Hz, 2H), 7.44 (d, J = 8.5 Hz, 2H), 7.40 (s, 1H), 3.91 (t, J = 7.4 Hz, 2H), 1.86 – 
1.78 (m, 2H), 1.45 – 1.35 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 148.50, 
133.58, 128.73, 127.21, 127.02, 124.32, 114.20, 46.74, 29.57, 29.56, 23.32, 14.26. MS (ESI-TOF) 
for C14H20N4 [M + H]
+ calculated 245.1761, found 245.1762. 
 
4-(2-Amino-1-pentyl-1H-imidazol-4-yl)benzamide hydrochloride (19f)  
Compound 14f was used as reagent. White solid (20 mg, 65%). 1H NMR (500 MHz, MeOD) δ 
7.96 (d, J = 8.5 Hz, 2H), 7.68 (d, J = 8.5 Hz, 2H), 7.46 (s, 1H), 3.91 (t, J = 7.4 Hz, 2H), 1.86 – 
1.79 (m, 2H), 1.45 – 1.35 (m, 4H), 0.96 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 171.28, 
148.58, 134.74, 131.93, 129.62, 127.40, 125.36, 114.71, 46.76, 29.58, 29.57, 23.33, 14.27. MS 
(ESI-TOF) for C15H20N4O [M + H]
+ calculated 273.1710, found 273.1707. 
Methyl 4-(2-amino-1-pentyl-1H-imidazol-4-yl)benzoate hydrochloride (19g)  
Compound 14g was used as reagent. White solid (22 mg, 68%). 1H NMR (500 MHz, MeOD) δ 
8.09 (d, J = 8.8 Hz, 2H), 7.69 (d, J = 8.8 Hz, 2H), 7.49 (s, 1H), 3.93 – 3.90 (m, 5H), 1.87 – 1.79 
(m, 2H), 1.46 – 1.35 (m, 4H), 0.96 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 167.73, 
148.71, 133.16, 131.37, 131.05, 127.33, 125.36, 115.15, 52.78, 46.79, 29.58, 29.55, 23.32, 14.25. 
MS (ESI-TOF) for C16H21N3O2 [M + H]
+ calculated 288.1707, found 288.1703. 
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Methyl 2-(2-amino-1-pentyl-1H-imidazol-4-yl)benzoate hydrochloride (19h)  
Compound 14h was used as reagent. White solid (24 mg, 74%). 1H NMR (500 MHz, MeOD) δ 
8.03 – 8.01 (m, 1H), 7.73 – 7.63 (m, 1H), 7.62 – 7.55 (m, 1H), 7.54 – 7.52 (m, 1H), 6.99 (s, 1H), 
3.91 (t, J = 7.3 Hz, 2H), 3.86 (s, 3H), 1.86 – 1.78 (m, 2H), 1.46 – 1.37 (m, 4H), 0.96 (t, J = 7.0 Hz, 
3H). 13C NMR (126 MHz, MeOD) δ 168.33, 147.51, 133.61, 132.50, 131.97, 131.37, 130.75, 
129.25, 127.23, 115.14, 52.93, 46.51, 29.62, 29.52, 23.33, 14.28. MS (ESI-TOF) for C16H21N3O2 
[M + H]+ calculated 288.1707, found 288.1705. 
 
4-(2-Methoxyphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (20a)  
Compound 15a was used as reagent. White solid (20 mg, 67%). 1H NMR (500 MHz, MeOD) δ 
7.52 (dd, J = 1.7, 7.7 Hz, 1H), 7.39 – 7.34 (m, 1H), 7.30 (s, 1H), 7.14 (dd, J = 1.0, 8.5 Hz, 1H), 
7.05 – 7.03 (m, 1H), 3.97 (s, 3H), 3.91 (t, J = 7.4 Hz, 2H), 1.86 – 1.77 (m, 2H), 1.45 – 1.36 (m, 
4H), 0.95 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 157.33, 147.32, 131.00, 127.10, 
124.94, 122.12, 116.87, 115.30, 112.74, 56.12, 46.55, 29.64, 29.58, 23.32, 14.27. MS (ESI-TOF) 
for C15H21N3O[M + H]
+ calculated 260.1757, found 260.1729. 
 
4-(3-Methoxyphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (20b)  
Compound 15b was used as reagent. White solid (23 mg, 78%). 1H NMR (500 MHz, MeOD) δ 
7.36 (t, J = 8.3 Hz, 1H), 7.32 (s, 1H), 7.16 – 7.12 (m, 2H), 6.96 – 6.93 (m, 1H), 3.89 (t, J = 7.4 Hz, 
2H), 3.85 (s, 3H), 1.85 – 1.78 (m, 2H), 1.45 – 1.34 (m, 4H), 0.96 (t, J = 7.0 Hz, 3H). 13C NMR 
(126 MHz, MeOD) δ 161.78, 148.16, 131.41, 129.89, 128.30, 117.77, 115.22, 113.41, 111.11, 
55.86, 46.63, 29.60, 29.59, 23.33, 14.27. MS (ESI-TOF) for C15H21N3O[M + H]
+ calculated 
260.1757, found 260.1770. 
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4-(4-Methoxyphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (20c)  
Compound 15c was used as reagent. White solid (25 mg, 85%). 1H NMR (500 MHz, MeOD) δ 
7.49 (d, J = 8.8 Hz, 2H), 7.11 (s, 1H), 6.99 (d, J = 8.9 Hz, 2H), 3.86 (t, J = 7.3 Hz, 2H), 3.83 (s, 
3H), 1.84 – 1.76 (m, 2H), 1.46 – 1.33 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
MeOD) δ 161.41, 148.16, 128.59, 127.08, 121.85, 115.55, 111.66, 55.84, 46.44, 29.71, 29.62, 
23.34, 14.28. MS (ESI-TOF) for C15H21N3O[M + H]
+ calculated 260.1757, found 260.1785. 
 
4-(4-Methoxy-2-methylphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (20d)  
Compound 15d was used as reagent. White solid (20 mg, 65%). 1H NMR (500 MHz, MeOD) δ 
7.29 (d, J = 8.5 Hz, 1H), 6.91 (s, 1H), 6.89 (d, J = 2.6 Hz, 1H), 6.85 (dd, J = 2.7, 8.5 Hz, 1H), 3.90 
(t, J = 7.4 Hz, 2H), 3.82 (s, 3H), 2.37 (s, 3H), 1.85 – 1.77 (m, 2H), 1.44 – 1.35 (m, 4H), 0.96 (t, J 
= 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 161.72, 147.44, 139.27, 131.05, 127.11, 120.53, 
117.39, 114.65, 112.70, 55.75, 46.47, 29.62, 29.61, 23.32, 21.00, 14.28. MS (ESI-TOF) for 
C16H23N3O[M + H]
+ calculated 274.1914, found 274.1901. 
 
4-(2-Methoxy-3-methylphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (20e)  
Compound 15e was used as reagent. White solid (19 mg, 61%). 1H NMR (500 MHz, MeOD) δ 
7.35 (dd, J = 1.6, 7.8 Hz, 1H), 7.31 (s, 1H), 7.24 (dd, J = 1.3, 7.5 Hz, 1H), 7.11 (t, J = 7.7 Hz, 1H), 
3.93 (t, J = 7.3 Hz, 2H), 3.69 (s, 3H), 2.35 (s, 3H), 1.86 – 1.78 (m, 2H), 1.45 – 1.36 (m, 4H), 0.95 
(t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 156.64, 147.70, 133.62, 133.02, 125.83, 125.74, 
124.85, 121.70, 115.43, 60.34, 46.59, 29.62, 29.59, 23.32, 16.07, 14.28. MS (ESI-TOF) for 
C16H23N3O[M + H]
+ calculated 274.1914, found 274.1872. 
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4-(2,3-Dimethoxyphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (20f)  
Compound 15f was used as reagent. White solid (23 mg, 71%). 1H NMR (500 MHz, MeOD) δ 
7.33 (s, 1H), 7.18 – 7.09 (m, 2H), 7.06 (dd, J = 1.6, 7.9 Hz, 1H), 3.95 – 3.88 (m, 5H), 3.85 (s, 3H), 
1.85 – 1.77 (m, 2H), 1.45 – 1.35 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) 
δ 154.73, 147.59, 147.13, 125.92, 124.62, 121.92, 118.77, 115.67, 114.06, 60.66, 56.42, 46.60, 
29.61, 29.58, 23.32, 14.28. MS (ESI-TOF) for C16H23N3O2 [M + H]
+ calculated 290.1863, found 
290.1807. 
 
1-Pentyl-4-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-amine hydrochloride (20g)  
Compound 15g was used as reagent. White solid (26 mg, 73%). 1H NMR (500 MHz, MeOD) δ 
7.32 (s, 1H), 6.89 (s, 2H), 3.90 – 3.87 (m, 8H), 3.78 (s, 3H), 1.86 – 1.79 (m, 2H), 1.46 – 1.35 (m, 
4H), 0.96 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 155.21, 148.05, 139.60, 128.43, 
124.46, 113.07, 103.20, 61.19, 56.80, 46.62, 29.59, 29.57, 23.33, 14.26. MS (ESI-TOF) for 
C17H25N3O3 [M + H]
+ calculated 320.1969, found 320.1957. 
 
4-(2-Chlorophenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (21a)  
Compound 16a was used as reagent. White solid (18 mg, 60%). 1H NMR (500 MHz, MeOD) δ 
7.58 – 7.53 (m, 2H), 7.45 – 7.40 (m, 2H), 7.31 (s, 1H), 3.93 (t, J = 7.3 Hz, 2H), 1.86 – 1.78 (m, 
2H), 1.45 – 1.36 (m, 4H), 0.96 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 147.88, 133.14, 
131.78, 131.44, 130.76, 128.68, 127.51, 124.74, 116.99, 46.68, 29.60, 29.56, 23.32, 14.28. MS 
(ESI-TOF) for C14H18ClN3 [M + H]
+ calculated 264.1262, found 264.1238. 
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4-(3-Chlorophenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (21b)  
Compound 16b was used as reagent. White solid (20 mg, 67%). 1H NMR (500 MHz, MeOD) δ 
7.64 (t, J = 1.9 Hz, 1H), 7.52 – 7.50 (m, 1H), 7.44 (t, J = 7.9 Hz, 1H), 7.40 (s, 1H), 7.39 – 7.36 (m, 
1H), 3.90 (t, J = 7.4 Hz, 2H), 1.86 – 1.78 (m, 2H), 1.46 – 1.35 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, MeOD) δ 148.47, 136.24, 131.85, 130.69, 129.55, 126.97, 125.45, 123.86, 
114.34, 46.72, 29.57, 29.55, 23.32, 14.26. MS (ESI-TOF) for C14H18ClN3 [M + H]
+ calculated 
264.1262, found 264.1271. 
 
4-(4-Chlorophenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (21c)  
Compound 16c was used as reagent. White solid (23 mg, 77%). 1H NMR (500 MHz, MeOD) δ 
7.57 (d, J = 8.6 Hz, 2H), 7.28 (d, J = 8.6 Hz, 2H), 7.00 (s, 1H), 3.77 (t, J = 7.3 Hz, 2H), 1.79 – 
1.73 (m, 2H), 1.42 – 1.32 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 150.99, 
135.85, 134.46, 132.40, 129.47, 126.58, 112.58, 45.77, 30.57, 29.85, 23.40, 14.34. MS (ESI-TOF) 
for C14H18ClN3 [M + H]
+ calculated 264.1262, found 264.1296. 
 
4-(2-Fluorophenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (21d)  
Compound 16d was used as reagent. White solid (20 mg, 70%). 1H NMR (500 MHz, MeOD) δ 
7.64 – 7.60 (m, 1H), 7.46 – 7.39 (m, 1H), 7.32 – 7.24 (m, 3H), 3.93 (t, J = 7.4 Hz, 2H), 1.85 – 1.78 
(m, 2H), 1.46 – 1.35 (m, 4H), 0.95 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 160.46 (d, 
J = 249.0 Hz), 148.16, 131.41 (d, J = 8.6 Hz), 127.60 (d, J = 2.7 Hz), 126.13 (d, J = 3.5 Hz), 122.27 
(d, J = 1.4 Hz), 117.32 (d, J = 21.6 Hz), 116.72 (d, J = 12.7 Hz), 116.42 (d, J = 10.8 Hz), 46.71, 
29.59, 29.56, 23.33, 14.27. MS (ESI-TOF) for C14H18FN3 [M + H]
+ calculated 248.1558, found 
248.1572. 
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4-(3-Fluorophenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (21e)  
Compound 16e was used as reagent. White solid (18 mg, 63%). 1H NMR (500 MHz, MeOD) δ 
7.50 – 7.45 (m, 1H), 7.41 – 7.33 (m, 3H), 7.16 – 7.07 (m, 1H), 3.90 (t, J = 7.4 Hz, 2H), 1.85 – 1.78 
(m, 2H), 1.45 – 1.34 (m, 4H), 0.96 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 164.61 (d, 
J = 245.2 Hz), 148.44, 132.27 (d, J = 8.6 Hz), 130.97 (d, J = 8.7 Hz), 127.22 (d, J = 2.8 Hz), 121.39 
(d, J = 3.1 Hz), 116.33 (d, J = 21.4 Hz), 114.28, 112.37 (d, J = 24.2 Hz), 46.71, 29.57, 29.56, 
23.33, 14.26. MS (ESI-TOF) for C14H18FN3 [M + H]
+ calculated 248.1558, found 248.1564. 
4-(4-Fluorophenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (21f)  
Compound 16f was used as reagent. White solid (20 mg, 70%). 1H NMR (500 MHz, MeOD) δ 
7.60 (dd, J = 5.1, 8.9 Hz, 2H), 7.26 (s, 1H), 7.23 – 7.17 (m, 2H), 3.89 (t, J = 7.4 Hz, 2H), 1.85 – 
1.78 (m, 2H), 1.45 – 1.34 (m, 4H), 0.95 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 164.19 
(d, J = 247.6 Hz), 148.25, 127.84 (d, J = 8.4 Hz), 127.54, 125.20 (d, J = 3.5 Hz), 117.18 (d, J = 
22.3 Hz), 113.12, 46.63, 29.58, 29.56, 23.33, 14.26. MS (ESI-TOF) for C14H18FN3 [M + H]
+ 
calculated 248.1558, found 248.1564. 
 
4-(4-Fluoro-2-methylphenyl)-1-pentyl-1H-imidazol-2-amine hydrochloride (21g)  
Compound 16g was used as reagent. White solid (20 mg, 67%). 1H NMR (500 MHz, MeOD) δ 
7.39 (dd, J = 5.7, 8.6 Hz, 1H), 7.13 – 7.10 (m, 1H), 7.07 – 7.02 (m, 1H), 7.00 (s, 1H), 3.91 (t, J = 
7.3 Hz, 2H), 2.40 (s, 3H), 1.85 – 1.79 (m, 2H), 1.44 – 1.37 (m, 4H), 0.96 (t, J = 7.0 Hz, 3H). 13C 
NMR (126 MHz, MeOD) δ 164.30 (d, J = 247.8 Hz), 147.71, 140.78 (d, J = 8.2 Hz), 131.89 (d, J 
= 8.8 Hz), 126.13, 124.58 (d, J = 3.2 Hz), 118.62 (d, J = 21.9 Hz), 115.52, 114.19 (d, J = 21.9 Hz), 
46.55, 29.60, 23.33, 20.80, 20.79, 14.29. MS (ESI-TOF) for C15H20FN3 [M + H]
+ calculated 
262.1714, found 262.1724. 
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1-Pentyl-4-(2-(trifluoromethyl)phenyl)-1H-imidazol-2-amine hydrochloride (21h)  
Compound 16h was used as reagent. White solid (24 mg, 72%). 1H NMR (500 MHz, MeOD) δ 
7.87 (d, J = 6.6 Hz, 1H), 7.76 (t, J = 7.6 Hz, 1H), 7.69 (t, J = 7.7 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 
7.02 (s, 1H), 3.93 (t, J = 7.2 Hz, 2H), 1.84 – 1.77 (m, 2H), 1.45 – 1.35 (m, 4H), 0.96 (t, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, MeOD) δ 147.84, 133.60, 131.23, 130.28 (q, J = 30.3 Hz), 127.68 (q, 
J = 5.4 Hz), 127.37 (q, J = 272.6 Hz), 127.35, 124.10, 121.93, 116.65 (q, J = 3.0 Hz), 46.55, 29.50, 
29.42, 23.27, 14.23. MS (ESI-TOF) for C15H18F3N3 [M + H]
+ calculated 298.1526, found 
298.1538. 
 
1-Pentyl-4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2-amine hydrochloride (21i)  
Compound 16i was used as reagent. White solid (22 mg, 66%). 1H NMR (500 MHz, MeOD) δ 
7.92 (s, 1H), 7.85 (d, J = 4.9 Hz, 1H), 7.70 – 7.63 (m, 2H), 7.49 (s, 1H), 3.91 (t, J = 7.3 Hz, 2H), 
1.87 – 1.78 (m, 2H), 1.46 – 1.35 (m, 4H), 0.95 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, MeOD) 
δ 148.61, 132.64 (q, J = 32.4 Hz), 131.23, 129.89, 129.10, 126.90, 126.11 (q, J = 4.1 Hz), 125.37 
(q, J = 271.6 Hz), 122.10 (q, J = 3.7 Hz), 114.72, 46.78, 29.57, 29.55, 23.33, 14.26. MS (ESI-
TOF) for C15H18F3N3 [M + H]
+ calculated 298.1526, found 298.1550 
 
1-Pentyl-4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-amine hydrochloride (21j)  
Compound 16j was used as reagent. White solid (24 mg, 72%). 1H NMR (500 MHz, MeOD) δ 
7.76 (d, J = 8.3 Hz, 2H), 7.72 (d, J = 8.4 Hz, 2H), 7.43 (s, 1H), 3.89 (t, J = 7.4 Hz, 2H), 1.85 – 
1.78 (m, 2H), 1.45 – 1.36 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 149.26, 
133.99, 130.64 (q, J= 32.5 Hz), 128.67, 127.02 (q, J = 3.8 Hz), 125.82, 125.54 (q, J = 271.1 Hz), 
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114.94, 46.60, 29.76, 29.63, 23.34, 14.28. MS (ESI-TOF) for C15H18F3N3 [M + H]
+ calculated 
298.1526, found 298.1562. 
 
Human TLR8 ectodomain expression, purification and crystallization  
The extracellular domain of human TLR8 (TLR8, residues 27–827) was prepared as described 
previously,230 and was concentrated to 16 mg/mL in 10 mMMES (pH 5.5), 50 mM NaCl. The 
protein solutions for the crystallization of human TLR8/17a complex contained TLR8 (8.0 
mg/mL) and saturated 17a. Crystallization experiments were performed with sitting-drop vapor-
diffusion methods at 293 K. Crystals of TLR8/17a were obtained with reservoir solutions 
containing 12.5% (v/v) PEG 3350, 0.2 M potassium formate, and 0.1 M sodium citrate pH 4.9. 
 
Data collection and structure determination  
Diffraction datasets were collected on beamlines SPring-8 BL41XU (Hyogo, Japan) under 
cryogenic conditions at 100 K. Crystals of hTLR8/17a were soaked into a cryoprotectant solution 
containing 7% (v/v) PEG 3350, 0.1 M potassium formate, 50mM sodium citrate pH 4.9, 5mM 
MES pH 5.5, 75mM NaCl, and 20% glycerol before flash-cooling.  
Datasets were processed using the HKL2000 package.251 Human TLR8/17a were determined by 
the molecular replacement method using the Molrep program252 with the hTLR8/CL097 structure 
(PDB ID: 3W3J) as a search model. The model was further refined with stepwise cycles of manual 
model building using the COOT program253 and restrained refinement using REFMAC254 until 
convergence of the R factor was achieved. Compound, N-glycans, and water molecules were 
modeled into the electron density maps at the latter cycles of the refinement. The quality of the 
final structure was evaluated with PROCHECK.255 The statistics of the data collection and 
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refinement are also summarized in Table S1. The figures representing structures were prepared 
with PyMOL (Schrödinger, New York, NY).  
 
Human TLR8-specific reporter gene assays (NF-κB induction), and TLR-2/-3/-4/-5/-7/-9 counter-
screens  
The induction of NF-κB was quantified using human TLR-2/-3/-4/-5/-7/-8/-9-specific, rapid-
throughput, liquid handler-assisted reporter gene assays as previously described by us.31, 91, 101-102 
HEK293 cells stably co-transfected with the appropriate hTLR and sAP were maintained in HEK-
Blue™ Selection medium. Stable expression of sAP under control of NF-κB/AP-1 promoters is 
inducible by appropriate TLR agonists, and extracellular sAP in the supernatant is proportional to 
NF-κB induction. Reporter cells were incubated at a density of ~105 cells/ml in a volume of 80 
µl/well, in 384-well, flat-bottomed, cell culture-treated microtiter plates in the presence of graded 
concentrations of stimuli. sAP was assayed spectrophotometrically using an alkaline phosphatase-
specific chromogen (present in HEK-detection medium as supplied by InvivoGen) at 620 nm.  
 
Immunoassays for cytokines  
Fresh human PBMCs were isolated from human blood obtained by venipuncture in Cell 
Preparation Tubes (CPT, Beckton-Dickinson) with informed consent and as per guidelines 
approved by the University of Minnesota Human Subjects Experimentation Committee. Aliquots 
of PBMCs (105 cells in 100 µL/well) were stimulated for 16 h with graded concentrations of test 
compounds. Supernatants were isolated by centrifugation, and were assayed in duplicates using 
analyte-specific multiplexed cytokine/chemokine bead array assays (HCYTMAG-60K-PX29 
MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel, EMD Millipore, Billerica, 
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MA) as reported by us previously.100 The following analytes were quantified: sCD40L, VEGF, 
TNF-β, TNF-α, TGF-α, RANTES, PDGF-AB/BB, PDGF-AA, MIP-1β, MIP-1α, MDC (CCL22), 
MCP-3, MCP-1, IP-10, IL-17A, IL-15, IL-13, IL-12 (p70), IL-12 (p40), IL-10, IL-9, IL-8, IL-7, 
IL-6, IL-5, IL-4, IL-3, IL-2, IL-1ra, IL-1β, IL-1α, IFN-γ, IFN-α2, GRO, GM-CSF, G-CSF, 
fractalkine, Flt-3 ligand, FGF-2, eotaxin, EGF. 
 
Intracellular PhosFlow™ flow cytometry for quantifying p38MAPK, ERK1/2, and NF-κB 
phosphorylation  
Heparin-anticoagulated whole blood samples were obtained by venipuncture from healthy human 
volunteers with informed consent and as per guidelines approved by the University of Minnesota 
Human Subjects Experimentation Committee. Serial dilutions of compounds in RPMI medium 
supplemented with 10% fetal bovine serum (fRPMI) were performed using a Bio-Tek Precision 
2000 XS liquid handler in sterile 96-well polypropylene plates, to which were added 100 µL 
aliquots of anticoagulated whole human blood. The plates were incubated at 37 oC for 15 min. 
Following incubation, the blood was transferred to a 96-well deep well plate containing 800 µL of 
pre-warmed Lyse/Fix buffer (BD Biosciences, San Jose, CA), incubated at 37o C for 15 min, then 
centrifuged at 300 g for 10 min. The supernatant was discarded, and the Lyse/Fix process was 
repeated twice. Cell pellets were washed once in fRPMI, and once in ice-cold methanol, 
resuspended in 800 µL ice-cold methanol and permeabilized for 30 min. After two washes in 
fRPMI, 2.5 µg (in 30 µL) of anti-human NF-κB (p65)-PECy7, p38MAPK-PE, and ERK1/2-
AlexaFluor 647 antibodies (BD Biosciences, San Jose, CA) were added to each well, and incubated 
on ice for 60 min. After two washes in fRPMI, cells were resuspended in 200 µL of fRPMI. Flow 
cytometry was performed using a FACSVerse (Becton-Dickinson Biosciences, San Jose, CA) 
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instrument for acquisition on 100,000 gated events. Compensation for spillover was computed for 
each experiment on singly-stained Comp Beads (Becton-Dickinson Biosciences, San Jose, CA). 
Flow cytometric data were analyzed and quantified using FlowJo v 7.0 software (Treestar, 
Ashland, OR). 
 
Flow-cytometric immunostimulation experiments  
Cell surface marker upregulation was determined by flow cytometry using protocols published by 
us previously,150 and modified for rapid-throughput. Briefly, heparin-anticoagulated whole blood 
samples were obtained by venipuncture from healthy human volunteers with informed consent and 
as per guidelines approved by the University of Minnesota Human Subjects Experimentation 
Committee. Serial dilutions of selected compounds were performed using a Bio-Tek Precision 
2000 XS liquid handler in sterile 96-well polypropylene plates, to which were added 100 µL 
aliquots of anticoagulated whole human blood. The plates were incubated at 37oC for 16 h. 
Negative (endotoxin free water) controls were included in each experiment. The following 
fluorochrome-conjugated antibodies were used: CD3-PE, CD19-FITC, CD56-APC (eBioscience, 
San Diego, CA), CD14-V500, CD28 PE-Cy7, CD40 V450, CD80 APC-H7, CD86 PerCP-Cy5.5 
(Becton-Dickinson Biosciences, San Jose, CA). Following incubation, 2.5 µg of each antibody 
was added to wells with a liquid handler, and incubated at 4oC in the dark for 60 min. Following 
staining, erythrocytes were lysed and leukocytes fixed by mixing 200 µL of the samples in 800 µL 
pre-warmed Whole Blood Lyse/Fix Buffer (Becton-Dickinson Biosciences, San Jose, CA) in 96 
deep-well plates. After washing the cells twice at 300 g for 10 minutes in RPMI, the cells were 
transferred to a 96-well plate. Flow cytometry was performed using a BD FACSVerse instrument 
for acquisition on 100,000 gated events. Compensation for spillover was computed for each 
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experiment on singly-stained Comp Beads (Becton-Dickinson Biosciences, San Jose, CA).  
 
Kinase inhibitions screens  
Kinase inhibition studies were performed at Reaction Biology (Malvern, PA). Compound 18f was 
tested against 365 wild-type kinases in single dose duplicate mode at a concentration of 10 μM. 
The following kinase panel was used for re-screening in 10-dose IC50 mode with three-fold serial 
dilutions starting at 100 μM: calmodulin kinase (CAMK) CAMK1α, CAMK1β, CAMK1δ, 
CAMK1γ, CAMK2α, CAMK2β, CAMK2δ, CAMK2γ, CAMK4, CAMKK1, CAMKK2. 
Staurosporine (positive control) was tested in 10-dose IC50 mode with four-fold serial dilution 
starting at 20 μM. IC50 values were determined using four-parameter logistic fits.  
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6.1 Introduction 
Following the successful SAR campaign on the 2-aminoimidazoles (Chapter 5), we sought to 
further examine the mechanisms of adjuvanticity of TLR8 agonists. The mechanisms of 
adjuvanticity for TLR8 agonists are less well understood than many of the other TLRs due to the 
inability of canonical TLR8 agonists to stimulate mouse TLR8.256 We therefore turned to the 
human system to examine the mechanistic basis of the adjuvantic activity of TLR8 agonists, with 
particular attention to their potential use in neonatal vaccines.  
 
Infants have a heightened susceptibility to infection257 and respond poorly to vaccination.258-260 
Although the mechanistic basis for the immunological differences between adults and neonates is 
yet to be understood clearly, it is thought that anti-inflammatory rather than pro-inflammatory 
responses to innate immune stimuli, as well as feeble plasma cell and germinal center T follicular 
helper and B cell induction and Th2-biased responses, contribute to the poor immunological 
responses in the very young.258  Vaccine adjuvants currently in use lack the ability to stimulate 
neonatal immune systems effectively and, consequently, may be suboptimal.261-264 It has been 
demonstrated that TLR8 agonists are unique in their ability to activate neonatal APCs by the 
induction of the proinflammatory cytokines, TNF-α and IL-12p40/70, upregulation of the co-
stimulatory molecule CD40, and phosphorylation of p38MAPK.222, 265  
 
The effects of TLR8 agonists on innate immune function suggest that these compounds could be 
potentially useful as vaccine adjuvants in neonatal vaccines. The consequences of TLR8 
engagement on downstream adaptive immune responses are largely unknown, especially given 
that murine TLR8 is not responsive to canonical, small-molecule TLR8 agonists.266  
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We examined how TLR8 agonists influence processing of soluble antigens by APCs. TLR8-active 
compounds were unique in inducing pyroptosis-like death in monocytes, leading to the formation 
of CD14+ Annexin V+ extracellular vesicles (ECV) of 100-400 nm diameter. This process was 
dependent on myeloid differentiation primary response gene 88 (MyD88), interleukin-1 receptor-
associated kinases (IRAK) 1 and 4, and p38MAPK. The monocyte-derived ECVs contain near-
intact soluble antigens, and were capable of stimulating antigen-specific recall responses in 
autologous CD4+ T lymphocytes. The formation of antigen-loaded, monocyte-derived ECVs may 
contribute to the adjuvantic effects of TLR8 agonists.   
 
6.2 Results 
TLR8 agonists induce ECV formation in monocytes 
Our initial goal was to explore antigen internalization in APCs (monocytes and dendritic cell 
subsets) by flow cytometry. In examining a panel of TLR agonists (Fig. 1), dramatic changes in 
the CD14+ monocytes were observed in samples that were stimulated with either pure TLR8, or 
dual TLR7/8 agonists: we noted a dose-dependent reduction in frequency of side scatter (SSC)high/ 
forward scatter (FSC)high CD14+ monocyte population, which was accompanied by the appearance 
of a new, SSClow/ FSClow CD14+ population (Fig. 2). The new population was dimorphic with 
respect to staining with DAPI and Annexin V, with approximately equal numbers of events being 
DAPI+/Annexin-, and DAPI-/Annexin+ (Fig. 3). The new CD14+ population was also human 
leukocyte antigen (HLA)-DR+ (data not shown). The apparent loss of the conventional monocytic 
population, and the concomitant appearance of CD14+, HLA-DR+ bodies with attenuated forward- 
and side-scatter properties with dimorphic DAPI and Annexin V staining properties suggested that 
these were monocyte-derived, possessing mixed apoptotic and pyroptotic properties. Isolation of 
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these bodies and examination by transmission electron microscopy confirmed that these were 
extracellular vesicles (ECVs) with a diameter ranging from 100 nm to 400 nm (Fig. 3). 
 
As noted earlier, only TLR8 or dual TLR7/8 agonists induced ECV formation, and neither the pure 
TLR7 agonist compound 1, nor agonists of TLR2, -3, -4, -5, or -9 elicited vesicles. The 
phenomenon appeared specific to TLR8 or TLR7/8 ligands themselves, and not to secondary, 
autocrine, or paracrine cytokine induction because incubation of PBMCs with TNF-α, IL-18, IL-
12, IL-6, IL-4, IL-2, IFN-α, and IFN-γ were unable to induce the formation of ECVs even up to 




Figure 1: Structures of TLR agonists. The TLR7 agonist is shown in blue, the TLR8 agonists are 
shown in red, and the dual TLR7/8 agonists are shown in purple. 
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 population showed that these were vesicles with a diameter of 
100-400 nm. 
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ECV generation is dependent on p38 MAPK, MyD88, and IRAK1/4  
Our observations indicated that ECV formation was dependent exclusively on TLR8 and not on 
TLR7. We sought to determine whether there was divergence in the signaling pathways distal to 
TLR7 and TLR8 engagement, and whether any signaling events were uniquely associated with 
TLR8 activation. Using a variety of inhibitors of the TLR signaling pathway, including a MyD88 
inhibitor,267 we examined if any of the inhibitors ‘rescued’ monocytes and reduced ECV formation 
induced by the TLR8 and TLR7/8 agonists. The MyD88 inhibitor 4210, IRAK 1/4 Inhibitor I, and 
SB20358 caused significant inhibition of monocytic loss and consequent ECV formation, 
implicating MyD88, IRAK 1 and 4, and p38MAPK (Fig. 4). The inhibitors for the caspases, P2X7 
extracellular ATP sensor, NF-κB, c-Jun N-terminal kinase (JNK), TANK binding kinase (TBK) 
1/inhibitor of NF- κB (IKKε), and the NLRP3 inflammasome were ineffective.  
 
Activation of p38MAPK in monocytes 
Signaling in both TLR7 and TLR8 are MyD88-dependent,268-269 and IRAK-4 acts as a kinase 
downstream from MyD88 and upstream from IRAK-1.270 Our attention therefore turned to 
p38MAPK which has been recently shown to be involved in TLR8-dependent priming of NADPH 
oxidase activation in human neutrophils.271 We compared p38MAPK activation in monocytes by 
TLR7, TLR8, and dual TLR7/8 agonists, using anisomycin 272 as a positive control. Kinetic 
experiments showed that measurable monocytic loss could be observed at 4 h following 
stimulation. In order to examine intact monocytes, PBMCs were treated with the TLR agonists for 
2 h. Both the dual TLR7/8 agonists and the TLR8 agonists induced significant, dose-dependent 
p38MAPK activation in CD14+ monocytes, comparable to that observed with anisomycin, whereas 
the TLR7 agonist compound 1 induced much lower levels of p38MAPK activation (Fig. 5).  
 149  
 
Antigen packaging in ECVs 
Reverting back to the question of how TLR8 agonists influence antigen internalization in APCs, 
we interrogated if exogenous, soluble antigens would be present in the monocyte-derived ECVs. 
PBMCs were cultured in the presence of 5 g/mL of compound 4, and 100 g/mL of either a 54.1 
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Figure 4: Inhibition assay to determine the signaling pathways leading to ECV formation. 
Compound 4210, IRAK 1/4 Inhibitor I, and SB203580 reduced ECV formation and ‘rescued’ 
monocytes, which indicated MyD88, IRAK 1 and 4, and p38MAPK, respectively, were critical to 
ECV development. 
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ZIKV) which we are currently evaluating as an immunogen in animal models, or the 58 kDa non-
toxic diphtheria toxin mutein, CRM197,147 which we have previously used as a model immunogen 
in animal immunization studies.24, 88 Monocyte-derived ECVs were isolated from the PBMC 
cultures by centrifugation, and washed at least three times in complete RPMI to ensure removal of 
extravesicular antigen. The washed ECVs were lysed using a two-step procedure using 1 N sodium 
hydroxide with sonication, followed by 1 N hydrochloric acid. Western blots with appropriate 
rabbit immune sera were performed not only to test whether antigens were present in the ECVs, 
but also to determine integrity (immunoreactivity) and the relative size of the antigens recovered 








































 1 (TLR7 agonist) 
 3 (TLR8 agonist)
 4 (Dual TLR7/8)
 Anisomycin
 Neg. Ctrl.
Figure 5: Induction of p38MAPK by TLR7 and TLR8 agonists. TLR8 and dual TLR7/8 agonists, 
but not the TLR7 agonist, induced dose-dependent activation of p38MAPK in CD14
+
 monocytes 
in a manner similar to the positive control anisomycin. 
 151  
dominant bands corresponding to 54 and 58 kDa, respectively (Fig. 6). In PBMC culture 
supernatants, as well as in ECVs, accessory bands of lower molecular weights were observed 
signifying a degree of proteolysis (Fig. 6). It is noteworthy that the degree of proteolytic 
degradation was significantly higher for CRM197, with prominent bands of approximately 40 and 
23 kDa (Fig. 6), which is likely a consequence of the cleavage of A and B fragments.273 The 
molecular weight profiles of antigens recovered from the culture supernatants appeared to match 
the antigen recovered from the ECVs suggesting that proteolysis occurs during incubation with 
PBMCs, and not within the ECVs. These results indicated that exogenous, soluble antigens were 
internalized in TLR8-activated monocytes, packaged, and then released as extracellular vesicles.  
 
Antigen-loaded ECVs stimulate recall in CD4+ Th cells 
Given that the ECVs were positive for HLA-DR and Annexin V, it was unclear if the antigen-
loaded vesicles would be immunostimulatory (as has been documented, for instance, for dendritic 
Figure 6: Antigen loading in ECVs. A. Lysates from ECVs loaded with the a 54 kDa MBP-ZIKV 
antigen were examined by Western blots. Intact MBP-ZIKV antigen was readily detectable in the 
ECV lysates. B. Intact antigen was also detectable from the lysates of ECVs loaded with CRM197. 
CRM197 showed degradation in the culture, which likely corresponded to cleavage of the A and 
B fragments.   
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cell-derived vesicles274), or tolerogenic, (as has been observed in human polymorphonuclear cell-
derived vesicles275). We sought to determine whether ECVs loaded with CMV tegument protein 
pp65 (pp65) were capable of stimulating autologous CD4+ lymphocytes. ECVs were generated as 
mentioned earlier from PBMCs cultured with 100 µg/mL pp65 and stimulated with 5 g/mL of 
compound 4. ECVs were cultured with freshly-isolated autologous PBMCs from either CMV 
seropositive (n = 4) or seronegative (n = 3) donors. Recall responses in CD4+ Th population were 
measured by quantifying bifunctional IL-2+ and IFN-γ+ populations. CD3/CD28 Dynabeads, used 
as a positive control, induced significant numbers of double positive T cells (Fig 7), while negative 
control samples lacking either antigen, or antigen and TLR7/8 stimulus showed sparse IL-2+/IFN-
γ+ double positive events. The assay was benchmarked using PBMCs from seropositive individuals 
stimulated with soluble pp65 alone, which elicited significantly higher numbers of IL-2+/IFN-γ+ 
events relative to unstimulated controls. ECVs loaded with pp65 were found to induce similar 
numbers of activated CD4+ cells, indicating that the ECVs were functional, and were causing pp65-
specific recall responses in CD4+ lymphocytes (Fig. 7).  
 
Antigen-loaded ECVs are unable to directly stimulate isolated CD3+ T cells 
The finding that pp65 packed ECVs were able to elicit antigen-specific CD4+ T cell responses in 
autologous PBMCs, coupled with the observation that the ECVs were positive for HLA-DR 
prompted us to examine if antigen-loaded ECVs could directly present antigen to T cells. CD3+ T 
cells were isolated using magnetic microbeads and stimulated with autologous ECVs loaded with 
pp65. Both soluble pp65 as well as ECVs loaded with pp65 failed to activate isolated T cells (Fig. 
8); PBMCs incubated with soluble pp65 showed similar responses to previous experiments and, 
as expected, CD3/CD28 Dynabeads also activated isolated T cells. These results suggested that 
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ECVs were not capable of directly stimulating T cells, despite the expression of MHC II molecules 
on their surface. 
 
ECVs are taken up by CD14+ monocytes in PBMC culture 
In light of the fact that direct activation of T cells by the ECVs was not observed, we examined if 
accessory cells (such as APCs) present in PBMCs were internalizing the antigen-bearing ECVs 
and secondarily causing antigen-specific T cell responses. ECVs loaded with pp65 were cultured 
with PBMCs, which was followed by fixation, permeabilization, and staining with anti-CMV pp65 
antibodies. The antibody signal was enriched using tyramide signal amplification168-169 to enhance 
the pp65 signal to such levels as are required for reliable detection by flow cytometry. Signals 
from both soluble pp65 and ECVs loaded with pp65 were detected in CD14+ monocytes to 
comparable levels (Fig. 8), indicating that antigen-packed ECVs were internalized primarily by 
monocytes, thereby possibly contributing to the activation of T cells observed ex vivo.  
 
6.3 Discussion 
We have been investigating TLR agonists for their potential utility as vaccine adjuvants. TLR8 
agonists were of particular interest to us because of their strong proinflammatory cytokine profile, 
including IL-1β, TNF-α, and IFN-γ, and their ability to directly act upon monocytes, macrophages, 
and CD1c+ dendritic cells to significantly upregulate co-stimulatory molecules, including CD40, 
CD80 and CD86.39, 276-277 We aimed to build upon the existing APC activation profiles and explore 
how TLR8 agonists impacted APC internalization of soluble antigen to better understand 
mechanisms of adjuvanticity. 
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Figure 7: Functional recall responses in PBMCs to CMV pp65-loaded ECVs. A. CMV 
seronegative (n = 3) and seropositive (n = 4) donors were examined for soluble CMV protein 






 T cells. Only CMV seropositive 
donors responded to soluble pp65. B. CMV pp65-loaded ECVs generated from PBMCs of 






 T cells 
in autologous PBMCs. The increases were comparable to samples stimulated with only soluble 
pp65. Autologous PBMCs mock-stimulated with ECVs not loaded with pp65 failed to show any 






 recall responses 
to either soluble pp65, or autologous ECVs loaded with pp65. Mock-stimulated PBMCs did not 
induced T cells responses. 
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TLR7 and TLR8 both recognize single-stranded RNA,2 but they differ dramatically in their innate 
immune activation signatures. TLR7 engagement is characterized by strong induction of Type I 
interferons, upregulation of the early activation marker CD69 in B cells, natural killer cells, and 
cytokine-induced killer cells, and upregulation of the co-stimulatory molecules CD40 and CD80 
in monocytes, plasmacytoid dendritic cells, CD1c+ conventional dendritic cells, and CD141+ 
conventional dendritic cells.27, 29, 39, 111 TLR8 activation, on the other hand,  is distinguished by 
strong Type II interferon induction, and upregulation of the co-stimulatory molecules CD40 and 




























































Figure 8: Failure to induce recall responses in isolated CD3
+
 T cells by pp65-loaded ECVs. 
Neither soluble pp65, nor ECVs loaded with pp65 activated T cells in autologous, isolated CD3
+
 
T cells from CMV-seropositive donors. CD3
+
 T cells stimulated with CD3/CD28 Dynabeads as 






 T cell 
responses as expected. 
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responses to TLR7 and TLR8 signaling are therefore distinct, which holds true in the present study 
demonstrating the apparent loss of CD14+ monocytes and consequent formation of ECVs, which 
occurred only following stimulation with TLR8-active compounds (Fig. 2).  
 
The loss of the monocytes bear similarities to inflammatory cell death observed during pyroptosis. 
Pyroptotic cells undergo DNA cleavage, swelling, and lysis that result in ECVs that are 
considerably smaller (<500 nm) than those occurring due to apoptosis (1-4 µm). Both pyroptotic 
and apoptotic bodies, however, expose phosphatidylserine on the outer leaflet of the ECV 279. The 
monocyte-derived ECVs described here were predominantly anuclear, possessed exposed 










































Figure 9: CMV pp65-loaded ECVs and soluble pp65 internalization in monocytes. ECVs 
loaded with pp65, as well as soluble pp65, were internalized by CD14
+
 monocytes in fresh, 
autologous PBMCs. Detection of the antigen was enhanced using tyramide signal amplification. 
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While similarities with pyroptotic outcomes were observed, it was not possible to determine with 
certainty that pyroptosis was the cause of monocyte loss. Caspase 1 activation is one of the defining 
characteristics of pyroptosis,279 but inhibition of caspase 1 did not inhibit ECV formation (Fig 4). 
The role of caspases in TLR8 induced monocyte death requires further investigation to determine 
the extent of their involvement in this form of cell death.    
 
The exact cellular processes leading to ECV formation remain elusive. The requirement for 
p38MAPK activation in ECV formation offered an interesting point of comparison to NETosis in 
neutrophils. NETosis, a form of cell death in neutrophils that centers on the release of chromatin 
structures loaded with antimicrobial molecules called neutrophil extracellular traps, was shown to 
be dependent on the activation of p38MAPK by reactive oxygen species.280 Recent reports of 
NETosis induction by the TLR7/8 agonist R848281 and our observations of TLR8 agonist-induced 
p38MAPK-dependent cell death (Fig. 5) show a possible link between p38MAPK driven cell death 
induced by TLR8 agonists across multiple leukocyte populations.282  
 
Much of the early work involving cell death and the clearance of ECVs did not distinguish between 
the various forms of cell death and showed them to be either immunoquiescent or 
immunostimulatory.283-284 It was shown more recently that the activation state of the cell at death 
and type of cell death can greatly influence how the immune system reacts with the dying cell and 
resulting ECVs.285-286 Furthermore ECVs, such as exosomes, were shown to possess the ability to 
present antigen via major histocompatibility complex class II to cognate T cells.287 It was with this 
in mind that we sought to determine if the ECVs we observed were able to present antigen to T 
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cells. These studies show that ECVs contained exogenous, soluble antigens from the culture using 
two distinct antigens: MBP-ZIKV and CRM197 (Fig. 6). We utilized the prevalence of CMV 
seropositivity in the population to explore antigen-specific recall in T cells to CMV antigen pp65 
using intracellular IL-2 and IFN-γ as markers for T cell activation. The strong responses in CD4+ 
T cells with ECVs loaded with CMV pp65 indicated that the internalized antigen was available for 
adaptive immune responses (Fig. 7).  
 
We next examined if the ECVs could directly present antigen to T cells. The failure of isolated 
CD3+ T cells to respond to pp65 loaded ECVs indicates that the antigen is likely not being 
presented on the surface of the ECVs, but rather retained within as near-intact protein requiring 
processing and presentation from additional APCs (Fig. 8). We demonstrate that monocytes from 
fresh PBMC culture internalize both the soluble pp65 antigen, as well as pp65-loaded ECVs (Fig. 
9), which is consistent with the known trafficking of antigen-laden exosomes of monocytes, 
macrophages and dendritic cells.288-290 No pp65 was detected in the lymphocyte populations 
indicating that the B cells were likely not contributing to the T cell responses observed.  
 
The induction of cell death and antigen packing we have described here are consistent with the 
reported mechanisms of adjuvanticity of other immunostimulants. Several groups have found 
correlations between vaccine adjuvant-induced cell death and antigen internalization in APCs that 
points to cell death and the release of danger associated molecular patterns as being central to 
adjuvant-induced immunostimulation.291-292 This is true, for example, of the adjuvantic extract of 
Q. saponaria (QS-21), which functions through the induction of the NLRP3 inflammasome to 
facilitate  IL-1β and IL-18 release, and induces caspase-1 and -11 independent cell death of 
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dendritic cells.293-294 Furthermore, alum, the most widely used FDA-approved vaccine adjuvant, 
has been shown to induce cell death at the site of injection, leading to the release of danger signals 




The unique immunostimulatory properties of TLR8 agonists, including inflammatory cell death, 
make them interesting candidates for vaccine adjuvants. The induction of pyroptosis-like cell death 
in monocytes and attendant cytokine responses are likely only part of the adjuvantic mechanisms 
at play with the TLR8 agonists and, as such, warrant further exploration into mechanisms of 
adjuvanticity.  
 
6.5 Materials and Methods 
TLR agonists 
The pure TLR7 agonist 1 (1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine) 91, the pure 8 
agonists 2 (3-pentylquinolin-2-amine),26 3 (5-(5-aminopentyl)-3-pentylquinolin-2-amine),24 and 
the dual TLR7/8 agonists 4 (1-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)-2-
methylpropan-2-ol),91 5 (1-(3-(amino-methyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-
amine), 6 (1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine),92 7 (2-butyl-
2H-pyrazolo[3,4-c]quinolin-4-amine)97 were synthesized as reported earlier by us (Fig. 1). 
Synthetic PAM2CSK4 (TLR2 agonist), Poly(I:C) (TLR3 agonist), ultrapure LPS from E. coli K12 
(TLR4 agonist), flagellin from S. typhimurium (TLR5 agonist), and ODN-2006 (TLR9 agonist) 
were procured from InvivoGen (San Diego, CA). 
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Synthesis of MyD88 inhibitor 
The precursor moiety ((S)-4-methyl-3-((3-phenylpropyl)amino)-1-(pyrrolidin-1-yl)pentan-2-one) 
was synthesized as reported by Bartfai and colleagues.296 The MyD88 inhibitor 4210 (N1,N4-
bis((S)-4-methyl-2-oxo-1-(pyrrolidin-1-yl)pentan-3-yl)-N1,N4-bis(3-phenylpropyl)cyclohexane-
1,4-dicarboxamide, Fig. 1)267 was synthesized as reported by Alam and colleagues with 
modifications as follows: trans-cyclohexane-1,4-dicarboxylic acid (3.0 mmol) was dissolved in 
ethyl acetate (3 mL) with N,N-diisopropylethylamine (15 mmol), compound 8 (7.5 mmol), and 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-
phosphate (HATU, 7.5 mmol) followed by stirring for 96 h at 40°C. The solvent was evaporated 
under vacuum. The oil was dissolved with ethyl acetate (150 mL), extracted with 1 M NaOH  (50 
mL), 1.2 M HCl (50 mL), and saturated NaHCO3 (50 mL), followed by drying over Na2SO4. The 
organic layer was evaporated and the residue was purified by silica gel flash chromatography with 
a CombiFlash® Rf (Teledyne Isco Inc., Lincoln, NE; methanol/DCM: 0→6%) instrument, 
followed by basic alumina flash chromatography (ethyl acetate/hexane 0→40%). An overall yield 
of 35% was obtained for Compound 4210.  
 
Antigens and antisera 
Diphtheria toxin mutant CRM197147-148 was purchased from List Biologicals (Campbell, CA), and 
Cytomegalovirus (CMV) pp65 antigen was purchased from Abcam (Cambridge, UK., catalog 
number ab43031). A 54.1 kilo Dalton antigenic construct consisting of an N-terminal mannose 
binding-protein fused to a Zika virus E-glycoprotein derived antigen (MBP-ZIKV) was expressed 
and purified by KanPro Research Corp., (Lawrence, KS). Rabbit immune sera to CRM197 and 
MBP-ZIKV were generated by us as previously described.171 
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Reagents 
The following antibodies were purchased from commercial sources as noted: CD14-APC, HLA-
DR-APC and Annexin V-FITC (eBioscience, San Diego, CA., catalog numbers 17-0149-42, 17-
9956-42, and 88-8005-74, respectively), CD14-BV421, CD4-V450, CD8-V500, Phosflow™ p38 
MAPK-PE, anti-IL-2-FITC, anti-IFN-γ-PE (BD Bioscience, Becton Dickinson Franklin Lakes, 
NJ., catalog numbers 563743, 560345, 560774, 612565, 555431, and 554701, respectively). TLR 
pathway inhibitors SP600125, BAY 11-7085, IRAK1/4 Inhibitor, A740003, SCP0094, and 
cytochalasin D were purchased from Sigma Aldrich (St. Louis, MO). SB203580, VX-765, 
Glybenclamide, VAD-FMK, BX795, and Gefitinib were purchased from InvivoGen (San Diego, 
CA). TNF-α, IL-18, IL-12, IL-6, IL-4, IL-2, IFN-α, and IFN-γ were purchased from R&D 
Biosystems (Minneapolis, MN). 
 
Ex vivo human whole blood stimulation  
Whole human blood was collected in heparinized Vacutainer™ tubes, and PBMCs were collected 
and isolated in CPT™ tubes (Becton Dickinson, Franklin Lakes, NJ) from healthy volunteers 
providing written informed consent in accordance with the University of Minnesota Institutional 
Review Board (IRB Protocol 1506M74641). All experiments were replicated using a minimum of 
three individual donors. Whole heparinized blood was 1:2 diluted in RPMI 1640 supplemented 
with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin (complete 
RPMI). Cells were cultured in either polypropylene U bottom 96-well plates or 5 mL 
polypropylene capped tubes at 37ºC for 4 to 16 h, as indicated for each experiment. Whole blood 
was incubated with graded concentrations of TLR agonists for 16 h.  
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Flow cytometry  
Samples were pre-cooled to 4ºC for 1 h, and then stained with combinations of 2.5 µg/well surface 
markers, Annexin V-FITC and/or DAPI. Erythrocytes were lysed and leukocytes fixed by 
transferring 200 µL of diluted blood to 800 µL of pre-warmed Lyse/Fix buffer (Becton Dickinson, 
Franklin Lakes, NJ) in a 96-deep well plate by liquid handler and incubated for 10 min at 37ºC. 
The Lyse/Fix process was carried out one additional time before washing with 800 µL complete 
RPMI. Samples were resuspended in 200 µL complete RPMI for acquisition on a BD FACSVerse 
flow cytometer (Becton Dickinson, Franklin Lakes, NJ) for 250,000 gated events. Monocytes were 
gated as CD14+ SSChigh while extracellular vesicles (ECVs) were gated as CD14+ SSClow. ECVs 
were evaluated for DAPI, Annexin V, and frequencies with FlowJo 10 (FlowJo LLC, Ashland, 
OR). For intracellular p38MAPK staining, cells were resuspended in 800 µL Perm Buffer III 
(Becton Dickinson Franklin Lakes, NJ) for 30 min on ice, and washed twice in 800 µL of complete 
RPMI before resuspension in 200 µL complete RPMI with Phosflow™ p38MAPK-PE overnight 
at 4ºC. Cells were washed twice in complete RPMI and acquired on a FACSVerse for 250,000 
gated events 
 
Inhibition of formation of monocyte-derived extracellular vesicles 
Fresh human whole blood was preincubated with graded concentrations of inhibitors or vehicle-
alone control (DMSO) for 30 min at 37ºC. The inhibitors used were: SP600125 (JNK inhibitor), 
BAY 11-7085 (irreversible inhibitor of IκBα phosphorylation), IRAK1/4 Inhibitor I, SCP0094 
(inhibitor of Group III caspases), cytochalasin D (inhibitor of actin polymerization), SB203580 
(inhibitor of p38 MAPK and MAPKAP kinase-2), A740003 (competitive P2X7 receptor 
antagonist), VX-765 (inhibitor of caspase-1 and -4), Glybenclamide (NLRP3 inflammasome 
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inhibitor), VAD-FMK (pan-caspase inhibitor), BX795 (inhibitor of TBK1/IKKε phosphorylation), 
and gefitinib (EGFR tyrosine kinase inhibitor). Then dual TLR7/8 agonists were added to the 
samples in a volume of 30 µL at a final concentration of 5 µg/mL, and the plates were incubated 
at 37ºC for 4 h. ECV formation was measured by flow cytometry as described above. 
 
Transmission electron microscopy for ECVs 
The ECVs were separated from intact cells by gentle agitation of the culture tubes followed by low 
speed centrifugation at 300 g. The supernatants were pelleted at 20,000 g in complete RPMI 
containing 15 mM CaCl2, and washed three times with the same medium. ECV samples were used 
either undiluted, diluted 1:10, or 1:100 in PBS. 30 µL droplets of ECV suspensions were placed 
on a piece of Parafilm M® in a glass Petri dish containing pre-moistened filter paper. 
Formvar/Carbon on 200 Mesh copper grids (Electron Microscopy Sciences, Hatfield, PA) were 
placed on the ECV drops for 30 min, rinsed three times with PBS, and fixed in 2% glutaraldehyde 
in PBS for 10 min.  The grids were rinsed with ultrapure water (NANOpure Infinity®; 
Barnstead/ThermoFisher Scientific; Waltham, Maryland), stained with 30 µL of 1% 
phosphotungstic acid (pH 7) for 10 min, then blotted dry on filter paper. Samples were examined 
with an FEI Philips CM 12 transmission electron microscope operating at 60 kV.  Images were 
recorded with a Maxim DL digital capture system. 
 
Isolation of ECVs and evaluation of antigen packing 
Plasma was decomplemented in a water bath at 56ºC for 1 h and clarified by centrifugation. 
PBMCs were isolated using CPT™ tubes and cultured in 5 mL tubes with RPMI supplemented 
with 15% decomplemented, autologous plasma. Protein antigen, either 54.1 kDa Zika virus 
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antigen, or CRM197 were added to PBMCs at 100 µg/mL. ECVs were generated using a fixed 
concentration of compound 4 at 5 µg/mL (determined to be optimal in dose-response experiments) 
for 16 h. The ECVs were separated from intact cells by gentle agitation of the culture tubes 
followed by low speed centrifugation at 300 g. The supernatants were pelleted at 20,000 g in 
complete RPMI containing 15 mM CaCl2, and washed three times with the same medium. ECVs 
were lysed by resuspension in 25 µL 1N NaOH with sonication for 15 minutes, and the pH was 
neutralized by the addition of 25 µL 1N HCl and 25 µL of RIPA buffer. The antigen packed within 
the ECVs was evaluated using Wes 12-230 kDa anti-rabbit kit (Protein Simple, San Jose, CA., 
catalog number SM-W004-1). Primary antibody was 1:5000 rabbit polyclonal immune sera 
generated to the specific antigen as mentioned above. Control antigen was treated in an identical 
manner to the ECV lysis to ensure protein integrity. 
 
Induction of recall responses with ECV 
PBMCs were cultured overnight as mentioned above with the antigen CMV pp65 at 100 µg/mL 
and compound 4 at 5 µg/mL, and the ECVs were isolated and washed as mentioned above. 
Following the final wash, the ECVs were resuspended in 100 µL RPMI supplemented with 15% 
decomplemented autologous plasma, and transferred to a 5 mL tube of either autologous PBMCs 
or autologous, autoMACS pro (Miltenyi Biotec, Bergisch Gladbach, Germany, Catalog number 
130-050-101) isolated CD3+ T cells. ECVs generated in the absence of CMV pp65, compound 4 
alone, and CD3/28 Dynabeads™ (Gibco, Gaithersburg, MD., catalog number 11161D) were used 
as controls. Stimulated cells were incubated for 2 h at 37ºC, followed by the addition of 10 µg/mL 
Brefeldin A (Sigma Aldrich, St. Louis, MO) and 12 additional hours of incubation. Cells were then 
stained with CD4-V450 and CD8-V500 for 30 min at 4ºC. Samples were fixed and permeabilized 
using Cytofix/Cytoperm kits (Becton Dickinson, Franklin Lakes, NJ). Fixed samples were stained 
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overnight in perm/wash buffer (supplied with Cytofix/Cytoperm kit) with anti-IL2-FITC and anti-
IFN-γ-PE. Samples were washed 3 times in perm/wash buffer then resuspended in complete RPMI. 
Samples were acquired on a FACSVerse for 3,000,000 events. CD4+ Th and CD8+ CTLs were 
evaluated for dual functional IL-2 and IFN-γ positive cells.  
 
Tyramide signal amplification 
PBMCs were co-cultured with ECVs loaded with CMV pp65 for 12 h. Following the incubation, 
cells were stained with CD14-BV421 and permeabilized as mentioned above with 
Cytofix/Cytoperm kits. Each sample was blocked with 10% goat serum in PBS (recommended 
blocking buffer for the Tyramide Superboost kit, described below) for 1 h at room temperature. 
Anti-CMV pp65 antibody (Abcam, Cambridge, UK., Catalog number ab53489) was utilized at 
1:100 dilutions in 100 µL blocking buffer to stain cells for 1 h at room temperature, followed by 
1 h of incubation with goat-anti-rabbit-HRP antibody conjugate. Tyramide signal amplification 
was carried out for 5 min according to the Tyramide SuperBoost kit’s manufacturer (Invitrogen, 
Carlsbad, CA., Catalog number B40922). Samples were acquired on a FACSVerse for 250,000 
gated samples. CD14+ Monocytes were evaluated for uptake of ECVs loaded with CMV pp65 and 
soluble CMV pp65. 
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